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1  Introduction 
Medicines have always been a mainstay of medical treatment for variety of different 
diseases. Physicians in Germany prescribed a total of 852 million drugs in 2015 [1]. As 
a matter of fact, there is additional large number of over-the-counter (OTC) drugs 
obtained in pharmacy without prescription. In total, more than 1.4 billion drug pack-
ages were delivered in Germany in 2015, of which 37 % were OTC drugs [2]. 
Before a drug is available on any market, it has to undergo a drug approval process by 
the ruling authority of a government. For instance, in the United States (US) there is 
the Food and Drug Administration (FDA), in European Union is the European Medical 
Agency (EMA) and in Germany there is the Federal Institute for Drugs and Medical 
Devices1 (BfArM). During the approval process, ruling authority assesses and confirms 
the efficacy, safety and quality of respective medicinal product. Subsequently, the 
medicinal product enters the market and it can be prescribed [3-5]. 
Nevertheless, authorisation of medicines by the ruling authority does not imply that 
medicinal products on the market are risk-free. Any pharmacologically active drug 
may have side effects, so-called adverse drug reactions (ADRs). ADR is defined as a 
response to a drug that is noxious and unintended. It occurs at doses normally used [6, 
7]. ADRs can be unavoidable in the intended use due to drug active mechanism. An 
example of this is the alopecia in chemotherapy, e.g. with doxorubicine. On the con-
trary, there are avoidable ADRs occurring when a drug is used incorrectly. Apart from 
ADRs, there are further problems and situations that may occur during the course of 
drug use. Any event or circumstance involving drug therapy that actually or potentially 
interferes with desired health outcomes is together defined as drug-related problem 
(DRP) [6, 7]. DRPs are ADRs, various types of interactions, under- or overdosing and 
non-adherence. Besides, DRPs include use of a drug without indication, absence of a 
drug despite an existing disease, inappropriate drug selection for certain high-risk   
patient group or existing contraindications. If a DRP could be avoided, i.e. an ADR 
that can be prevented by correct dose adjustment, then it is considered as medication 
error [6, 8]. To a great extent, medication errors are caused due to complexity of the 
entire medication process. Medication process includes, by definition, all stages of 
drug therapy from medication history to drug prescribing, patient counselling, OTC, 
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 2 
drug distribution, delivery, administration, documentation, therapy monitoring and 
testing, as well as communication, medication reconciliation up to the outcome evalu-
ation [6]. In different levels of the medication process, different participants are in-
volved such as physicians, pharmacists, nurses, caregivers, relatives and patient 
himself. Each participant serves as a safety barrier, but at the same time as a potential 
hazard for development of a medication error [9]. A set of measures to ensure optimal 
medication process with the aim of reducing medication errors and thereby avoidable 
risks for a patient in drug therapy, is defined in Germany as medication safety2 
(AMTS) [6]. 
The global attention was drawn to medication safety at the beginning of the millenni-
um when in 2000 the US Institute of Medicine (IOM) published the report “To Err Is 
Human: Building a Safer Health System”. The report presented evidence demanded 
considerable improvement in patient safety. For the first time the frequency of pre-
ventable medical errors in the health care system was described. Two out of 100    
patients admitted to American hospitals encounter preventable ADR, and up to 
98,000 patients/year in the US die because of medical errors [10]. The subsequent 
report of the IOM estimated that 1.5 million preventable ADRs occur each year [11]. In 
the report from 2008, the World Health Organization (WHO) has also addressed the 
issue of patient safety underlining the need for research and intervention in the field. 
According to the report estimates between 7.5 % and 10.4 % of patients in acute care 
settings experience an ADR. ADRs alone lead annually to 140,000 deaths in the US. 
Further, the WHO estimated that from 28 up to 56 % of ADRs are preventable [12]. 
Results of a prospective observation study of 18,820 patients from England showed 
6.5 % prevalence of ADRs leading to the hospital admission [13]. German ministry of 
health has recognised the problem and extrapolated that there is no difference be-
tween western countries, such as the US or the United Kingdom (UK) and Germany, 
regarding medication errors and ADRs [14]. A longitudinal analysis of routine ICD-10 
data from 2003 to 2007 showed that an ADR complicated more than 5 % of hospital 
stays in Germany [15]. The modelling approach from 2007 estimated that total health 
care costs related to ADRs in outpatient care in Germany were € 816, where the mean 
cost per case was € 381. This illustrates the great potential for cost savings through 
increased medication safety [16]. The most frequent reported medication errors are 
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incorrect dosing, particularly disregarding renal function, then non-consideration of 
contraindications, neglecting allergies and various drug interactions [17]. 
Concepts to reduce medication therapy risk: medication safety 
Available data on medical errors and drug-related problems is growing. Medication 
therapy is recognised as a high-risk process. As a result, nationally and internationally 
the development of concepts and strategies for risk reduction and patient safety is 
promoted. 
In 2004 the World Alliance for Patient Safety was launched to improve patient safety 
worldwide and strengthen research in this area. For the first time heads of agencies, 
health policy-makers, representatives patients’ groups and the WHO came together to 
advance the patient safety goal of “First do no harm”, and reduce adverse health and 
social consequences of unsafe health care. Among other things, recommendations 
included more active patient involvement in the therapy and adequate patient educa-
tion and counselling related to the medication therapy [18]. In 2017, WHO launched a 
global initiative The Global Patient Safety Challenge on Medication Safety to reduce 
severe, avoidable medication-associated harm world-wide by 50 % over the next five 
years. The Challenge aims to make improvements in each stage of the medication use 
process including prescribing, dispensing, administering, monitoring and use. WHO 
works toward providing guidance and developing strategies, plans and tools to ensure 
that medication process has the safety of patients at its core, in all health care facilities. 
Besides, the focus is to increase awareness among patients about risks associated with 
the improper use of medication [19].  
The IOM published the report about preventing the medication errors. Besides elec-
tronic prescribing, they recognised pharmacists’ participation in clinical rounds in 
hospitals and in medication management in outpatient care as effective prevention 
strategy. The report calls for a patient-oriented treatment where patients and corre-
sponding medical care providers collaborate as partners, and patients continuously 
provide necessary information for safe and effective drug usage. Other recommenda-
tions were maintaining a complete list of patient’s medications as well as checking 
their accuracy and appropriateness on a regular basis [11]. Recent Cochrane systematic 
review indicated medicines self-monitoring and self-management programmes were 
effective to improve medicines use, adherence, adverse events and clinical outcomes. 
The intervention to prevent ADRs and improve other key medicine-related outcomes 
had a pharmacist involved in medication management, medicines reviews and phar-
Introduction 
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maceutical care services. However, the review underlined that this favourable inter-
vention requires further investigation in order to be more certain of its effect [20].  
In addition to transformation of care from provider-centred to patient-centred, models 
of care need to move from reliance on independent, individual performance excellence 
to interdependent, collaborative, multi-professional teamwork [21]. That represents a 
central point to enhance patient and medication safety [21, 22]. 
In Germany, the Federal Ministry of Health3 (BMG) took the decisive step in 2007 to 
promote medication safety. They published the first action plan for improvement of 
medication safety. The aim was an establishment of a safety culture by raising aware-
ness of risks of medication therapy, increasing cooperation between physicians and 
pharmacists, improving information on medicines, developing and implementing 
strategies for preventive risk management and initiating research on medication safety 
[14]. The action plan was valid for 2008 and 2009 and was then revised in two-year 
cycles. The current action plan was presented in June 2016 and is valid from 2016  
until 2019. The focus of the current action plan is to foster awareness of medication 
safety among patients, physicians, pharmacists and caregivers, to improve information 
on medicines and intersectional communication about drug therapy as well as facilita-
tion of medication safety research. A central point represents the need for greater 
involvement and information of the patient with regard to his medication therapy 
[22]. 
In 2012, the German Advisory Council for the Evaluation of Development in Health 
Care4 published a special report. They concluded that cross-sectional care in the field 
of medication therapy can only be guaranteed if physicians have a complete overview 
of all currently used medicines. That includes OTC medication and, in some cases, also 
medicines formerly taken, e.g. cytostatic agents in tumour patients. The prerequisite 
for a safe medication therapy is a comprehensive drug history with review of interac-
tions, dosages and dosage forms based on patient-specific characteristics. That implies 
characteristics such as renal function, weight, age, allergies and living conditions. 
Therefore, this information should be available in a standardised and clear format 
across sectors [23]. 
                                                   
3 German: Bundesministerium für Gesundheit (BMG) der Bundesrepublik  
Deutschland 
4 German: Sachverständigenrat zur Begutachtung der Entwicklung im  
Gesundheitswesen 
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There are activities with the same direction on the federal state level, too. For instance, 
the regional health conference in North-Rhine-Westphalia in 2012 addressed the im-
portance of medication safety. In support with the regional Ministry of Health, specific 
recommendations for action were developed. Recommendations urged for implemen-
tation and evaluation of multi-professional models to ensure medication safety. 
Thereby, they drew attention to the value of a complete medication record and clearly 
defined roles within the multi-professional teams, especially for patients with 
polypharmacy [24] (commonly reported as use of five or more medications daily [25]). 
Further, in order to ensure adequate medication safety they defined the aim of phar-
macotherapy management. The aim was precise allocation of tasks and responsibilities 
to all participants in a team. The task allocation should be in accordance with the 
complete medication record that is individually adjusted to each patient [24]. 
The coordinating group on implementation and updating of the action plan for im-
provement of medication safety5 in Germany published a memorandum on research 
development in this field. Objectives of medication safety research included develop-
ment of risk-minimizing interventions and implementation of effective interventions 
in the routine service. Special emphasis was laid on collaboration within medication 
process adjusted to requirements of the routine service [26]. One already successfully 
implemented measure is development of a uniform patient medication record. The 
uniform medication record was standardised on the national level [27]. From October 
2016, the German Federal Government on E-Health Act has initiated that every in-
sured person in Germany who receives at least three prescribed drugs at the same time 
is entitled to the standard national medication record issued by a physician [28]. On 
the other hand, there is still great room for improvement in terms of successful collab-
oration of multi-professional teams working in the medication process that is optimal-
ly adjusted to requirements of the routine service. 
                                                   
5 German: Koordinierungsgruppe zur Umsetzung und Fortschreibung  
des Aktionsplans zur Verbesserung der Arzneimitteltherapiesicherheit in 
Deutschland (Aktionsplan AMTS) 
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2 Model I 
Multi-professional medication safety model  
reducing drug-related readmission in care-dependent 
elderly - study protocol 
2.1 Introduction  
Background and rationale 
In response to the National Research Council’s report “To Err Is Human: Building a 
Safer Health System” considerable effort is undertaken to restructure the hospital   
environment to reduce risk of medical errors and maximize quality of healthcare   
delivery [10]. Quality driven improvements in health care have brought patient and 
medication safety into sharp focus. In patient-oriented health care high priority was 
given to reduction of errors and harm from medicines based on their safe use [29]. The 
German Ministry of Health (BMG) has recognized the relevance of medication errors 
for health care and published already four action plans to improve medication safety in 
Germany [22]. 
All medications carry risk of an ADR, but elderly patients are more prone to ADRs due 
to an increased disease burden and a corresponding complex medication therapy in 
conjunction with deteriorating organ function [30]. At least one in ten elderly patients 
will experience an ADR during their hospital stay [31]. In the US, patients with ADR 
had higher risk of spending additional days in the hospital and the adjusted median 
monthly cost of care was 1.90 times higher [32]. Moreover, poor communication of 
medical information among caregivers at transition points from inpatient to outpa-
tient care was responsible for up to 20 % of ADRs [29]. Within the 45-day post hospi-
talisation period, 35 % of ADRs identified were deemed preventable, of which 32 % 
were characterized as serious [33]. In the UK, out of 100 patients readmitted to hospi-
tal within one year of discharge, 20 patients were readmitted due to a suspected ADR. 
Approximately 10 of these 20 patients exhibited ADRs, which were possibly preventa-
ble [34]. In Germany is estimated a rate of 3.8 % admissions where ADRs led directly 
to hospitalisation [35]. A German study on the internal medical ward estimated that 
the incidence of hospitalisation due to at least ‘possible’ serious outpatient ADRs was 
3.25 %. Average treatment cost of a single ADR was € 2250. Considering the           
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proportion of 20 % of preventable cases this equals a saving potential of € 87 million 
per year [36]. 
There is clearly a need to reduce readmission rates to hospital. This is important in 
terms of patient care, medication safety and in relieving the burden on over-stretched 
hospitals. One of the essential strategies is to establish an active and effective collabo-
ration model amongst health care professionals. The multi-professional collaboration 
represents a complex intervention consisting of several interacting components re-
garding behavioural adaptation required by those delivering or receiving the interven-
tion and a certain degree of flexibility in the form of the designed intervention [37-39].  
The worldwide attempts to evaluate and implement different multi-professional medi-
cation safety models in the hospital setting confirm how challenging the task is. Ran-
domised controlled studies evaluating collaborative models with integrated medicines 
management service showed a reduced length of the hospital stay and prolonged time 
to readmission [40-42]. Further studies revealed more appropriate use of medicines 
during and after the hospital stay, improved patients’ health-related quality of life [41], 
even 80 % reduction of drug-related readmissions and considerable economic benefit 
in one Swedish study [43]. A key benefit of these services was intra- and inter-sectorial 
partnership established between patients, their caregivers and a number of health care 
professionals [41, 43]. In Denmark, however, collaborative model with systematic 
medication review and medication counselling did not show any effect on in-hospital 
length of stay, readmission or mortality of elderly patients in a randomised control 
study. Interesting and quite likely critical point is relatively low clinicians’ acceptance 
of medication changes recommended by clinical pharmacists and clinical pharmacolo-
gists. Less than half of the provided drug counselling resulted in changes in patients’ 
medication. This fact has weakened the effect of the intervention and probably influ-
enced study results in the direction of no difference [44]. Finally, a recent Cochrane 
systematic review of complex interventions using medication reviews in the hospital 
setting indicated uncertain evidence for their effect on mortality and hospital readmis-
sions. However, the number of emergency department contacts was reduced compared 
to the standard care. The authors concluded that there is a need for new multi-
professional medication safety intervention trials focussing on high-risk populations. 
The team performing medication review should include members that are competent 
to change patient medications. Moreover, well-described methods when conducting 
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the medication review, a long-term follow-up and a ward- or team-based cluster ran-
domisation should be used [45]. 
Substantially highlighted evidence confirms that the diversity of methodological      
approaches and variability in individual level outcomes make it extremely hard to 
ensure strict standardisation of multi-professional medication safety models. Those 
practical and methodological struggles that any successful evaluation must overcome, 
have led to a consensus (i.e. the Medical Research Council (MRC) framework) among 
health science researchers in form of guidelines for the development and process eval-
uation, and criteria for evaluation of complex interventions [37-39]. In accordance 
with the consensus, the complex intervention of a multi-professional medication safety 
model may work best if tailored to the local circumstances. There are numerous stud-
ies describing the status quo, consequences and potential solutions of DRPs in German 
hospitals. Many German hospitals have started improving the local services to reduce 
DRPs and enhance medication safety. Examples were shown in the field of cardiology 
concerning better medication adherence [46], less readmissions in patients with     
ischemic stroke [47] and better quality of life for oncology patients [48]. 
To the best of our knowledge, there is no project in Germany which has developed and 
evaluated the multi-professional medication safety model in the hospital setting in 
order to comprehensively improve medication safety and quality of delivering 
healthcare by reduction of drug-related readmissions (DRRs). The project is at the 
University Hospital RWTH Aachen (UKA) where the basis of collaboration between 
physicians, nurses, pharmacists and patients was established through previous      
research work. The collaboration showed considerable potential and may undergo 
process evaluation. 
Previous work on the model 
Based on the evidence of medication safety issues in the existing literature worldwide, 
the need to determine local evidence was recognised. In the development study, a 
multi-professional medication safety model was proposed. The new complex interven-
tion model (i.e. care team) had a pharmacist, in addition to the standard ward team of 
physicians and nurses. Thus, the collaborative complex intervention setting consisted 
of a patient, a physician, a nurse and a pharmacist having a close personal interaction, 
where the physician had the main responsibility and final decision about the patient’s 
pharmacotherapy (Table 2.1) [49]. The model was assessed identifying DRPs on the 
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three medical departments at the UKA: urology, neurology and internal medicine III 
(gastroenterology and metabolic disorders) evaluation (Figure 2.1).  
For 306 included patients 702 DRPs were detected. The collaborative multi-
professional care team accepted 77 % of pharmacist recommendations on documented 
DRPs. The high acceptability and practicability of the model underlined benefit of 
multi-professional collaboration. As a result, a guideline for the comprehensive medi-
cation safety review (MSR) was developed [49]. The guideline represents a valuable 
contribution to the methodology of medication safety complex interventions. This 
guideline became part of the Standard Operating Procedure (SOP) for medication 
safety, developed for and used in the present evaluation study (Attachment Model I). 
It is, therefore, explained in detail in the section 2.2 Methods. Modelling the process 
showed patients’ age and number of drugs as statistically significant risk factors [49]. 
Hence, in the further step focus was narrowed on elderly inpatients (patients 65 years 
of age or older). Results of initial testing in the development study encouraged further 
examination of model’s key uncertainties in the pilot study. The key uncertainties 
were: feasibility of the intervention in other medical departments, on high-risk popu-
lation, and effectiveness of the model on other patient-relevant outcomes during a 
long follow-up. 
 
 
Figure 2.1: Development and evaluation process in accordance to the MRC guidelines 
  
Development 
Piloting 
Evalution 
Implementation 
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Table 2.1 Task description of each partaker of the multi-professional medication safety mod-
el  
Partakers Tasks of each partaker 
Patient Recipient of care continuously reporting and describing personal condi-
tions, symptoms, feelings and wishes relevant to the treatment and drug 
therapy to the care providers 
Nurse A care provider who is a first ‘inspector’ of the patient treatment reac-
tions, conditions and symptoms; continuously reporting them to attend-
ing physician and pharmacist, and applying physician’s and 
pharmacist’s recommendations according to the treatment plan 
Pharmacist A care provider who optimises use of medicines and improves health 
outcomes by providing pharmaceutical care [50] including a medication 
review based on medication history, medication reconciliation, medica-
tion safety checks, and recommendations on drug therapy to the medi-
cal team members 
Physician A care provider with main responsibility for provision of optimal and 
comprehensive medical care to the patient, working in close collabora-
tion with other care providers; negotiates an agreement with the patient 
about the therapeutic objectives  
Besides urology, neurology, internal medicine III (gastroenterology and metabolic 
disorders), another internal department was added at this stage: internal medicine I    
(cardiology, pulmonology and angiology) [51]. The intervention model and the com-
prehensive MSR were performed according to the previously defined assignments 
(Table 2.1) and guideline [49]. More suitable measures were chosen: preventable 
/ameliorable ADRs and DRRs. Preventable/ameliorable ADR is a fraction of DRPs 
that is potentially avoidable by medical teamwork. DRR represents a reliable patient-
relevant, short- as well as long-term outcome. Follow-up period of 12 months was   
chosen [51]. Empirical evidence identified patients with dependent living situation as a 
vulnerable group for DRRs [52]. Hence, in the pilot study the focus was narrowed on 
nursing home residents and home-cared elderly admitted to the UKA [51]. 
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Sixty participants were randomly assigned to either control group (standard care) or 
intervention group (multi-professional medication safety model). An independent and 
blinded outcome assessment panel made final decision on ADR causality, severity and 
preventability/ameliorability. In a two-step valuation procedure, the panel assessed 53 
ADR-suspicious symptoms as ADRs. One third of ADRs was classified as preventable 
or ameliorable. Thirteen DRRs occurred during 12-month follow-up (7 patients in the 
control group vs. 3 patients in the intervention group – one patient in the intervention 
group was readmitted three times to the hospital). The time to DRR was longer in the 
intervention group than in the control group (1-year readmission rate under interven-
tion: πIntervention = 0.1; 1-year readmission rate under standard: πStandard = 0.3;            
Figure 2.1: Log-rank-test, p = 0.0684). Statistical significant risk factors for DRRs 
were age, duration of initial hospital stay, and number of medication changes after 
discharge during 12-month follow-up. After adjusting for significant risk factors the 
multivariable Cox Proportional Hazard Model showed that the control group patients 
had 5.588 times more risk (Hazard Ratio = 5.588) to experience a DRR (p = 0.0247; 
KI: 1.245 – 25.085) [51, 53]. These results provided strong motivation to extend the 
study into an evaluation phase. 
The multi-professional medication safety model, however, showed no difference in the 
number of medication changes, and in the number and type of potentially inappropri-
ate medication. Further, there was no difference between treatment groups in the 
number and time-related occurrence of ADR [51, 53]. 
A notable tendency of reduction of DRR in the pilot study outlines a positive impact of 
the multi-professional approach on patient and medication safety. It calls to perform a 
full-scale evaluation of the multi-professional medication safety model in a larger 
study. Finally, the proposed model includes all currently lacking parameters in the 
existing literature recommended for future trials of complex interventions in the hos-
pital setting [45]. 
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Figure 2.1: Kaplan-Meier-plot of the intention-to-treat-analysis for the primary outcome 
drug-related readmissions [51] 
2.1.1 Objectives 
The study aim is to assess the effectiveness and to evaluate the quality of the multi-
professional medication safety model in the hospital setting. 
Scientific objectives are: 
1.   To assess whether the multi-professional medication safety model    
affects the time to DRR (primary outcome); 
2.   To assess whether the multi-professional medication safety model affects the 
number of DRR (secondary outcome); 
3.  To evaluate the value of the multi-professional medication safety model to de-
tect and resolve preventable or ameliorable ADRs (secondary outcome); 
4.   To evaluate the quality of the multi-professional medication safety model in 
light of internal model interaction and communication (secondary outcome).  
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2.2 Methods 
The present study protocol is prepared according to the SPIRIT outline [37, 38]. The 
study is an open randomised controlled trial (RCT) supplemented by a qualitative 
evaluation of the intervention. The study consists of a holistic approach using quanti-
tative methods to measure effects and qualitative methodology to assess interaction 
patterns and communication customs between partakers of the model.  
The RCT part of the evaluation study represents PROBE design (Prospective Random-
ised Open, Blinded End-point) because it is a prospective study, which uses randomi-
sation and has an open-label and blinded endpoint (i.e. outcome). Integrating 
qualitative methodologies in this case implies studying individuals in their natural 
setting to explain behaviour pattern. The mixed-methods approach uses multiple ways 
to explore the research problem and overcomes the limitations of a single design. 
Methods are combined in a way that enables gradual accumulation of know-ledge of 
how the intervention is delivered, and how and why it works (triangulation).  
Study setting 
The project is conducted in the academic hospital, UKA in Germany, on the four study 
departments: urology, neurology, internal medicine III (gastroenterology and meta-
bolic disorders) and internal medicine I (cardiology, pulmonology and angiology). The 
study departments are the same as in the pilot study [51]. In hospitals team members 
can have daily in-person contact. Close contact of team members should assist in   
implementation of the multi-professional medication safety model in the routine  
practice.  
2.2.1 Patient recruitment 
Patients who fulfil the inclusion criteria are eligible to enter the study. The criteria is 
identical to the one in the pilot study [51]. In case of patient’s mental disorder, their 
caregiver may be a surrogate decision maker. Beside the failure to meet inclusion cri-
teria or unwillingness to participate in the study, patients will be excluded if they have 
already entered the study during preliminary stages. 
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The inclusion criteria:  
• Patient is hospitalised at one of the project departments: urology, neurology, in-
ternal medicine III (gastroenterology and metabolic disorders) and internal 
medicine I (cardiology, pulmonology and angiology), 
• Patient is 65 years of age or older, 
• Patient requires daily-provided care (i.e. dependent living situation: nursing 
home/home-cared patients/Care Level I, II, III), 
• Patient must stay a minimum of three days at UKA hospital,  
• Patient has an existing medication therapy on admission,  
• Patient gives an informed consent. 
Recruitment procedure and Informed Consent  
A recruitment procedure is planned for 12 months. The procedure and supporting 
documentation (information sheets and informed consent) are prepared according to 
the German legal requirements. Regular medical team on study wards informs their 
patients about the existing study and encourage their participation. Afterwards, the 
research assistant 1 (RA1) performs the structured recruitment interview in a way that 
the rights of potential participants are respected. Patients are verbally informed by 
RA1 as to what their participation involves and how the data is used. They have an 
opportunity to ask questions and considerably enough time to make their decision. 
Participation is voluntary. Patients are free to accept an invitation to participate in the 
project, as well as to opt out at any time. Stopping the participation would not affect 
further medical treatment, health care nor their rights in any way. Informed consent 
and project information leaflet are provided during the structured recruitment. Will-
ingness to participate in the study and permission for data procession is confirmed by 
a written informed consent. For all patients who decide not to participate in the study, 
reasons are documented. 
Sample size 
Bio-statistical group of PD Dr. Nicole Heussen (UKA) performed the sample size cal-
culation based on the results of the pilot study [51]. It was assumed a 1-year-
readmission rate under intervention of 0.1 (exponential hazard 0.1054) compared to a 
1-year-readmission rate under standard of care of 0.3 (exponential hazard 0.3567). All 
patients are simultaneously followed for one year. During the study period an expected 
dropout rate is 20 %. Acting on these assumptions, sample size of 69 patients per 
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group (i.e. 138 patients altogether) is required to obtain a power of at least 80 % for 
the Log-rank test comparing two survival curves with two-sided significance level of 
5 %. All patients in the intervention group (69) are potential participants in qualitative 
assessment.  
Randomisation  
Block randomisation is implemented to secure unbiased effect estimates. The study is 
placed on four clinical departments with structural differences. The department differ-
ences have influenced DRP patterns in previous work [49]. As a result, randomisation 
is stratified with regard to the participating study clinical departments. Due to the low 
number of comparable study departments, there is no cluster randomisation.  
After successful recruitment in the study, stratified blocked randomisation takes place. 
Randomisation list is generated using the R package randomizeR [54]. RA1 randomly 
assigns patients to either an intervention group or a control group. Implementation of 
randomisation is performed via opaque sealed envelopes. 
Contamination effects 
The risk of contamination effects between control and intervention patients is low 
because of the individualised pharmaceutical intervention (PI). Pharmacists have a 
special training before the study begins. The research team has an appropriate training 
too, in order to handle requests of control-group patients in a clear and respectful way. 
The research team provides sustained contact to control-group patients during their 
hospital stay.  
Blinding 
It is a non-blinded study. Nature of the intervention in the intervention group –    
patients’ counselling, patients’ education and close collaboration between ward-base 
members – does not allow the blinding of any of ward-team members (patients, physi-
cians, nurses, pharmacists). Non-blinded study needs an objective assessment of the 
primary outcome. Therefore, an independent and blinded review committee performs 
the outcome assessment (2.3.3 Outcome assessment panel).  
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2.2.2  Participant timeline 
The following schematic diagram (Table 2.2) represents the participants’ timeline. 
Table 2.2: Participant timeline 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
TIMEPOINT -t1 0 t1 t2 t3 t4 t5 t6 t7 
ENROLMENT:       
 
  
Eligibility screen X         
Informed con-
sent  X      
   
Allocation  X        
INTERVEN-
TION GROUP:       
   
Medication 
history   X    
   
MSR          
Case conference          
Discharge coun-
selling     X  
   
Patient inter-
view     X  
   
Follow-up exam-
ination       
   
CONTROL 
GROUP:       
   
Follow-up exam-
ination       
   
ASSESSMENTS:          
Study geriatric 
assessment X      
   
OUTCOME 
VARIABLES:       
   
ADR-suspicious 
symptoms       
   
PIM    X      
DRP (interven-
tion group only)   X X   
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Legend: MSR – medication safety review, ADR – adverse drug reaction, PIM – potentially inappro-
priate medication, DRP – drug-related problem, -t1 – admission tot he UKA hospital, t1 – within the 
first three days of the hospital stay, t2 – inpatient stay, t3 – hospital discharge, t4 – one week after the 
hospital discharge, t5 – two months after the hospital discharge, t6 – six months after the hospital 
discharge, t7 – 12 months after the hospital discharge 
2.2.3 Geriatric assessment  
Supplementary to physicians’ and nurses’ routine assessment of elderly patients, RA1 
performs a geriatric assessment for all the recruited patients. The geriatric assessment 
in the study includes: functional assessment using the Vulnerably Elderly Survey score 
[55], cognitive assessment with the Mini-Cog tool [56] and ADR assessment with the 
GerontoNet ADR risk score [57]. The Vulnerably Elderly Survey identifies elderly 
patients at risk for health deterioration considering age, self-rated health, and limita-
tions in physical function, and functional disabilities [55]. The Mini-Cog is a brief and 
sensitive screening tool designed to identify individuals at high-risk for dementia. It 
combines two simple cognitive tasks (three-item word memory and clock drawing) 
with an empirical algorithm for scoring [56]. The GerontoNet ADR Risk score helps 
identify elderly inpatients at risk of an ADR. It contains information about comorbidi-
ty, number of drugs, renal failure, heart failure, liver disease and previous ADRs [57].  
2.2.4  Control group  
Participants randomly allocated to the control group are treated according to the cur-
rent medical standard of care, where a ward-based medical team includes physicians 
and nurses. Pharmacists are not included in the team. RA1 is responsible for control 
group patients and maintains a regular daily contact with them. Daily visits are part of 
patient retention strategy. RA1 documents ADR-suspicious symptoms and potentially 
inappropriate medication (PIM) from the PRISCUS list [58]. If any symptom of a 
serious or life threatening ADR occurs, the research team discusses the case with an 
attending physician. Shortly before the patients’ discharge, RA1 meets the control-
group patients and prepares them again individually for the upcoming follow-up.  
Methods 
 19 
2.2.5 Intervention group 
Participants randomly allocated to the intervention group, are treated according to the 
multi-professional medication safety model. The complex intervention model, besides 
physicians and nurses, has a study pharmacist (SP) as an integrated part of the ward-
based multi-professional health care team (Attachment Model I: SOP for medication 
safety). The SP provides pharmaceutical care throughout the patient’s hospital stay. 
Pharmaceutical care is patient-centred, structured intervention that includes a close 
collaboration with other ward-based team members, as well as patients and their care-
givers. It consists of different activities described in the following paragraphs. 
Admission in this study represents the period of first three days in the hospital. It is 
t1 in the participant timeline (Table 2.2), where medication history, and first medica-
tion safety review and case conference take place. 
Medication history 
Up on arrival on the study ward, SP assesses every study patient and takes his medica-
tion history. Medication history is the most accurate list of all home medications, pre-
scribed and OTC drugs (including drug name, dosage, frequency, and route of 
administration), and the history of medication use (any known previous DRP). Various 
information sources are used to facilitate the accuracy of the medication history list 
e.g. patient’s medical records in the hospital, prescriptions from primary care centres, 
communication with the responsible nurse, as well as communication with a patient 
and his caregiver.  
Medication Safety Review  
After completing the medication history, SP performs a comprehensive Medication 
Safety Review (MSR). In the MSR, patient’s pharmacotherapy is reviewed and as-
sessed according to the SOP for medication safety (Attachments Model I). For every 
DRP detected in the MSR that leads to PI, SP prepares pharmaceutical recommenda-
tion (PR).  
The comprehensive review consists of certain assignments. Main assignments of the 
review are based on the guideline established in the development study [49]. Detailed 
description is presented in the SOP for medication safety (Attachments Model I): 
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1.  Medication reconciliation: comparison of home medication list against the    
physician’s admission order 
2.  Diagnosis-medication plausibility check 
3.  Search/check for known patient allergies  
4. Review of renal function values  
5. Review of hepatic function values  
6.  Review of all relevant laboratory values  
7.  Review of medication plausibility and contraindication 
8.  Review of drug dosages, interactions, adherence to the relevant guidelines, PIM; 
9.  Preoperative medication management 
10.  Review of medication in terms of planned examinations during the hospital stay  
11.  Check on duration of medication therapy  
12.  Patient counselling and education about medication, particularly about newly 
prescribed ones 
13.  Therapeutic Drug Monitoring (TDM) for drugs with a narrow therapeutic range  
Case conference 
The comprehensive MSR results in understandable and specific recommendation on 
each DRP leading to PI. From PRs it should be clear from which source the advice is 
based on. PRs are documented and added into the patient medical record. Further-
more, SP discusses the recommendation on patient’s medication with the attending 
physician, and if needed with the attending nurse too, as part of a case conference. The 
case conference is performed during the routine work of attending physicians and 
nurses. As the patient’s viewpoint is actively sought, the advice (PR) is given in a   
patient-centred manner. Lastly, the attending physician makes the final decision re-
garding the patient’s medication.  
Inpatient stay in this study represents patients’ time in the hospital. It is t2 in the 
participant timeline (Table 2.2), where SP performs comprehensive pharmaceutical 
care. Any change in the patient’s pharmacotherapy calls for additional MSR (see 
above: Medication Safety Review) and adjustment of the medication plan. Should any 
DRP occur, SP assesses it. When the PI is needed, the DRP is documented and appro-
priate recommendation is provided. Accordingly, PRs are discussed with attending 
physicians and nurses (see above: Case conference) and the patient is counselled. 
Discharge in this study represents the last two days in the hospital. It is t3 in the 
participant timeline (Table 2.2). Before leaving the hospital, the study patient meets 
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SP again for a discharge counselling. The discharge counselling aims at educating the 
patient on changes in the medication plan and what should be considered in following 
ambulatory care. SP provides PR to the attending physician, too. It is proposed to add 
PRs in a discharge letter. The attending physician decides whether PRs are part of the 
discharge letter and has the responsibility to hand over the discharge letter to the 
patient. At discharge, research assistant 2 (RA2) interviews patients in the interven-
tion group (2.2.7 Patient interview). 
2.2.6 Follow-up  
In order to assess the long-term effects of the multi-professional medication safety 
model, a 12-month follow-up is planned. It starts after the hospital discharge. RA1 
contacts the study participants from both patient groups at four time points during the 
follow-up: one week after and then two, six and twelve months after the discharge. 
Time points in the follow-up schedule assessment are identical to those in the pilot 
study [51]. The schedule is developed after reviewing previous international studies 
and discussing it with the colleague [43] who successfully performed the follow-up 
study in the Swedish hospital.  
Participants are asked about their current condition (including relevant vital parame-
ters) and medication plan, laboratory test results, hospital visits and admission as well 
as reasons for admission (discharge letters when available), ADR-suspicious symp-
toms and any other new symptom/complaint (Table 2.3).  
Dropout refers to a patient who has been originally recruited in the study, but with-
drew before the completion of actual study time. Considering the low dropout rate of 
1.6 % in the pilot study [51], it is unlikely that special measures are needed to adjust 
the drop outs.  
Lost to follow-up refers to a patient who at one point in time was actively participating 
in the study, but was lost at the point of the follow-up. These patients can be lost for 
many reasons: they may have opted to withdraw from the study, they may have moved 
away from the particular study site during the study time, or became ill and unable to 
communicate or even passed away. In the pilot study [51] 20 out of 61 patients were 
lost to follow-up. In order to protect the patients and the integrity of the study out-
come, RA1 should make a reasonable effort to ascertain reasons, while fully respecting 
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the rights of participating patients. If the cause of early cessation is independent of 
prognosis of the primary outcome, the data is considered as censored. 
Table 2.3 Examinations during the follow-up period 
EXAMINATIONS 
 
 
TIME POINTS 
Medication 
plan 
Lab 
data 
Hospital 
visit/ 
admis-
sion 
ADR- 
suspi-
cious 
symp-
toms 
Any 
symp-
tom/ 
com-
plaint 
1. One week after the 
discharge 
✔ ✔ ✔ ✔ ✔ 
2. Two months after the 
discharge 
✔ ✔ ✔ ✔ ✔ 
3. Six months after the 
discharge 
✔ ✔ ✔ ✔ ✔ 
4. Twelve months after 
the discharge 
✔ ✔ ✔ ✔ ✔ 
2.2.7 Patient interview  
Individual assessment of patients’ views and experiences in terms of 
communication with the model associates 
Patient’s perspectives are increasingly seen as important in informing the future of 
healthcare. Interviews provide an opportunity for this contribution. [59] All partici-
pants in the intervention group are potential participants for the individual interview. 
For those patients in the intervention group, where a caregiver as surrogate decision 
maker has signed the informed consent, the caregiver is a potential participant. At the 
hospital discharge, RA2 (further in this chapter referred as interviewer) provides to all 
participating patients or corresponding caregivers in the intervention group a semi-
structured individual interview. This interview comprises both structured and open-
ended questions. It represents the most appropriate interview form in this case,    
because it provides information on both: (a) predetermined structured measures and 
(b) a more detailed examination of pertinent views and experiences of participating 
patients.  
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(a) Quantitative evaluation of patients’ satisfaction 
Quantitative part of the interview contains closed questions about patients’ satisfac-
tion with the multi-professional model in terms of supervision and communication. 
Closed questions are documented in writing and have a range of predictable responses 
according to the five-point Likert rating scale [60], ordinal level.  
(b) Qualitative evaluation of patients’ experience and communication 
Further, individual semi-structured interview contains open-ended questions about 
patients’ experience and communication with the model. This part of the interview has 
an unpredictable range of responses. Participating patients or corresponding caregiv-
ers have an opportunity to express their own views in their own words [59]. According 
to the interview guide, qualitative enquiry provides a framework for the interview. The 
interview in the present study contains following open-ended questions and probing 
questions: 
• Opinion/remark/comment about multi-professional team supervision 
• Opinion/remark/comment about communication with the multi-professional 
team 
• What would you particularly emphasize as an advantage of the teamwork? 
• Have you experienced any difficulty in communication/supervision with physi-
cians, nurses or pharmacists? 
• What do you think has caused this difficulty? 
• When did the difficulty occur? 
• Has the difficulty with the medical team influenced your hospital stay? 
• Did you consider taking any measures in order to solve the difficulty in com-
municating with the medical team? 
• What would you improve in terms of communication/supervision of the multi-
professional team? 
If a patient tends to provide a very brief response, skilled interviewer (RA2) should ask 
for a clarification or more details in relation to any question so that the responses are 
more meaningful.  
However, the actual direction and content of the interview in terms of discussed issues 
are determined by patients’ experiences, views, and perceptions. The interviewer 
should discover what is important to the interviewed patient. It is up to the interviewer 
to use his skills to ensure that the interview fully explores these perspectives rather 
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than being influenced by his own agenda or preconceptions [59]. Finally, the interview 
is used to explore issues from patients’ perspective in order to improve future commu-
nication between patients and multi-professional model associates. The individual 
interview with open-ended questions is digitally recoded and transcribed verbatim. 
2.2.8  Focus group 
Qualitative assessment of the multi-professional model interactions 
A focus group is conducted to assess how the multi-professional model works. This 
group discussion is planned in form of a retreat after the intervention period is con-
cluded. The retreat takes place outside of the daily setting, in a comfortable venue, free 
from distraction. Nine care providers are invited to participate: four clinicians and 
four nurses (one from each study department), and the SP. The interaction between 
participants that occurs in the focus group is the main difference in comparison with 
individual interviews and at the same time the key to a successful group discussion 
[61]. The interaction between contributing care providers may stimulate a wide-
ranging discussion as participants stimulate each other. The care providers may 
change viewpoints on hearing arguments of the others. This is going to be used for 
generating information on collective views and meanings that lie behind those views, 
in order to gain an insight on how the model works. In the focus group, however, there 
may be a reluctance to express opposing viewpoints. Some participants may tend to 
dominate the discussion. Inevitably, as in any group there are more and less vocal 
members. Therefore, the facilitator (RA2) plans and adopts strategies and styles of 
questioning to promote and encourage wide participation, to elicit contribution from 
all participants, to value all contributions and treat all as equally valid [59]. The fol-
lowing interview structure is used: 
Engagement questions:  (1) How do you feel about working in the multi-professional 
model (in general)? (2) What do you consider as an ad-
vantage/disadvantage? 
Exploration questions:  (1) How do you assess communication within the model? 
Taking into account the way of interaction (face-to-
face/E-mail/ phone), timing, colleague’s motiva-
tion/interest in cooperation, equal and respectful partner-
ship, and hierarchy. (2) Patient case discussion (a case from 
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the intervention period, where the disagreement was met 
and reasons were not clear): where the disagreement        
occurred, why, how it was solved, what could be changed in 
the future. (3) Recommendations for the safety culture im-
provements within the model.  
Exit questions:  (1) Is there anything else you would like to say about the 
function of the model? 
The focus group is guided and monitored by a facilitator (RA2) trained in qualitative 
methods and guiding group discussions. The facilitator should facilitate group discus-
sion, keeping it focussed without leading it. The co-facilitator (RA1) digitally records 
the focus group. In addition to the digital recording, notes are taken to document the 
non-verbal interaction. The recording is transcribed verbatim. 
Patient is not part of the focus group because of the following aspects:  
– Emotional – for the care-dependent elderly patients an additional meeting for the 
focus group after the official hospital discharge represents an emotional burden; even 
if the focus group takes place at the end of the hospital stay, which is the earliest pos-
sible point for its execution, an emotional burden caused by the prolongation of the 
hospital stay of patients is hardly favourable; 
– UKA organisation – the focus group is not feasible during the time span when the 
intervention is provided and patients are hospitalised at the UKA, because of organisa-
tional issues of the daily health care routine and the additional intervention process. 
2.3   Data management  
Data collection  
With the signed informed consent, patients’ medical records are available for the pro-
ject research team. All data is primarily collected in the Case Report Forms (CRFs) in 
paper form as in the pilot study [51] and then inserted into an electronic database that 
bio-statistical group of PD Dr. Nicole Heussen (UKA) has prepared particularly for this 
project stage of process evaluation. During the study process, the bio-statistical UKA 
group performs quality checks for the entered data in the database.  
For the time being in the hospital, RA1 documents reasons for not participating in the 
study; and for participating patients demographic data such as age, gender; care and 
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living situation; weight and height; vital signs and laboratory values; functional status 
with the Vulnerable Elderly Survey [55]; cognitive status with Mini-Cog tool [56]; ADR 
risk factors such as comorbidity, number of drugs, liver disease, heart and renal fail-
ure, previous ADRs, with the GerontoNet ADR risk score [57]; reasons for admission; 
complete medication; ADR-suspicious symptoms and recommendation if needed 
(i.e. when the symptoms of ADR are present); PIM drugs from the PRISCUS list [58]; 
length of stay on the study department. RA1 treats all patients the same to assure reli-
ability and validity of patient data.  
Independently, SP has contact exclusively with the patients in the intervention group. 
For those patients, SP documents information about DRPs and PRs for DRPs; recom-
mendations regarding PIM; acceptance of PRs by the physicians; time needed for the 
pharmaceutical care service.  
RA2 digitally records patient interviews while RA1 records the focus group. 
During the follow-up period the RA1 tracks and updates the medication plan, vital 
signs and laboratory values, document information about hospital visits, readmissions 
and ADR-suspicious symptoms of all patients in the same and predefined manner 
(2.2.6 Follow up).  
Data monitoring 
While the study is ongoing, RA1 is the person on-site to monitor the patient safety. If 
any symptom of a serious or life threatening ADR occurs, RA1 discusses the case firstly 
within the research team on-site, and then as quickly as possible with an attending 
physician.  
Important step in the process of conducting the study is transcribing data from CRFs 
into electronic form. Double data entry will be applied. It is a widely used method 
consisting of two steps: an initial entry step and a verification step. An independent 
data-entry technician performs each step. Bio-statistical team of Ms Heussen supports 
the study at this stage, as they provide the electronic database too. 
2.3.1 Study instruments 
Vulnerably Elderly Survey (VES-13) [55] is an international function-based tool used 
to assess the risk of health deterioration of older adults by considering a number of 
factors including disabilities, age, self-reported health status and functional limita-
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tions. This assessment is a 4-question, 13-item simple function-based questionnaire 
that is used in the study’s geriatric assessment. Validity: The VES-13 correlates with 
the Comprehensive Geriatric Assessment (CGA) with a value of r = 0.4 and with the 
Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) with a 
value of r = 0.5, showing it as a valid tool [62]. Reliability: Internal consistency for the 
VES-13 in the same study by Luciani et al. (2001) found a Cronbach’s alpha of 0.9 
when compared against the CGA. Sensitivity was reported to be 87 % and a specificity 
of 62% versus CGA, and 90 % and 70 % versus ADL/IADL scales. This shows that the 
VES-13 is a highly sensitive and predictive instrument of functional vulnerability. 
Mini-Cog [56] is a brief, three-step cognitive screening instrument planned as a part of 
the geriatric assessment in the study. Validity: The Mini-Cog has proved to have a 
more superior discriminatory power (86.8 %) than either Clock Drawing Test (CDT) 
(72.6 %) or Mini-Mental State Examination (MMSE) (78.1 %) (p < 0.01 each) and had 
demonstrated to be the valid instrument to administer in the geriatric setting [63].  
GerontoNet ADR risk score [57] is a practical tool for identification of elderly patients 
who are at increased risk for an ADR and a target for interventions aimed at reducing 
ADRs. The tool is used in the study’s geriatric assessment. Validity: The area under 
the curve (AUC) showing an ability of the risk score to predict ADRs in the develop-
ment sample was 0.70 (95 % CI 0.63 – 0.78) [57]. 
PRISCUS list [58] represents a list of potentially inappropriate medications for elderly 
patients. The list is defined particularly for the German market.  
ID-Diacos® Pharma provides drug-interaction assessment as part of the local clinical 
decision support system (CDSS). Mediq® is a drug-interaction software for German 
speaking countries.  
APS-Doc® [64] is a classification system for DRPs in the hospital setting in Germany. 
Reliability: Inter-ratter reliability in the same study was found to be substantial in the 
main categories (k = 0.68, 95 % CI 0.66 – 0.69) and moderate in subcategories 
(k = 0.58, 95 % CI 0.58 – 0.59). The tool is used during MSR in the intervention 
group. 
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2.3.2 Outcome variables 
The following primary and secondary outcomes are defined as dependent variables for 
the quantitative analysis.  
The primary outcome: 
• Time to DRR during 12-month follow-up 
The secondary outcomes: 
• Number of DRRs during 12-month follow-up 
• Number of ADRs during the hospital stay and 12-month follow-up 
• Number of prescribed PIM drugs 
• Number and type of DRPs in the intervention group 
• Patient’s satisfaction (Likert-type scale [60] as part of the patients’ interview) 
The following information will be used for qualitative analysis: 
• Verbatim transcripts of patients’ interviews 
• Verbatim transcripts of the focus group 
2.3.3 Outcome assessment panel 
The ADR-suspicious symptoms and potential DRRs monitored for both patient groups 
are assessed further in an outcome assessment panel consisting of three external  
experts (outcome assessors). In the present study, ADR-suspicious symptoms were 
defined as symptoms occurring in plausible context of medication use including inher-
ent ADRs, medication errors and changes in laboratory data in a clinically relevant 
manner. DRR was defined as re-hospitalization of a discharged patient due to an ADR 
in any hospital [53].  
RA1 is responsible for organizing the panel. The research team and experts meet   
before the official start for an introduction of the outcome assessment procedure. The 
second meeting takes place after the data collection procedure is completed.  
The outcome assessors are blinded. The procedure is planned as a two-step evaluation 
with an aim to characterise ADRs in terms of causality, severity and preventability/ 
ameliorability. The panel assesses ADR-suspicious symptoms and readmissions and 
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makes a final judgement. That means the panel assess whether ADR-suspicious symp-
toms are in fact ADRs and whether potential DRR are truly drug-related. The outcome 
assessment procedure uses the tools proposed in the pilot study [51, 53]. The ADR-
suspicious symptoms are classified as ‘no ADR’, ‘potential ADR’ or ‘ADR’ according to 
Arimone et al. causality criteria [65]. The potential ADRs are further classified in seven 
causality levels: “ruled out”, “unlikely”, “doubtful”, “indeterminate”, “plausible”, “like-
ly”, “certain”. The causality levels “certain”, “likely” and “plausible” are regarded as 
ADR. The approach from Schumock and Thornton [66] is used for assessment of pre-
ventability and ameliorability of ADRs. The preventable and ameliorable are finally 
categorised according to their severity using an algorithm from the National Coordi-
nating Council for Medication Error Reporting and Prevention (NCC-MERP) [67]. The 
algorithm has eight categories: from “no harm” through three “error, no harm” and 
three “error, harm” to the most severe one “error, death”.  
2.3.4  Statistical analysis 
Statistical analysis is performed with support of the bio-statistical group of PD Dr. 
Nicole Heussen (UKA). The provided database uses pseudonymised data. RA1 is   
responsible for quantitative and RA2 for qualitative analysis.  
The primary outcome is analysed using the stratified (by department) log-rank test. 
Sensitivity analysis uses the Cox-model (stratified by department) to assess the influ-
ence of single or groups of covariates (age, sex, living situation, comorbidity, length of 
stay on the study department, number of PIM, number of changes in medication dur-
ing the follow-up, number of drugs during the stay on study department, GerontoNet 
ADR score, Vulnerable Elderly Survey score).  
The analysis of the secondary outcomes is descriptive and explorative. It uses regres-
sion techniques (linear models for continuous outcomes (score results), logistic     
regression for binary outcomes, and Poisson regression for count data). As explained 
before, ADRs are analysed in the blinded panel (2.3.3 Outcome assessment panel). 
The individual patient interviews and the focus group are digitally recorded and tran-
scribed verbatim. The verbatim transcripts are analysed according to the Mayring‘s 
“Qualitative content analysis” [68]. The software MAXQDA is used. Rigor in qualita-
tive analysis of the focus group and individual interviews is assured with multiple 
coding - two individual coding. Analyses are discussed and discrepancies are solved. In 
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case two researchers do not find an agreement, a third researcher should be added. In 
a structured discussion, hearing pros and cons of the two researchers, should assist in 
finding a final agreement. Moreover, another two independent individuals code 20 % 
of the transcripts additionally as a peer review.  
2.4  Ethics and dissemination 
Data protection: access to data and confidentiality  
Participants’ right to confidentiality is fully respected. The members of the project 
research team at the UKA have access to health and personal information of partici-
pants if and only if their informed consent is obtained. Participant files are stored in a 
secure and accessible place and manner. Participant names are stored separately and 
only members of the project research team at the UKA have access to identity codes. 
Patient names are omitted during the transcribing process (from CRFs) when inserted 
in the database. Local data entry enables fast correction of missing or inaccurate data. 
The data in the database is pseudonymised.  
For qualitative analysis: when transcribing the recordings of patients’ interviews and 
focus group personal data, e.g., names, are replaced with placeholders. After having 
checked the accuracy of the transcripts, the recordings are deleted.  
Research results are available for public dissemination. The publication is with anon-
ymous patient data only, where no patient data allows backtracking of patient’s per-
sonal information. 
Research Ethics approval 
The proposed project follows the Declaration of Helsinki (2013). Despite the randomi-
sation in the project, every patient receives the current standard of care treatment. The 
participation in the project is voluntary and only patients who have agreed on the 
informed consent and data processing are included in the project.  
The local Ethics Committee is consulted throughout the project conduction. The Clini-
cal Research Ethics Committee of the UKA formally reviewed and approved the project 
at the stage of the development and piloting (Internal file reference EK 195/11). The 
study protocol of the evaluation phase has not yet been submitted.  
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2.5   Discussion 
Good cooperation between different professions is the core value in provision of health 
care. The goal of all health care providers is to maximize the quality of healthcare  
delivery and to minimise the treatment-associated risk as much as possible. Multi-
professional care models have a great potential to enhance patient and medication 
safety. Some trends of improvement were observed in previous investigation of models 
of this kind [40-45], highlighting the important role of communication and inter-
professional interaction. The present longitudinal evaluation study of multi-
professional medication safety model should provide important insights into effective-
ness of such a model and why it is effective. 
Although, it was not planed to record any economic endpoint, the importance of re-
duction of drug-related readmission (primary endpoint) could be illustrated from the 
previous work on the model. Even though in the previous work the number of cases is 
low, there was a difference in duration of DRRs. The average duration of all DRRs was 
19.8 days and an average duration of DRRs caused by preventable/ameliorable ADR 
was 13.4 days. Further, there was a tendency to prolong time to DRRs, especially early 
DRRs up to 10th week after the hospital discharge. [51] That demonstrates an enor-
mous economic benefit should the developed model be implemented in the routine 
care. The suggested reduction of early DRRs is of long-term economic interest not only 
for the health-care system, but also for the hospitals in time of DRG-based reim-
bursement system. The discharging hospital is strained by early DRRs. The present 
model could lessen the burden. This proposal is complemented with the analysis by 
Rottenkolber et al. Analysing ADRs in patients of all ages on the internal medical 
ward, they showed that the average treatment costs of a single ADR were € 2250. Con-
sidering the proportion of 20 % of preventable cases, this equals a saving potential of 
€ 87 million per year [36]. 
Limitations 
The Hawthorne effect could have influenced the behaviour of physicians, nurses,  
patients and relatives. Care providers in our model are not blinded, which may en-
courage some of them to more attentive care in both patient groups and cause perfor-
mance bias. No specific nurse or physician is trained. Instead the training takes place 
for the whole medical department. Given the high frequency of physician rounds, 
differences in provided health care are to be expected in every day routine work.  
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However, that should not influence the study procedure. Our trained research team 
(for this task RA1) documents outcome measures for both patient groups. RA1 treats 
patients equally, independently from the group patient has been allocated to. Finally, 
blinded outcome assessment panel assesses outcome measures and makes the final 
decisions about the primary and some of the secondary outcome measures. The two 
strategies should assure the objectivity of the study. 
The follow-up interviews are not blinded and a detection bias may influence the re-
sults. A recall bias may be induced in the long follow-up, as patients or contact persons 
might not remember less severe events that happened long ago [53]. However, stand-
ardized questions are used in the follow-up interviews to control the potential bias.  
UKA has not yet fully integrated CDSS in the routine work. That limits the generalisa-
bility of the model in the hospitals with different structures (e.g. with CDSS). Alt-
hough, this assumption is arguable, the study does not provide mere comparison of 
the hospital’s logistic and structural issues. Even though some local adjustment of the 
external application of our model might be needed, the study generates an in-depth 
insight of inter-professional issues providing how effective and fruitful communication 
and collaboration work. This embedded qualitative evaluation encourages transporta-
bility of the model.  
Strengths and transportability of the model 
The study is designed as a RCT with a long follow-up of 12 months underlining the 
need of high-quality and long follow-up trials, as stated in a Cochrane Review [45]. 
Parallel-group design is preferred to minimize possible time-dependent bias [53]. The 
equality of observation for both treatment groups is ensured through independent 
work of the SP and the RA1/RA2.  
Our multi-professional model may serve as a convenient example for further research 
and implementation of multi-professional hospital care models in daily routine. After 
project completion study material will be available for the public. Particularly im-
portant are: The SOP with tasks for each model associate, the detailed guideline for the 
comprehensive MSR and CRFs (Attachments Model I: SOP for medication safety). On 
that basis it will be possible for other researchers to develop a comparable model in 
their local setting and structure trainings for model associates.  
The qualitative output of the intervention is of great benefit not only for the local  
hospital rather for general improvements of the multi-professional teams, and patient 
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and medication safety. The qualitative output will answer: how to communicate with 
different professionals and how to communicate with a patient; where are potential 
stumbling stones – is that maybe hierarchy or time pressure; how would certain care 
providers prefer to interact with their colleagues; what kind of working environment 
has been developed so far; has culture of blame been broken down and how good is 
safety culture implemented; how do care providers think safety culture and patient 
safety may be improved? Those questions represent the general health care and    
multi-professional issues. They are going to be answered with the qualitative analysis 
and as a result, they are transportable in every other health care team. Interaction 
among different professionals has a general understanding. However, each local team 
should then adjust individually on account of logistic issues of their local setting.  
Finally, wider generalisation of our model should support further multicentre evalua-
tion and implementation of the multi-professional model. That is the most appropriate 
next step according to the MRC guidelines for evaluating complex interventions 
[37, 39]. This project outlines how to maximize effectiveness of health care and en-
hance patient and medication safety by reducing DRR. Thereby, it provides a starting 
point for the model conceptualisation. 
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3  Model II  
Development of a prediction model to estimate  
the risk of drug-related problems on the oncology ward 
– pilot study 
3.1   Introduction 
Cancer in Germany 
Cancer is the second most common cause of death in Germany after cardiovascular 
diseases [69]. Every year there are approximately 480,000 people diagnosed with 
cancer. Between 2002 and 2012, the absolute number of newly diagnosed cancer cases 
has increased by 13 % in men and 10 % in women. The 5-year prevalence in 2012 was 
810,300 for men and 790,500 for women. According to the current state, every second 
man (51 %) and 43 % of all women develop cancer in the course of life. A further   
increase of incidence rate of about 20 % is expected by 2030 [70]. The estimate in the 
US even suggests a 45 % increase in cancer incidence by 2030 [71]. This is mainly due 
to the demographic change in population and improved early detection [70]. Despite 
increasing rate of disease in younger people, cancer remains a disease of age. The 
frequency increases sharply beyond the age of about 60 years. The median age of the 
disease is 69 years [69, 70]. But, the mortality rate of cancer patients has been contin-
uously declining for several years. This is due to intensive research and development 
in the field of oncology and rising rate of available and effective antineoplastic drugs. 
Overall, the total number of cancer patients continues to rise steadily. The 5-year  
survival rate in 2011-2012 was 62 % for men and 67 % for women [70]. Therefore, it is 
to expect a growing number of cancer patients over 60 years that have to be treated 
over an increasingly longer period of time. 
Complexity of cancer treatment  
Cancer treatment has a special role in medication safety [72]. Cancer therapeutic area 
represents one of the most intensively researched areas. The market of available active 
ingredients is constantly growing. In 2016, the European Medicines Agency, EMA, 
approved 13 drugs for the treatment of solid tumours and haematological disorders, 
just slightly down from 16 novel oncology products approved in the year before. These 
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included immunotherapies, small molecules and even more traditional chemotherapy-
based products. In the same year (2016), 18 already approved products received a 
positive evaluation, extending their indication or gaining approval for a new indication 
[73]. The complexity of therapies increases by the same degree but with simultaneous 
loss of clarity and comprehensibility.  
Depending on underlying tumour, cytostatics with different mechanisms of action are 
usually used in combinations in order to increase the effect without increasing toxicity 
and to avoid occurrence of resistance [74]. This leads to a very complex therapy regi-
men with several different drugs that are administered simultaneously or sequentially 
and cyclically, intravenously or perorally for several weeks or months.  
For example, the most widely used treatment for diffuse large B-cell lymphoma 
(DLBCL) is a combination of chemotherapy and monoclonal antibody rituximab. The 
treatment is called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, 
and prednisone) and it is usually given in 21-day cycles. In some cases another chemo-
therapy drug, etoposide, is added to the regimen, resulting in a drug combination 
called R-EPOCH. To treat patients with DLBCL whose disease is refractory or relapsed 
following the initial chemotherapy, high-dose chemotherapy coupled with hematopoi-
etic stem cell transplantation (HSCT) is used [75]. 
The cytotoxic effect of most antitumoural drugs is not limited to the degeneration of 
tumour cells. It attacks every proliferating tissue in the body leading to a high toxicity 
[74]. Even if used as intended, it may cause a large number of ADRs that are partly 
dose-dependent or lead to treatment discontinuation. Some example are: a bone mar-
row apoplasty with the corresponding effects on the blood counts, such as neutropenia 
and anaemia, inflammation and ulcers of oral and gastric mucosa (mucositis, stoma-
titis) and alopecia. In addition, renal and hepatic impairment, severe nausea and vom-
iting, constipation or diarrhoea, fatigue, and other substance-specific ADRs such as 
neuropathy or ototoxicity may occur [74, 76]. Toxicity is less predictable in elderly 
patients, as a decline in organ function in some elderly can alter pharmacokinetics of 
many commonly used chemotherapeutic agents [77]. In spite of above-mentioned 
toxic properties of cytostatics, to assure acceptable quality of life compatible support-
ive measures are included in cancer treatment. These measures include i.a. supportive 
therapy with antiemetic substances such as 5-HT3 receptor antagonists, steroids and 
neurokinin-1 receptor antagonists during and after chemotherapy, the administration 
of colony-stimulating factors in neutropenia, the administration of allopurinol to avoid 
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urate nephropathy and administration of MESNA for the prevention of urotoxicity of 
cyclophosphamide. The adequate therapy of pain and the prevention and therapy of 
mucositis belong to the supportive therapy in cancer patients, too [75, 78, 79]. 
As mentioned before, the average age when the cancer disease is diagnosed for the first 
time is 69 years. Because of this relatively high age, at the beginning of therapy many 
patients suffer from other chronic diseases, called comorbidity. A cross-sectional study 
on prevalence of comorbidity in cancer patients with lung, prostate, breast or colon 
cancer showed that more than 80 % of 301 cancer patients included had at least one 
other disease. These were mainly cardiovascular and pulmonary diseases. The most 
common diseases were hypertension, arthritis, coronary heart disease (CHD) and 
diabetes mellitus [80]. The frequent occurrence of other diseases causes chronic use of 
other drugs. This phenomenon is called polypharmacy. On average, patients take five 
to nine drugs prescribed by physician before chemotherapy begins [81]. These are 
primarily antihypertensives, drugs for reducing plasma lipids and anticoagulants [82]. 
The drug therapy of comorbidity, complex chemotherapy, and supportive therapy 
together provide a variety of drugs that must be administered or taken regularly by 
cancer patients [81, 83]. In addition, it has been assessed that up to 35 % of patients 
use complementary oncological therapies. This includes a treatment supplementary to 
standard therapy, for example food supplements [84]. 
As organ performance diminishes with age, a further consequence of high age of can-
cer patients is a relatively large proportion of patients with impaired renal or hepatic 
function. A cohort study from France with over 4600 patients reported that over 16 % 
of cancer patients had a creatinine clearance less than 60 ml/min according to     
Cockcroft-Gault equation [85]. Older studies report a proportion of up to 33 % of can-
cer patients with a creatinine clearance below 80 ml/min [86]. Disregarding existing 
renal or hepatic impairment may lead to overdose and severe toxic effects of chemo-
therapy. 
Increased risk of drug-related problems 
Given above-mentioned points, it could be said that the number of cancer patients is 
rising. There are mainly elderly cancer patients. Over an increasingly extended period 
of time, these patients often need to take a variety of drugs with complex therapy reg-
imens and partial serious toxic effects. In addition, these patients have a considerable 
proportion of organ function limitations. The risk of drug-related problems and    
medication errors is therefore particularly high in drug-related cancer therapy [72]. 
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Results of a retrospective American study in the oncological-ambulatory area showed 
that medication errors occur at approximately 8 % of hospital visits, of which approx-
imately 57 % had potential to cause harm [87]. After the group of psychoactive and 
analgesic drugs, cytotoxic drugs are the second most common cause of fatal medica-
tion errors [88]. In addition to adverse drug effects and incorrect dosing, drug interac-
tions occur quite frequently resulting in excessive toxicity or reduced efficacy of 
tumour drug therapy. Interactions between drugs of chemotherapy and supportive 
therapy, therapy of companion disease and complementary therapies play a role, as 
well as interactions between medicines and additionally used food supplements or 
diets. It is particularly important to recognize this increasingly common problem in 
medical practice to avoid potentially hazardous effects. [72, 89-94] 
Concepts to reduce risks in cancer drug therapy  
In 2008 the German Ministry of Health (BMG) initiated the National Cancer Plan. 
Thereby, the BMG together with the German Cancer Society6 (DKG), the German 
Cancer Aid7 (DKH) and the Working Group of German Tumour Centres8 (ADT), began 
a goal-oriented approach to improve the health-care situation for cancer patients in 
Germany. Certain fields of action were defined where an urgent action was needed, 
such as further development of oncological care structures and quality assurance. This 
includes, for example, improving the interdisciplinary cooperation and networking 
within oncological care to ensure cross-sectoral, integrated oncological care. Further 
defined field of action is strengthening patient orientation in therapy decision-making 
process by i.a. strengthening patient competency [95]. 
For this purpose, the establishment of multi-professional centres for cancer treatment, 
so-called “Comprehensive Cancer Centre” was launched. The development began with 
certification and support of top oncological centres by DKH. These centres provide i.a. 
an interdisciplinary cancer treatment for all types of cancer, interdisciplinary tumour 
boards and cancer-specific treatment pathways in form of guidelines [96]. Further, the 
DKG has certified specialised cancer centres in Germany. The certification criteria is 
very similar and involves an establishment of a quality management system [97]. The 
aim of these concepts is to promote standardisation of patient treatment. 
                                                   
6 German: Deutsche Krebsgesellschaft, DKG 
7 German: Deutsche Krebshilfe, DKH 
8 German: Arbeitsgemeinschaft Deutscher Tumorzentren, ADT 
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Medication management and pharmaceutical care 
Medication management where a pharmacist has an active role was seen in the field of 
oncology as well. On the oncological ward of Swedish university hospital, pharmacist's 
participation in morning rounds, medication checks and patient interviews resulted in 
detection of 114 DRPs in 58 patients, and drug therapy was subsequently optimised. 
The pharmacist’s contribution was recognised and welcomed by participating physi-
cians and nurses [98]. In Germany, several studies from Bonn were able to show the 
value of pharmacist's involvement in medication management. Intensified pharma-
ceutical care of cancer patients could improve adherence and persistence of the pa-
tients treated with peroral capecitabine [99, 100]. Often the therapy-limiting side 
effect of capecitabine is hand-foot syndrome (HFS). In addition to the adherence man-
agement, the patients were informed in writing and in oral form about their therapy 
and possible side effects, especially the HFS, and trained to take certain prophylactic 
and therapeutic measures. Although available recommendations were empirical only, 
intensive education and monitoring of patients in terms of HFS showed signs of a 
positive impact on the severity of HFS [101]. In the following study, influence of inten-
sified care was investigated, including drug management on onset of nausea and vom-
iting under chemotherapy in patients with breast or ovarian carcinoma. Participating 
pharmacist trained study patients for prophylactic and therapeutic measures regard-
ing the occurrence of nausea and vomiting during chemotherapy. Trainings were con-
sistently repeated during the time of chemotherapy treatment. In addition, pharmacist 
carried out on a regular basis a review of medication on interactions, and an optimisa-
tion of antiemetic supportive therapy. The result was significant reduction in incidence 
of vomiting in the intervention group, i.e. significantly increased response to antiemet-
ic prophylaxis [48]. Results showed that additional and intensified patient care pro-
vided by pharmacists in the context of medication management, could positively 
influence clinical endpoints, such as the occurrence of ADRs. Generally speaking, 
pharmaceutical care of oncologic patients during the medication management can 
identify and reduce medication errors and DRPs. These include, further, the avoidance 
of interactions, the reduction of ADRs and the increase in adherence [72]. Tasks and 
services performed within oncological and pharmaceutical care vary dramatically, 
ranging from medication history and optimisation of supportive therapy to develop-
ment of therapeutic guidelines and optimal use of economic resources [102, 103]. For 
an effective implementation of pharmaceutical care in oncology, it is necessary to 
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provide a competence in the field of drug discovery, monitoring and patient counsel-
ling as well as an adequate training [104]. 
Assessment of risk for drug-related problems 
During recent years, attempts were made to determine the risk factors for occurrence 
of DRPs. Risk factors are also referred to as predictors, covariates, risk indicators, 
prognostic factors, determinants, test results, or—more statistically—independent 
variables [105, 106]. According to a systematic review from 2016, ten most frequently 
reported risk factors associated with medication-related issues that may potentially 
lead to a hospital PI are as follows (ranked in descending order of frequency): pre-
scription of certain drugs or classes of drugs, polypharmacy, elderly patients, female 
gender, poor renal function, presence of multiple comorbidities, length of patient stay, 
history of drug allergy or sensitivity, patient compliance issues, and poor liver func-
tion. These risk factors may be used to identify patients at risk, with a perspective of 
targeting PI in order to minimise risks concerning medicines and improve efficiency of 
pharmaceutical care service [107].  
The following idea was to develop a tool for a fast and reliable identification of patients 
with present risk factors to direct pharmaceutical care approach at the patients at risk 
and thereby increase service efficiency and save resources. Different tools are available 
in the literature. Canadian researchers were pioneers developing self-administered 
questionnaires to identify patients at risk for medication-related problems in primary 
care [108-110] followed by the Australian [111] and US researchers [112, 113]. The team 
from Switzerland proved feasibility and acceptability of the developed tool: Drug Asso-
ciated Risk Tool (DART). The DART is based on a combination of a systematic litera-
ture search, with the professional experience, and knowledge of a multidisciplinary 
expert panel. That enabled comprehensive finding of risk factors for DRPs represent-
ing real-life situation in the Swiss healthcare setting. The self-assessment question-
naire asks about patient’s health, inquiring thereby about comorbidities such as 
renal/hepatic/cardiac disease, about certain medication and general about the medi-
cation use habit, compliance and tolerability. Although, it is a resource-saving tool 
with direct patient involvement, it has a limited validity. The tool limitations show the 
need for statements rephrasing in the questionnaire, validation in a more specific 
patient population and development of a scoring system [114]. 
In another hospital in Switzerland, clinical pharmacists performed efficient and rapid 
electronic screening of 500 patients to identify patients at risk of DRPs in preparation 
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for the ward round. The queries aimed at identifying patients receiving drugs such as 
cytochrome P450 inducers/inhibitors, those with renal impairment, those on digoxin 
with low serum potassium, those with intravenous anti-infectives and elderly patients 
with polypharmacy. The screening helped clinical pharmacist to prioritise their medi-
cation reviews and to optimise their workload and team’s contribution. However, no 
external validation of the tool has been reported [115]. Finally, a Spanish research 
team, Urbina et al., designed and validated the first predictive score to detect DRP in 
hospitalised adults. The score has a scoring system and it is applicable in daily clinical 
practice. It contains following parameters: age > 60 years, Charlson index = 2,     
Number of drugs during hospitalisation >10 and certain major diagnostic categories. 
This strategy has contributed to optimisation of resources for drug treatment monitor-
ing of general inpatient population in Spain [116].  
However, all available tools refer to general inpatient population. To the best of our 
knowledge, no multivariable predictive model has been developed to estimate the risk 
of DRPs during the stay on the oncology ward. The multivariable predictive model 
(also commonly called “prognostic model” or “risk score” [105, 106]) may aid health 
care providers in their decision-making. Moreover, communication failures and 
knowledge gaps as shown in the literature underpin factors for the DRP occurrence. It 
is recommended that the DRP risk assessment is not performed separately, but rather 
accompanied by team optimisation [117].  
Multi-professional teams 
Given the complexity of modern drug therapy, an effective patient care is solely possi-
ble in a multi-professional cooperation [21, 118, 119]. Development and improvement 
of multi-professional cooperation is one of the objectives of current AMTS action plan 
of the BMG and the National Cancer Plan [22, 95]. Multi-professional teams include 
all professions involved in the medication process. In the hospital settings, these in-
clude physicians, pharmacists and nurses. Possible further cooperation partners in the 
field of oncology are nutritionists and psycho-oncologists. The structure of the team 
can vary depending on the setting, patient’s needs and other resources. It is vital that a 
patient is seen and included as an indistinguishable member of the team [21]. Besides 
the common goal and mutual trust, clear distribution of roles and allocation of func-
tions and responsibilities as well as effective communication, provide the basis of 
patient care in teams. Moreover, regular measurement of endpoints should be used to 
determine success of the multi-professional care [119]. 
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Establishment of multi-professional treatment teams worldwide is a crucial compo-
nent to ensure high-quality cancer patient care. For example, the American Society for 
Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) are 
calling for multidisciplinary cancer care. They have stated that optimal treatment of 
cancer should be provided by a team that includes, where appropriate, multidiscipli-
nary medical expertise composed of medical oncologists, surgical oncologists, radia-
tion oncologists, oncology pharmacists and palliative care experts, as well as oncology 
nurses and social workers. In this joint consensus statement about the quality of can-
cer treatment, it is stated that patients should also have access to counselling for their 
psychosocial, nutritional, and other needs [120].  
A study, initiated within the clinical pharmacy group of the University of Bonn and 
conducted with collaborators on the national level, aimed at defining task allocation 
and responsibilities in a multi-professional cancer medication management. Using 
focus group meetings and the Delphi technique, tasks were identified and allocated to 
physicians, pharmacists and nurses. Members of the German Cancer Society assessed 
the acceptance of the proposed task allocation and perceptions on multi-professional 
teamwork. Total of 38 tasks were identified and allocated. Tasks allocated to a phar-
macist were prevention of drug-related problems, and patient education and counsel-
ling for prophylaxis, therapy of ADRs as well as for dietary supplements and nutrition. 
Further tasks were encouraging adherence, preforming a drug interaction check, dose 
adjustment, adaptation of supportive therapy and conduction of drug history [121].  
The existing scientific evidence shows benefits of multi-professional cancer teams 
when the pharmacist is included. However, the critical step towards the optimisation 
of treatment and quality of patient care is to transfer this evidence, guidelines and 
political demands into everyday practice [122, 123]. To ensure this, it has been sug-
gested to start with optimisation of patient care and treatment process from the pa-
tient's point of view. That means evidence-based decision-making and improved 
communication between team participants, where patient is in the centre of attention. 
That is followed by the improvement of workflows in terms of communication and 
consultation, continuous review and enhancement of the process, primarily from the 
patient's point of view [123]. 
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Patient-Reported Outcomes version of the Common Terminology Criteria 
for Adverse Events (PRO-CTCAETM) 
An essential aspect in cancer clinical trials and oncology routine care is monitoring 
and documentation of toxicity and adverse events (AEs) to ensure patient safety and to 
provide safety data on medicinal products. With the complexity of cancer treatments, 
methods of AE reporting in clinical trials have evolved. AEs are usually reported using 
standard instruments such as the United States National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) or the Medical Dictionary 
for Regulatory Activities (MedDRA) [124, 125]. For systematically grading and report-
ing treatment-related toxicity in cancer clinical trials, CTCAE is the predominant sys-
tem [126]. The latest version 4.03 of the CTCAE released by the NCI contains 790 
items including laboratory tests, clinical events, and symptom evaluation [127, 128]. It 
represents a long-standing, empirically developed, comprehensive lexicon of symp-
toms often found in oncology [125]. It has been developed to facilitate recognition, 
assessment and documentation of AEs by clinical investigators [126]. The contribution 
is seen in standardisation and comparability of published study results. However, an 
underestimation of AE severity by healthcare professionals has been repeatedly 
demonstrated [129-132]. Interest to incorporate patient’s perspective is thereby greatly 
expanding [124, 126, 133, 134]. Moreover, the empiric evidence showed that collection 
of this information directly from patients improves precision and reliability of symp-
tomatic AE detection in trials [124, 129, 130, 132]. This type of self-assessment is  
referred to as “Patient-Reported Outcome (PRO)”. According to the US FDA, PRO 
represent all reports on status of patient’s health condition that comes directly from 
the patient, without interpretation of patient’s responses by a clinician or anyone else 
[135]. Covering different aspects of AE reports, clinician-reported and patient-
reported approaches are complementary [124, 127]. 
In closely related areas, such as evaluation of health-related quality of life, satisfaction 
with treatment and drug adherence, PRO has long been the gold standard in data 
collection [124, 136-138]. The FDA has therefore published a guide for industry to 
establish PRO as a standard for the collection of symptoms as endpoints [135]. Feasi-
bility of symptom evaluation by patients has been confirmed several times, even with 
patients in the terminal phase of illness and with a high symptom burden [139-141]. 
To improve precision and patient-centeredness in capturing the symptomatic AEs, the 
NCI developed a library of PRO items to supplement the CTCAE, called the             
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Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse 
Events (PRO-CTCAETM) as it has been previously described [125, 142]. Of the 790 AEs 
in the CTCAE, 78 were identified as amenable to patient self-report. For each of these 
AEs, PRO items were created reflecting attributes of frequency, severity and interfer-
ence with usual daily activities. One to three attributes were selected for any given AE 
depending on the content of the CTCAE criteria for that AE and the nature of that 
particular AE. In total, 124 individual items represent 78 symptomatic AEs currently 
in the PRO-CTCAE item library [143]. In order to transfer corresponding CTCAE 
symptoms into a patient-friendly version, medical terminology was removed and dif-
ferent educational levels of the patients were observed. Afterwards, items were opti-
mised in a multicentre study with cognitive interviews to ensure item clarity, 
comprehension, and ease of response judgment in different patient populations [144]. 
English items were subsequently evaluated using both qualitative and quantitative 
techniques, and have demonstrated favourable measurement properties in terms of 
validity, reliability, and responsiveness [145]. To make PRO-CTCAE item questions 
available to scientists, physicians and patients worldwide, English items are gradually 
being translated into different languages. At present, certified translation is available 
in Danish, German, Italian, Japanese, Korean and Spanish. A Chinese, Czech, Dutch-
Flemish, French, Greek, Hungarian, Polish, Portuguese, Russian and Swedish version 
are under development and are being tested [143].  
A Swiss working group from Basel has translated English items into German language 
and linguistically validated in a sample of patients undergoing haematopoietic stem 
cell transplantation [146]. A German working group from Bonn went a step further. Of 
124 items contained in the PRO-CTCAE German language item library, 31 were select-
ed for validation and defined as a “core item set” [147]. Selected items reflect 14 symp-
tomatic toxicities and were chosen on basis of their prevalence across cancer treatment 
types and disease sites [145, 148] and based on expert consultation [147]. The working 
group from Bonn showed first quantitative evidence of a subset of the PRO-CTCAE 
item library in German language. The core item set met accepted criteria with respect 
to item quality, reliability, and validity for use as a patient-reported measure of symp-
tomatic toxicity in cancer clinical trials [147]. 
Model II 
 44 
3.1.1  Study background 
Back in 2014 in the University Hospital RWTH Aachen (UKA) in Germany, hospital 
pharmacy and department of haematology, oncology, hemostaseology and stem cell 
transplantation extended their cooperation from routine work into joint research. 
With an overall goal to optimise treatment and quality of patient care, a multi-
professional team decided to tackle an issue of drug-drug interactions (DDIs) [149] - 
one of the most prominent issues among oncological patients where the role of phar-
macist in other hospitals has shown to be beneficial [72, 89-94]. The research team at 
that time, aimed to assess number of clinically relevant DDIs in cancer patients on the 
local oncology ward by two independent clinical pharmacists. Over a period of seven 
weeks, 78 patient medical records were prospectively evaluated. DDIs were identified 
in Mediq® interaction software. As shown in the Table 3.1, clinical pharmacists and 
oncologists agreed which symptoms were clinically relevant to be reported (stated in 
the table as considered “X”) and which were redundant being regularly controlled and 
adjusted on the oncology ward (stated in the table as not considered ”─”).  
Mediq® interaction software alone reported a large amount of information not equally 
relevant to the daily clinical practice. The software evaluation provided 1180 of 
all DDIs, 15 DDIs per patient. Considering the physician-pharmacist agreement    
(Table 3.1), two clinical pharmacists assessed 456 DDIs (6 DDIs/patient) as clinically 
relevant. Selected DDIs with appropriate recommendations on each interaction, were 
fully accepted on the oncology ward and represented a useful supporting tool in the 
oncological routine practice [149].  
Next step toward the overall goal was to establish an effective pharmaceutical care on 
the oncology ward as integrated part of the effective multi-professional ward-based 
team. These needs were recognised and the present pilot (feasibility) study was     
accordingly designed. 
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Table 3.1: Clinically relevant DDIs [149] 
DDI effect Clinical relevance* 
Blood counts X 
Neurological function X 
Renal function X 
Skin reactions X 
Prolongation of the QT interval X 
Therapeutic drug level X 
Blood pressure ─ 
Blood sugar level ─ 
Electrolyte level ─ 
Legend: DDI effect: effect cased by drug-drug interaction; Clinical relevance*: clinical relevance 
according to agreement between clinical pharmacist and oncologists in the local setting, X : consid-
ered effect, ─ : not considered effect, regularly controlled and adjusted on the oncology ward 
 
3.1.2 Objectives 
In this feasibility study the aim was to develop multivariable prognostic predic-
tive model to estimate the probability of DRPs (primary outcome) during the 
stay on the oncology ward. 
In order to optimise pharmaceutical care service at the UKA oncology ward, following 
scientific objectives (secondary outcomes) were defined: 
1. To assess number and type of DRPs leading to a PI; 
2. To evaluate type of PIs provided and determine the implementation rate; 
3. To assess PRO-CTCAE symptom burden. 
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3.2  Methods  
3.2.1 Study design 
The study was conducted as a prospective cohort. It was an open cohort as study pa-
tients entered and left the study at different time points. For the report of the cohort, 
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) 
statement was used [150, 151]. Further, this was a feasibility study aiming to uncover 
strengths and weaknesses of the pharmaceutical care service provided on oncology 
ward. Prospect of future successful multi-professional cancer ward team should have 
been proposed. The primary outcome, a multivariable predictive model to estimate the 
probability of DRPs during the stay on the oncology ward, was reported according to 
the TRIPOD (Transparent Reporting of a multivariable prediction model for Individu-
al Prognosis or Diagnosis) statement [105, 106]. 
The study was not a subject of German drug law9 as individual drug therapies were not 
tested for efficacy and safety. Patients were treated with drugs approved to be on the 
market. Pharmaceutical team examined optimality of existing patient drug therapy. 
There were no changes to legal situation in regard to legal responsibilities. According 
to the German medical prescription regulation10, medical staff continued to provide 
medical prescriptions [152]. Pharmaceutical care service offered by pharmacists was 
provided under section § 20 of Pharmacies' Operating Regulations11. According to 
these regulations, pharmacists are obliged to provide information and advice to pa-
tients, nurses and physicians about drug therapy, in particular regarding aspects of 
drug safety. This means pharmaceutical care is one of statutory pharmacist tasks. 
Although pharmacists advised attending physicians about drug therapy, physicians’ 
decision about the patient drug therapy was not a subject of any restriction at any 
moment. PRs are based on published findings. Information on drug therapies is, 
therefore, concisely provided knowledge within the scope of patient drug therapy.  
                                                   
9 German: das Arzneimittelgesetz 
10 German: die Arzneimittelverschreibungsverordnung (AMVV);  
§§1-2 Regulation on Drug Prescription from December 21st 2005, amended by Article 1 
of the Regulation from December 19th 2014  
11 German: die Apothekenbetriebsordnung (ApBetrO) 
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3.2.2  Setting 
The study was conducted at the UKA. Cooperating partners in the hospital were the 
hospital pharmacy research group and the department of haematology, oncology, 
hemostaseology and stem cell transplantation (Internal medicine IV “IM42”). The 
department includes two wards: haematology-haemostasis and oncology ward and 
allogeneic stem transplantation ward. Additionally, there is an interdisciplinary tu-
mour ambulatory service. The study was solely conducted on the haematology-
haemostasis and oncology ward, hereinafter referred to as study ward.  
On the study ward, every attending physician and nurse was part of the study, herein-
after referred to as medical (ward) team. The routine work on study ward was undis-
turbed. Pharmaceutical team providing intervention on the study ward consisted of a 
research pharmacist (author of this work) and an oncology pharmacist (from the on-
cology department of UKA hospital pharmacy).  
3.2.3 Data management 
Data collection  
Electronic and paper patients’ records were available to the pharmaceutical team. 
Paper patients’ records stayed during the entire study procedure on the study ward. 
Research pharmacist collected anonymous data in paper form in study case report 
forms (CRF).  
Anonymously collected data included: medication history data on admission, oncolog-
ical and general demographic patient characteristics (CRF 1 Arznemittelanamnese), 
data for ADR risk score (CRF 0.1 The GerOnto ADR risk score) and answers on PRO-
CTCAE survey (CRF 0.2 PRO-CTCAE). For each patient, relevant data for MSR was 
recorded, for example: laboratory parameters, vital signs, drug indication, and therapy 
plan (CRF 1 Arznemittelanamnese). Patient medication list (CRF 2 Stationäre Medi-
kation) was updated daily during the stay on ward. The outcome of the MSR was pre-
sented in CRFs for DRPs (CRF 3 Datenerfassung Arzneimittelbezogene Probleme, and 
CRF 5 Empfehlungen aus der Medikationscheck). Besides, time exposure was tracked 
i.e. the time invested in patient recruitment, documentation and complete pharmaceu-
tical care (CRF 4 Zeiterfassung für die Intervention). CRF templates are presented in 
Attachments Model II, Model II CFRs. 
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Data protection 
Each study associate fully respected patients’ right to confidentiality. Personal patient 
name was used during the stay on ward and continuous provision of pharmaceutical 
care. Research pharmacist had a patient list with patient number, name and date of 
birth used solely during the study time (CRF 0 Patientennummer in Attachments 
Model II/Model II CFRs). Once the data collection was completed, patient list was 
deleted and merely anonymous data was used for data analysis. Research results are 
available for public dissemination. The publication is going to be with anonymous 
patient data where it is not possible to track patient related data back to its origin in 
patient records.  
The study follows the Declaration of Helsinki (2013) [153]. Current standard of care 
was provided to every patient. The study ward director signed the agreement confirm-
ing collaboration in the present study (Approval from the study ward in Attachments 
Model II). Within the study framework, pharmaceutical team provided drug therapy 
advice to the medical ward team and to patients. Pursuant to § 20 German Pharmacy 
work regulations (ApBetrO) that also applies to hospital pharmacists according to §1 
ApBetrO, indicates that a pharmacist is obliged to provide information and advice on 
drugs. Planned pharmaceutical care was therefore an activity that belongs to the legal 
areas of a pharmacist's legal duties and no informed consent from patients was need-
ed. The local Ethics Committee at the UKA was consulted throughout the project con-
duction, and formally reviewed and approved the study (Internal file reference EK 
142/16, Ethic Committee opinion in Attachments Model II).  
Data analysis 
To perform a statistical data analysis and graphical data presentation, software     
Microsoft Excel® 2011 and IBM SPSS Statistics® 24 were used. Paper-based collected 
data was transferred into electronic data. Thereby a codebook was prepared defining 
and labelling each of the variables. For categorical data, numbers were assigned to 
each of the possible responses. Before starting an analysis, datasets were checked for 
errors [154]. The errors were found and corrected in the data file. 
The collected data were investigated descriptively and explorative. The frequencies 
were calculated absolutely and relatively. Mean, median, standard deviation, range 
and interquartile range were included in data characterisation.  
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Descriptive statistics was used to describe the cohort (variable such as “ age” “gender”, 
“number of drugs”, “body mass index”), oncology patient specific characteristics (such 
as “cancer type”, “therapy regimen”, “ECOG performance status", “CTx complexity”) 
cohort subgroups, DDIs, variables of ADR risk score and the score itself.  
3.2.4 Participants  
The main focus of the study ward was diagnosis and treatment of haematological dis-
eases (leukaemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, myel-
odysplastic syndromes, aplastic anaemia, etc.) and oncological diseases with particular 
expertise in the area of the bronchial carcinoma, the head and neck tumours; sarcoma, 
brain tumours, and melanomas. According to the medical team on the study ward, 
majority of solid tumour patients on the ward were complex cases with advanced can-
cer, as patients with local not-advanced tumours were threated either on organ-
specific wards (e.i. gynaecology, urology, surgery) or in ambulatory (outpatient) care. 
In the time frame of four months, it was planned to enrol 100 eligible patients. Pa-
tients entered the study upon their arrival on the study ward and left the study when 
they were discharged from the study ward, either home/care facility or to another 
ward (internal/external). Participants’ inclusion criteria was defined by:  
• Minimum three-day stay on the study ward;  
• Oncological/haematological main diagnosis;  
• Existing drug therapy on admission.  
An exclusion criterion was patient’s prior participation in the study. There were no 
eligibility limitations with respect to the type of treatment currently being received or 
disease site.  
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Participant timeline 
Table 3.2: Participants timeline 
 
STUDY PERIOD 
Enrolment Allocation Post-allocation 
TIMEPOINT -t1 0 t1 t2 t3 
ENROLMENT:      
Eligibility screen X     
Allocation  X    
PHARMACEUTICAL 
CARE:      
Medication history   X   
Medication reconciliation   X   
Medication safety review      
Pharmaceutical recom-
mendations*      
Discharge counselling*     X 
MEASUREMENTS:      
Performance score   X   
ADR risk score   X   
Drug-drug interactions   X   
PRO-CTCAE      
DRP      
Legend: -t1 – admission to the study ward; t1 – within the first three days of the hospital stay; t2 – 
inpatient stay; t3 – hospital discharge and study close-out; * – as the circumstances require; ADR – 
adverse drug reaction; PRO-CTCAE – Patient-Reported Outcomes version of the Common Terminolo-
gy Criteria for Adverse Events; DRP – drug-related problem 
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3.2.5  Intervention: pharmaceutical care  
Pharmaceutical team in the present study consisted of oncology pharmacist (from the 
oncology department of UKA pharmacy) and research pharmacist (the author of this 
work). From admission to discharge pharmaceutical team provided pharmaceutical 
care on the study ward. Pharmaceutical care included extended medication history, 
medication reconciliation and ADR risk score calculation on admission, and medica-
tion safety review (MSR). MSR was performed on admission and repeated after every 
change in the pharmacotherapy. The review is based on the checklist of SOP for medi-
cation safety (Checklist AMTS Prüfung in Attachments Model I, SOP for medication 
safety) and adjusted to oncology patients including DDI assessment and PRO-CTCAE 
(3.2.6.2 DDI assessment and 3.2.6.3 PRO-CTCAE).  
For any DRP leading to PI, detected during the MSR, pharmaceutical team suggested a 
potential solution. The solution for DRPs leading to PI was finalised in PR paper form. 
Pharmaceutical team discussed recommendations with the medical team on the study 
ward and if necessary with the patient. The PR was scanned in the internal patient 
documentation system. 
Pharmaceutical team was available for consultation about new drug prescription and 
instruction for drug use. For any drug-related issue, pharmaceutical team was a con-
tact person and an advisor to the medical team and patients on the study ward during 
the study time. Research pharmacist attended ward rounds at least once a week, and 
thereby additionally supervised study patients. Before a patient was discharged from 
the study ward, pharmaceutical team provided additional recommendations concern-
ing drug therapy changes and instructions for their safe use in the outpatient care.  
Medication history 
In a personal pharmacist-patient discussion (or when needed with patient’s care pro-
vider), the research pharmacist conducted extended medication history within first 
three days of patient’s stay on the study ward – as early as routine workflow allowed it. 
For this purpose medication history documentation sheet was used (CRF 1 Arznemit-
telanamnese in Attachments Model II/Model II CFRs). Besides the basic demographic 
data, the aim was to collect as much information about patients’ medication as possi-
ble: what he had used before the admission, all prescribed and over-the-counter medi-
cines, recent previous ADRs and recent changes in drug therapy. The medication used 
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before admission to the study ward was home medication (if patient was admitted 
from home), or care-home medication (if patient was admitted from the care home 
facility), or medication from the last visited ward (if patient was admitted from the 
internal or external health care facility). The current medication prescribed on admis-
sion to the study ward was documented, too. 
Medication reconciliation 
The research pharmacist documented incomprehensible, or from the pharmaceutical 
side unsupported discrepancies between the pre-admission medication and admission 
ward medication in the comment field of the medication history documentation sheet 
(CRF 1 Arznemittelanamnese in Attachments Model II/Model II CFRs). For instance: 
when a patient had not voluntarily reported to the attending physician some over-the-
counter medicine, or any medication or transmission error on admission. Research 
pharmacist suggested a solution for each discrepancy. Oncology pharmacist assessed 
the suggested solutions and made the final decision on clinical relevance. Clinically 
relevant discrepancies were treated as DRPs, and documented with their solutions in 
CRFs for DRPs (CRF 3 Datenerfassung Arzneimittelbezogene Probleme, and CRF 5 
Empfehlungen aus der Medikationscheck in Attachments Model II/Model II CFRs). 
Medication safety review  
Information collected during medication history and medication reconciliation repre-
sented the basis for the MSR. Besides, pharmaceutical team used available patient 
records (paper form/internal UKA software). The review was conducted at the begin-
ning of the hospital stay on the study ward, as well as every time the patient’s drug 
therapy was changed. It considered the following steps: 
• Plausibility review of each medication on patient’s therapy plan (including 
indication, dosage, application of drug) 
• Review of drug dosage, DDIs, contraindications 
• Review of any potential ADR symptom 
• Review of relevant laboratory data 
• Adjustment review: review of allergies, renal and liver dysfunction and ad-
justment of doses, if required 
• Review of TDM and adequate duration of drug therapy (e.g. antibiotic  ther-
apy) 
• Review of medication before interventions (e.g. surgery) 
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• Review of a need for patient counselling, particularly if a new drug therapy 
is initiated 
Further details are provided in the checklist of SOP for medication safety (Checklist 
AMTS Prüfung in Attachments Model I, SOP for medication safety). Supporting in-
formation tools available in the UKA pharmacy for resolving drug-related issues were: 
German prescribing information register Fachinfo-Service® (Summary of Product 
Characteristics), Micromedex DRUGDEX®, an updated drug knowledge portal, and 
interaction software: Mediq®, ID Diacos Pharma Check®, Lexicomp®. 
Having all relevant information, each member of the pharmaceutical team inde-
pendently assessed patient drug therapy. Research pharmacist and oncology pharma-
cist presented each other identified DRPs and discussed potential solutions. In case of 
disagreement the oncology pharmacist made a final decision, based on broader and 
longer experience on the study ward. Final decision of the pharmaceutical team on 
DRP leading to an intervention resulted in PR. Within first five days of the hospital 
stay, the first recommendation was provided, if there was need for any.  
The recommendations contained explained DRP and an appropriate solution, and 
were also discussed on the study ward with the medical team, and if necessary with the 
patient. Having the PR in the paper form, physicians were able to go back to them at 
any time and include the relevant information in the patient letter. Exclusively the 
DRPs that led to PI ended in the PR and were tracked in the study documentation.  
3.2.6  Study measures 
Demographic and oncological variables 
Basic demographic data was in continuous variables “age” and observation (study) 
time “time on the study ward”, and in categorical variables “gender”, existing “allergy”, 
“alcohol” consume and “smoking” habit. Oncological characteristics were distributed 
in categorical variables:  
• “Cancer type” was divided into haematological or solid tumour patient group; 
• “Cancer diagnosis” were according to the International Statistical Classification 
of Diseases (ICD) [155]; 
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• “Therapy regimen” was a treatment option prioritised in lines of therapy: 
1st line, 2nd line, 3rd line therapy, etc. A criteria how to assess therapy regimen 
was finalised with study physicians (Table 3.3); 
• “Therapy plan” was divided into: palliative, curative and unclear therapy goal 
(where further diagnostics was needed); 
• “Chemotherapy complexity” was divided into low, moderate or high complexity;  
• “Chemotherapy cycle” was a number of a chemotherapy cycle of a patient; 
• “Current chemotherapy” was whether a patient received chemotherapy during 
the study time (yes/no). 
Table 3.3: Therapy regimen criteria 
CRITERIA THERAPY 
REGIMEN 
COMMENTS 
Chemotherapy (CTx) and radiotherapy 
(RTx) 
1st line Together one therapy 
line 
After complete remission occurrence of 
new tumour type 
1st line Or any current therapy 
line 
Autologous HSCT (Initial therapy, condi-
tioning treatment (CTx/RTx), transplant 
(optional double transplantation), and 
maintenance therapy (optional)) 
1st line All steps considered as 
a one therapy line 
Disease relapse 2nd line Or any following line 
Disease progress 2nd line Or any following line 
Therapy switch (allergic reaction, adverse 
reaction, no respond on initial therapy 
choice) 
2nd line Or any following line 
 
Number of prescribed drugs 
In order to analyse the number of prescribed drugs, the drugs prescribed on the ward 
were counted (continuous variable “number of drugs”). Products containing more than 
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one active substance were considered as one drug. In the count, paused or discontin-
ued drugs were not included. Change of drug dosage was not counted as a new pre-
scribed drug. On contrary, change of the dosage form (e.g. change from intravenous to 
oral dosage form) was considered as a new prescription. Solutions carriers or agents 
for volume substitution (e.g. NaCl 0.9%, Ringer's solution) were not recognised as 
drugs. Medicines used both as food supplements as well as drugs (e.g. potassium, 
magnesium) were evaluated as drugs. Medical products such as saline nasal sprays, 
moistening eye drops, mouthwash etc. were also regarded as drugs. 
Body Mass Index (BMI) 
BMI is a measure for indicating nutritional status in adults. BMI is an estimate of body 
fat and a good gauge of risk for diseases that can occur with more body fat. The higher 
BMI is, the higher is the risk for certain diseases such as heart disease, high blood 
pressure, type 2 diabetes, gallstones, breathing problems, and certain cancers [156]. 
Although BMI can be used for most men and women, it does have some limits: it may 
overestimate body fat of athletes and others who have a muscular build, and it may 
underestimate body fat of older persons and others who have lost muscle [157].  
BMI is defined [156] and accordingly calculated in the present study: 
 !"# =  !"#$%!!! !"#$ℎ! (!")!"#$%!!! ℎ!"#ℎ! (!) !  
BMI nutritional status is divided in ranges (Table 3.4) based on the effect that exces-
sive body fat has on diseases and death. The ranges relate reasonably well to adiposity 
[156]. 
Table 3.4: BMI ranges [156] 
BMI Nutritional status 
Below 18.5 Underweight 
18.5 – 24.9 Normal weight 
25.0 – 29.9  Overweight/Pre-obesity 
30.0 – 34.9 Obesity (class I) 
35.0 – 39.9 Obesity (class II) 
Above 40 Obesity (class III) 
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Liver function 
Total bilirubin in µmol/l (mg/dl), serum albumin in g/dl and prothrombin time (INR) 
prolongation in s, were information obtained from available UKA laboratory data. 
Diagnoses of ascites and hepatic encephalopathy were available in the patient medical 
records, when the disease was present. With these five parameters, the research phar-
macist calculated Child-Pugh score and interpreted into the Child-Pugh class [158, 
159] (Table 3.5 and Table 3.6). Given that this study was not focused on chronic liver 
diseased patients where the interpretation of Child-Pugh class in terms of survival is 
vital, this interpretation (Table 3.6) was irrelevant to the study results and it was omit-
ted in the further discussion. 
Table 3.5: Child Pugh score [158, 159] 
Child –Pugh score  
Measures 1 point 2 points 3 points 
Total bilirubin 
(µmol/l) < 34 (< 2) 34 – 50 (2 – 3) > 50 (> 3) 
Serum albumin (g/dl) > 3.5 2.8 – 3.5 < 2.8 
Prothrombin time 
(INR) prolongation (s) < 4.0 4.0 – 6.0 > 6.0 
Ascites diagnosis None 
 
Mild  
(or suppressed 
with medication) 
Moderate to severe 
(or refractory) 
Hepatic encephalopa-
thy diagnosis None Grade I – II Grade III – IV 
Table 3.6: Child –Pugh score interpretation 
Child –Pugh score interpretation 
Points Class One year survival Two year survival 
5 – 6 A 100% 85% 
7 – 9 B 81% 57% 
10 – 15 C 45% 35% 
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Renal function 
The Creatinine Clearance rate (CrCl) and Glomerular Filtration Rate (GFR) were re-
viewed and documented during the MSR. In laboratory hospital data, Serum creati-
nine (Scr) and estimated GFR using the CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration) formula were provided. The research pharmacist esti-
mated CrCl using Cockcroft-Gault (CG) formula [160]:  
!"!# =  140− !"#  × !"#$ℎ!72 × !"#  × 0.85 !" !"#$%"  
Where CrCl was in ml/min, age in years, weight in kg and Scr in mg/dl.  
The stages of Chronic Kidney Disease (CKD) are mainly based on measured or esti-
mated GFR. There are five stages (Table 3.7), however, the kidney function is normal 
in Stage 1, and minimally reduced in Stage 2 [161].  
Table 3.7: CKD stages [161] 
Stage GFR* Description 
1 90 + Normal kidney function but urine findings or structural abnor-
malities or genetic trait point to kidney disease 
2 60 – 89 Mildly reduced kidney function, and other findings (as for stage 
1) point to kidney disease 
3A 
3B 
45 – 59 
30 – 44 
Moderately reduced kidney function 
 
4 15 – 29 Severely reduced kidney function 
5 < 15 or on 
dialysis 
Very severe, or end-stage kidney failure (sometimes call estab-
lished renal failure) 
* All Glomerular Filtration Rate (GFR) values are normalised to an average surface area of 1.73m2 
Eastern Cooperative Oncology Group (ECOG) performance status 
Tumour board is a cancer treatment planning approach in which a number of doctors 
who are experts in different specialties review and discuss the medical condition and 
treatment options of a patient. Designed to optimise patient outcomes, tumour boards 
are essential to clinical decision-making and patient management.  
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ECOG performance status [162] was one of the parameters determined and docu-
mented for each patient on the tumour board. The grading system (Table 3.8) was 
developed to spur further standardization among researchers who design and evaluate 
cancer clinical research [163].  
Table 3.8: ECOG performance status [162] 
GRADE  ECOG PERFORMANCE STATUS 
0 Fully active, able to carry on all pre-disease performance without re-striction 
1 
Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g. light house work, office 
work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50 % of waking hours 
3 Capable of only limited self-care; confined to bed or chair more than 50 % of waking hours 
4 Completely disabled; cannot carry on any self-care; totally confined to bed or chair 
5 Dead 
 
3.2.6.1 Adverse drug reaction risk score  
Original version of ADR risk score [57] was translated into German and used as sup-
porting measure for each patient on the study ward. Each score variable: diagnosed 
hearth failure, diagnosed liver disease, diagnosed renal failure, having four or more 
comorbidities, weights one point. If a patient had previous ADRs, it was scored two 
points. For the variable number of drugs, there was a following scoring criteria: lower 
or equal than five drugs – no points, six or seven drugs – one point, and more or equal 
than eight drugs – four points. This variable was called in the present study “number 
of drugs coded” and it is to be distinguished with the continuous variable “number of 
drugs”. The maximum ADR risk score was 10 points. As suggested in the original study 
[57], the cut off point was 4 and patients with more than 5 points were considered 
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prone to ADRs. Thereby, score interpretation “ADR probable” and “ADR definite” 
were referred together as “high” ADR risk score (Table 3.9).  
Table 3.9: ADR risk score interpretation 
SCORE    ADR occurrence 
0 point    Doubtful 
1 – 4 points    Possible 
5 – 8 points    Probable 
9 – 10 points    Definite 
3.2.6.2 Drug-drug interactions 
During the MSR important step was assessment of DDIs. During this task, pharma-
ceutical team followed DDI assessment steps A – E (explained below) and provided 
clinically relevant PRs to attending physicians. Pharmaceutical DDI assessment steps 
were developed on basis on the previous work [149] and expanded in the present 
study. These steps were:  
A. Independently each pharmacist assessed patient’s current clinical picture and 
drug therapy; and documented all potential DDI problems. 
B. Independently each pharmacist assessed previous DDI problems. If any previ-
ous DDI problem was available and known, it was documented.  
C. Independently each pharmacist assessed complete drug therapy in the Mediq® 
interaction software. Interactions marked red representing highly relevant DDI 
potential risk with severity degree 3 (according to the software) were always in-
cluded in the recommendation. Interaction marked orange (middle DDI poten-
tial according to the software) and yellow (low DDI potential according to the 
software) needed additional pharmaceutical expert assessment. Independently 
each pharmacist did that while considering particularities of single patient. 
Each pharmacist decided first on his own whether to include the potential DDI 
in the professional recommendation, or not. 
D. Each pharmacist proposed clinically relevant PRs in the team discussion.  
In case of ambiguity, additional clinical decision support tools were used: 
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Fachinfo-Service®, Micromedex DRUGDEX®, or additional interaction soft-
ware: ID Diacos Pharma Check®, Lexicomp®. 
E. After discussing individual recommendations and agreeing on a single solution, 
pharmaceutical team communicated PR to the study ward. Clinically relevant 
DDIs were treated as DRPs.  
The results were presented in two parts: Mediq® software output and pharmaceutical 
DDI assessment output. It was crucial to distinguish the term “clinically relevant” in 
the context of the study. Mediq® software had orange-marked potential DDI (middle 
DDI potential) as clinically relevant but in our study clinically relevant DDI was the 
one individually assessed for each patient in the pharmaceutical DDI assessment and 
chose as relevant. Any further notice of clinically relevant DDIs is referred to the out-
come of the pharmaceutical DDI assessment, and not to the software output.  
3.2.6.3 Patient-Reported Outcomes version of the 
Common Terminology Criteria for Adverse 
Events (PRO-CTCAETM) 
Principal extension of the MSR was inclusion of the PRO-CTCAE questionnaire.  
German PRO-CTCAE core item set used in this study includes 31 items about 14 dif-
ferent symptoms. The symptomatic toxicities were clustered as shown in Table 3.10 
[147]. Responses were provided on a five-point Likert scale. Recall period for 
PRO-CTCAE was the past 7 days [143] and in the present study weekly assessment of 
PRO-CTCAE symptoms was considered. 
PRO-CTCAE attributes included frequency (e.g. how often did you have nausea), 
severity (e.g. what was the severity of your pain), and interference with daily activi-
ties (e.g. how much did fatigue interfere with your usual or daily activities) [143]. The 
inclusion of multiple attributes intended to improve precision of PRO-CTCAE in cap-
turing the latent construct (e.g. pain that is severe but infrequent) [147].  
Research pharmacist explained purpose of the questionnaire and directed the 
PRO-CTCAE questions to patients on admission, after the medication history. Patients 
had enough time to provide their sincere and subjective answer. Personal contact with 
the research pharmacist promoted the response rate but not in any way did the  re-
search pharmacist influence patients’ self-reported answer or interpreted patients’ 
answer. On random occasions, the oncology pharmacist joined the research pharma-
Methods 
 61 
cist during the patient-researcher meeting, monitoring and controlling the process but 
not actively participating in it. Thereby, the method to minimise missing patient-
reported data and real-time monitoring was employed [164]. If the patients’ condition 
was not sufficient, pharmacist referred PRO-CTCAE item questions to the care provid-
er. This was considered as a backup data collection method [164]. 
The PRO-CTCAE answers were documented in paper form. Further possible admin-
istration modes were tablet, computer- or interactive voice response system admin-
istration mode. None of them was feasible in this setting. Uncontrolled symptoms 
were considered in the MSR and when needed, appropriate PRs were given to the 
medical team on the ward. 
Table 3.10: PRO-CTCAE item clusters [147] 
Item cluster Number of items Item dimensions 
Anxiety and sadness 6 Frequency, severity,  
interference 
Nausea and vomiting 4 Frequency, severity 
Appetite loss 2 Severity, interference 
Fatigue 2 Severity, interference 
Pain 3 Frequency, severity,  
interference 
Mucositis and xerostomia 4 Severity, interference 
Dyspnoea 2 Severity, interference 
Mental concentration 2 Severity, interference 
Numbness and tingling 2 Severity, interference 
Insomnia 2 Severity, interference 
Constipation 1 Severity 
Diarrhoea 1 Frequency 
Legend: PRO-CTCAE – Patient-Reported Outcomes version of the Common Terminology Criteria 
for Adverse Events 
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PRO-CTCAE symptom burden 
Responses on PRO-CTCAE items were scored from 0 to 4. There has not yet been 
defined a standardised scoring rule on how to combine attributes into a single score or 
how best to analyse PRO-CTCAE data longitudinally [143]. Uncontrolled PRO-CTCAE 
item clusters that enforced pharmaceutical recommendations and PRO-CTCAE scores 
for each attribute (frequency, severity, interference) were presented descriptively.  
For the purpose of presentation and comparability of symptom burden, the cohort 
PRO-CTCAE item cluster score was calculated according to the following equations 
[147] averaging the component items of each of the clusters according to: 
RS = I1 + I2 + … +Inn  
Where I1,2,…,n were item values, RS was a raw score and n was the number of items. 
To ease the interpretation, the PRO-CTCAE item cluster were linearly transformed to a 
0 –100 scale so that higher scores indicated worse symptoms, using the formula: 
!"#$% =  !"!"#$%  × 100 
Range referred to the difference between the maximum possible value and the mini-
mum possible value of answer options (range = 4 – 0 = 4) [147]. 
To compare low and high mean cohort PRO-CTCAE attribute scores, and interde-
pendent main cohort characteristics as low and high, multiple chi-squared tests for 
binary scales were used. Thereby, the null hypothesis in the testing was the low/high 
mean cohort PRO-CTCAE attribute score is independent of low/high main cohort 
characteristics. An alternative hypothesis was that the two are dependent (PRO-
CTCAE attribute score is associated with main cohort characteristics). The PRO-
CTCAE attributes had potential values from 0 to 4 indicating increasing intensity. 
Values 0 and 1 was no or very low, and 4 was very high attribute intensity. Thus, the 
mean cohort PRO-CTCAE attribute scores (frequency, severity interference) was de-
fined as low score 0 - 1 and high score ≥	2. Independent main cohort characteristics 
were recoded into binary variables: “number of drugs” low (<8 drugs prescribed) and 
high (≥8 drugs prescribed); “ECOG performance status” low (0 – 1) and high (2 – 4) 
impaired performance status [145]; “ADR risk score” low (0 – 4 where ADR is doubt-
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ful or possible) and high (5 – 12 ADR probable and definite). Variable “cancer type: 
solid/haematological tumours” was already binary in the initial data entering. The 
approach was appropriate because the sampling method was simple random sampling, 
the variables were categorical, and the expected frequency count was at least 5 in each 
cell of the contingency table [165]. The results of multiple testing of Pearson's chi 
square test of independence were presented with two-tailed significance level 0.05. 
3.2.6.4 Drug-related problems 
The APS-Doc® system was used for measurement and classification of DRPs leading to 
an intervention. The system was developed for systematic documentation of DRPs 
within the hospital setting in Germany. All relevant DRP categories from the interna-
tional classification systems like PI-Doc and PCNE for the hospital setting were in-
cluded and further DRP categories were added [64].  
APS-Doc® consisted of 48 subcategories that describe DRPs (e.g. “missing drug in 
medication history”). Those subcategories were linked to ten main categories: “drug 
(Rx)”, “dosage form/drug strength (DS)”, “dosage (DOS)”, “indication (IND)”, “contra-
indication (CI)”, “drug-drug interactions (DDI)”, “adverse drug reaction (ADR)”, “ad-
ministration/compliance” (AC) nowadays called “adherence”, “administration (AP)” 
and “other (O)” [64]. Two further subcategories were added to the main category  
“others”, “O3: information requirement by patient”, “O4: information requirement by 
physician/nurse” [49].  
Variable “DRP day” reflected the day when it was intervened on the particular DRP. 
The outcome of PRs provided on DRPs was assessed as:  
• “Preventive measures taken” where the pharmaceutical recommendation 
did not urged for a direct change of the drug therapy, but a particular clini-
cally relevant preventive measure was suggested, e.g. a further diagnostic 
test because of unclear drug indication/uncontrolled laboratory measure-
ment/patient’s complaint, or recommendation could be implemented at a 
later point because of instability of clinical symptoms which required further 
observation of the patient state, or where a patient with a particular previous 
ADR had numerous drugs with the same adverse effect (more solutions were 
provided and attending physicians made the decision); 
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• “Implemented” where the pharmaceutical recommendations were explicit 
and indicated direct change in the drug therapy; 
• “Not applicable” when the medical team did not find PR relevant and did 
not implement the recommendation.  
PIs resulting in PRs on the ward were classified using DokuPIK® system for the hospi-
tal setting developed by the German Society of Hospital Pharmacists. Eight "DokuPIK" 
measurements have been used (Table 3.11). For purpose of the present study, three 
additional categories (M9, M10, M11) were added. 
The implementation rate (IR) of recommendations on the DRPs was calculated as 
quotient of the number of implemented PRs (Ipr) to the total number of PRs provided 
(Tpr) : 
!R= IprTpr 
Table 3.11: Doku-PIK® 
Measurement 
number 
“DokuPik” categorisation of pharmaceutical recommendations 
M1 Instruction on the drug application 
M2 Stop/pause the drug 
M3 Change of the drug 
M4 Suggestion for the prescription of a new drug 
M5 Change of the drug dose 
M6 Change of the drug form 
M7 Information to the attending physician/nurse 
M8 Information to the patient 
M9* Symptom surveillance 
M10* Further diagnostic tests 
M11* Change of the drug interval 
Legend: DokuPik – Dokumentation Pharmazeutischer Interventionen im Krankenhaus; * – added for 
the purpose of this study. 
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3.2.7 Drug-related problem prediction model  
Since "number of DRPs" was statistically rare event, the frequency distribution repre-
sents a Poisson distribution [165]. The Poisson regression model was chosen to deter-
mine the influence of 17 different predictors on the number of DRPs, first in a 
univariable and then in a multivariate analysis. These 17 predictors were following 
variables: "age", "sex", “body mass index”, “ECOG performance status", ”number of 
drugs", “number of comorbidities”, “liver disease”, “renal failure”, “heart failure”, 
“previous ADR”, “ADR risk score”, “cancer type”, “therapy plan”, “CTx cycle”, “current 
CTx”, “CTx complexity” and “therapy regimen”. Variables were chosen as potential risk 
factors contributing to the occurrence of DRPs in divers’ patients groups [107, 166] or 
representing relevant characteristics of oncology patients.  
Additionally, adjusted Poisson regression model was used to determine the influence 
of ADR risk score on the number of DRPs. In the adjusted model, ADR risk score was 
used as a fixed variable. ADR risk score was a validated and useful method in clinical 
practice to identify inpatients at risk of an ADR [57]. Thereby, it represented a useful 
starting point for developing a DRP prediction model (DRP risk score). Variables 
”number of drugs", “number of comorbidities”, “liver disease”, “renal failure”, “heart 
failure”, “previous ADR” that are considered DRP risk factors [107, 114, 116], were 
already components of ADR risk score. However, ADR represented only a part of all 
DRPs that may occur. Therefore, further predictors were needed in order to perform 
the DRP assessment, and as a result to develop the DRP prediction model. Under 
those circumstances, from previously mentioned 17 variables remaining 16 supporting 
variables were exploratively examined in the adjusted model.  
A univariable Poisson regression model analysis was used as a selection mechanism. 
Each of 17 potential predicting factors was tested. Variable with p value less or equal of 
20 % were selected as candidates for a multivariate analysis.  
In the multivariate Poisson regression model, both, forward selection and backward 
elimination, selection procedures were used to yield the most appropriate regression 
equation. The prognostic prediction model combined multiple predictors by signing 
relative weights to each predictor to obtain a risk or probability. In the final model, the 
significant level was set to 5 %. The results were presented with predicted incidence 
rates and risks, two-sided p values, coefficient estimates (B) with 95% Wald Confi-
dence Interval (Cl). The prognostic ability of the model was graphically plotted in the 
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Receiver Operating Characteristic (ROC) curve, true-positive rate (sensitivity or prob-
ability of detection) against false-positive rate (fall-out, probability of false alarm, 1 - 
specificity). Sensitivity and specificity levels of the prognostic models were interpreted. 
Performance measure was reported with an area under the ROC curve (AUC) of the 
model included the area under the curve (AUC). An area under the ROC curve (AUC) 
of 0.5 indicates no discrimination, whereas an AUC of 1.0 indicates perfect discrimina-
tion. The estimated AUC was presented with 95 % CI, standard error (SE) and p value. 
3.2.8  Bias 
Three potential biases were detected. Each bias was considered to limit its impact and 
certain measures were undertaken, as described below. 
Infrastructure bias could arise based on the UKA infrastructure. Standard medical 
team on the ward consisted of physicians and nurses. Pharmacists were in the hospital 
pharmacy, doing their routine work in the separate building. Pharmaceutical care, 
though a legal requirement of pharmacist routine work, had not yet been integrated in 
routine of any ward in the UKA.  
Having an established first research interaction on the study ward (3.1.1 Study back-
ground), this study aimed to extend the joint work and come closer to the multi-
professional routine collaboration. To do so, pharmaceutical team in this study pre-
sented the project on the ward. The project was implemented in a way routine work-
flow on the ward was undisturbed and study outcomes were valuable for patients. 
Pharmaceutical and medical team set structural daily appointments such as discussion 
of PRs ahead of ward rounds or access to the paper form of patient records on the 
study ward in between nursing rounds.  
Information bias could arise as consequence of UKA infrastructure bias, where phar-
maceutical team and medical team worked in different departments and a pharmacist 
was rarely present in the routine workflow. Professional exchange of patient infor-
mation within the medical team routinely did not include a pharmacist. To overcome 
this potential bias, pharmaceutical team (1) had attended ward rounds once a week, 
(2) had regular afternoon appointment with an attending physician to discuss uncer-
tainties about the patient therapy. (3) Both pharmaceutical team and medical team 
had an opportunity to communicate via internal phone and E-mail, when necessary. 
On the other side, separate work routine of two teams contributed to the objectivity of 
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DRP assessment. In a way, pharmaceutical team was an external objective examiner of 
DRP existing on the ward.  
Detection bias could arise on account of the DRPs detection and pre-selection. As 
mentioned before in 3.2.5 Intervention/Medication safety review, only DRPs leading 
to an intervention i.e. where the pharmacist could contribute to their resolution were 
tracked and discussed with the medical team. Baring in mind the pharmacist had not 
yet been integrated part of the study ward routine, the pre-selection of the DRPs 
through a pharmacist is considered as a tool to prevent overflow of the information 
communicated on the ward. Being aware of the issue, the inclusion of oncology phar-
macy in the pharmaceutical team who did the independent assessment approach in-
creased internal validity of the study.  
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3.3  Results 
3.3.1  Participants 
Data was collected for four months, from mid August 2016 until mid December 2016 
on the study ward. The study consisted of 55 (54.5 %) male and 46 (45.5%) female 
participants, making the sample of 101 patients.  
On average, patients were 65 years old (SD 13.3, median 64, range 26 – 91, IQR 75 – 
58) and stayed 10 days on the study ward (SD 7.4, median 7, range 3 – 49, IQR 12 – 4).  
Mean BMI was 26.1 kg/m2 (SD 7.3, median 25.4, range 14.8 – 56.4, IQR 29.1 – 21.3). 
Seven patients were underweight. Normal weight was observed in 29 (28.7 %) pa-
tients. The BMI over 25 kg/m2 had 38 (36.8 %) patients, 21 (20.8 %) were overweighed 
and 17 (16.8 %) were obese.  
Ten (9.9 %) patients had allergies: food/dust/drug allergy. Only one patient (1 %) had 
an alcohol abuse problem. Twenty-nine (28.7 %) patients were smokers. Among 
smokers, 12 (41.4 %) patients had a diagnosis of malignant neoplasm of bronchus or 
lung. 
Oncological characteristics  
Cohort had patients with 44 different diagnoses; presented separately in the attach-
ment (Patient Diagnosis in Attachments Model II). Solid and haematological tumour 
diagnoses were almost evenly distributed (50.5 % vs. 49.5 %). The most frequent solid 
tumour type was malignant neoplasm of bronchus or lung (24 patients, 23.8 %), and 
the most frequent haematological tumour diagnosis was diffuse large B-cell lymphoma 
(16 patients, 15.8 %). The second most frequent haematological diagnosis was multiple 
myeloma (14 patients, 13.9 %). Other diagnoses had very low relative frequency, from 
1 up to 3 %.  
Six patients (5.9 %) had normal performance status (ECOG = 0) according to the 
ECOG grading system. Forty-one patients (40.6 %) were slightly restricted in physical-
ly strenuous activity (ECOG = 1) and almost half of the patients, 45 of them (44.6 %), 
had to certain extend impaired performance status (ECOG = 2 – 4).  
Main oncological characteristics are shown in the Tables 3.12 and 3.13 in a gender 
distribution and in total values. Values where the total number was different from the 
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sum of women and men were marked with a star (*). For each gender the total number 
was calculated independently and this disparity was a result of number rounding.  
Table 3.12: Main oncological characteristics (part 1) 
 Female Male Total 
ECOG performance status 
0 
1 
2 
3 
4  
Missing values 
 
1 (1.0 %) 
20 (19.8 %) 
9 (8.9 %) 
9 (8.9 %) 
0 (0 %) 
 
5 (5.0 %) 
21 (20.8 %) 
13 (12.9 %) 
11 (10.9 %) 
3 (3.0 %) 
 
6 (5.9 %)* 
41 (40.6 %) 
22 (21.8 %) 
20 (19.8 %) 
3 (3.0 %) 
9 (8.9 %) 
Cancer type 
Solid tumours 
Haematological tumours 
 
22 (21.8 %) 
24 (23.8 %) 
 
29 (28.7 %) 
26 (25.7 %) 
 
51 (50.5 %) 
50 (49.5 %) 
Cancer diagnosis 
Malignant neoplasm of  
bronchus or lung 
Diffuse large B-cell lymphoma 
Multiple Myeloma 
Others 
 
12 (11.9 %) 
 
8 (7.9 %) 
9 (8.9 %) 
17 (16.8 %) 
 
12 (11.9 %) 
 
8 (7.9 %) 
5 (5.0 %) 
30 (29.7 %) 
 
24 (23.8 %) 
 
16 (15.8 %) 
14 (13.9 %) 
47 (46.5 %) 
Therapy regimen 
First line therapy 
Second line therapy 
Third line therapy 
Fourth line therapy 
Unknown 
 
26 (25.7 %) 
11 (10.9 %) 
5 (5.0 %) 
2 (2.0 %) 
0 (0 %) 
 
31 (30.7 %) 
15 (14.9 %) 
7 (6.9 %) 
2 (2.0 %) 
2 (2.0 %) 
 
57 (56.4 %) 
26 (25.7 %)* 
12 (11.9 %) 
4 (4.0 %) 
2 (2.0 %) 
Therapy plan 
Curative 
Palliative 
Unclear further diagnostics 
needed 
 
10 (9.9 %) 
28 (27.7 %) 
8 (7.9 %) 
 
9 (8.9 %) 
38 (37.6 %) 
8 (7.9 %) 
 
19 (18.8 %) 
66 (65.4 %) 
16 (15.8 %) 
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Table 3.13: Main oncological characteristics (part 2) 
 Female Male Total 
Chemotherapy complexity 
Low  
Moderate 
High 
Unknown 
 
16 (15.8 %) 
5 (5.0 %) 
0 (0 %) 
25 (24.8 %) 
 
24 (23.8%) 
2 (2.0%) 
3 (3.0%) 
26 (25.7%) 
 
40 (39.6%) 
7 (6.9%) 
3 (3.0%) 
51 (50.5%) 
Chemotherapy cycle 
First 
Second 
Third 
Fourth 
Fifth 
Sixth 
Tenth 
Chemotherapy is planed but it is 
unknown when does it start 
 
16 (15.8 %) 
11 (10.9 %) 
2 (2.0 %) 
4 (4.0 %) 
1 (1.0 %) 
1 (1.0 %) 
1 (1.0 %) 
10 (9.9 %) 
 
20 (19.8 %) 
13 (12.9 %) 
5 (5.0 %) 
2 (2.0 %) 
1 (1.0 %) 
1 (1.0 %) 
0 (0 %) 
13 (12.9 %) 
 
36 (35.6 %) 
24 (23.8 %) 
7 (6.9 %)* 
6 (5.9 %)* 
2 (2.0 %) 
2 (2.0 %) 
1 (1.0 %) 
23 (22.8 %) 
Chemotherapy during          
the study time 
Yes 
No 
       sdsfdkjfh  
26 (25.7 %) 
20 (19.8 %) 
       sdsfdkjfh  
33 (32.7 %) 
22 (21.8 %) 
       sdsfdkjfh  
59 (58.4 %) 
42 (41.6 %) 
Solid tumour vs. haematological tumour patients 
There were 51 (50.5 %) patients with solid tumour and 50 (49.5 %) patients with hae-
matological tumours. Patients with haematological tumours had a slightly lower medi-
an age (64 vs. 65) and slightly shorter stay on the study ward (6.5 vs. 8), but higher 
median BMI (26 vs. 23), median ADR risk score (7 vs. 6) and incidence rate of DRPs 
per day on the ward (0.19 vs. 0.17), when compared with patients with solid tumours. 
In the Tables 3.14 – 3.18 characteristics of those two patient subgroups are presented. 
Concerning PRO-CTCAE symptoms that required a PR, there were seven (6.9 %) pa-
tients with solid tumours and six (5.9 %) patients with haematological tumours. The 
PRO-CTCAE symptoms were: shortness of breath (twice), fatigue (twice), insomnia 
(twice) and concentration (once) by solid tumour patients and nausea (once), de-
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creased appetite (once), numbness and tingling (once), fatigue (once), insomnia 
(once), anxiety (once) by haematological tumour patients.  
Table 3.14: Solid tumour patients 
Solid tumours (51 patient) 
Characteristic mean SD median IQR 
Age 64.9 11.6 65 74 – 58 
Days on the study 
ward 
9.3 6.7 8 12 – 5 
BMI 24 5.6 23 27 – 20 
Number of drugs 12.9 4.4 13 16 – 10 
Incidence of DRPs 0.2 0.3 0.2 0.3 – 0 
ADR risk score 6.1 1.7 6 7 – 5 
Number of clinically 
relevant DDIs 
3.1 5.1 1 5 – 0 
Table 3.15: Haematological tumour patients 
Haematological tumours (50 patient) 
Characteristic mean SD median IQR 
Age 63.7 14.9 64  75.3 – 57.5 
Days on the study 
ward 
9.4 8 6.5  14.3 – 4 
BMI 27.8 8.1 26.2  31.6 – 22 
Number of drugs 13.2 4.6 13  15.3 – 10 
Incidence of 
DRPs 
0.3 0.2 0.3  0.3 – 0 
ADR risk score 6.6 1.8 7  8 – 5.8 
Number of  
clinically relevant 
DDIs 
3.8 4.8 2  7 – 0 
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Table 3.16: Solid and haematological tumour patients- counts (part 1) 
 Patients with 
 Solid tumours   
(51) 
Haematological tumours 
(50) 
Gender                 
Female 
Male 
 
22 
29 
 
24 
26 
BMI range 
Underweight  
Normal weight 
Overweight 
Obese 
Missing values 
 
5 
15 
9 
5 
17 
 
2 
14 
12 
12 
10 
ECOG performance status 
0 
1 
2 
3 
4  
Missing values 
 
4 
18 
13 
11 
1 
4 
 
2 
23 
9 
9 
2 
5 
Therapy regimen 
First line therapy 
Second line therapy 
Third line therapy 
Fourth line therapy 
Unknown 
 
30 
14 
4 
2 
1 
 
27 
12 
8 
2 
1 
Therapy plan          
Curative 
Palliative 
Unclear. further diagnostics 
needed 
 
2 
41 
8 
       
17 
25 
8 
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Table 3.17: Solid and haematological tumour patients- counts (part 2) 
 Patients with 
 Solid tumours 
(51) 
Haematological tumours 
(50) 
Chemotherapy complexity 
Low  
Moderate 
High 
Unknown 
 
21 
4 
2 
24 
 
19 
3 
1 
27 
Chemotherapy cycle       
First 
Second 
Third 
Fourth 
Fifth 
Sixth 
Tenth 
Chemotherapy start unknown  
 
16 
12 
6 
1 
1 
1 
0 
14 
 
20 
12 
1 
5 
1 
1 
1 
9 
Chemotherapy during the 
study time 
Yes 
No 
 
28 
23 
 
31 
19 
Number of comorbidities  
Less than 4  
4 or more 
 
13 
38 
 
12 
38 
Previous ADRs             
Yes  
No 
 
37 
14 
 
37 
13 
Allergies                    
Yes 
No 
 
3 
48 
 
7 
43 
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Table 3.18: Solid and haematological tumour patients- counts (part 3) 
 Patients with 
 Solid tumours 
(51) 
Haematological tumours 
(50) 
Alcohol consume           
Yes  
No 
 
0 
51 
 
1 
49 
Smoking                    
Yes  
No 
 
23 
28 
 
6 
44 
Diagnosed renal failure 
Yes 
No 
 
5 
46 
 
13 
37 
Diagnosed liver disease 
Yes  
No 
 
3 
48 
 
2 
48 
Diagnosed heart failure 
Yes  
No 
 
10 
41 
 
19 
31 
 
Organ-specific function  
 
Liver function 
Five (5 %) patients had diagnosed liver disease, documented in patients’ records. The 
mean total bilirubin was 0.4 µmol/L (SD 0.4, median 0.3, IQR 0.53 – 0.19), the mean 
serum albumin 3.1 g/dL (SD 0.7, median 3.2, IQR 3.8 – 2.5) and the mean INR 1.1 
(SD 0.3, median 1, IQR = 1.16 – 0.98). For 67 (66.3 %) patients at least one parameter 
was missing and Child-Pugh score could not be calculated (Table 3.19). From the re-
maining patients, 22 (21.8 %) patients had Child-Pugh class A and 12 (11.9 %) patients 
had Child-Pugh class B. 
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Table 3.19: Child Pugh score 
Child-Pugh score Frequency Percent (%) 
5 9 8.9 
6 13 12.9 
7 9 8.9 
9 3 3.0 
Missing data 67 66.3 
Total 101 100 
Renal function 
Eighty-three (82.2 %) patients had normal renal function. According to patient rec-
ords, impaired renal function was diagnosed in 18 (17.8 %) patients. Mean Scr was 1.1 
(SD 0.8, median 0.90, IQR 1.2 – 0.6). Estimated GFR using the CKD-EPI formula had 
the mean of 76.3 ml/min (SD 29.4, median 83, IQR 99 – 55.5). Estimated CrCl using 
Cockcroft-Gault (CG) formula was possible to calculate for 69 (68.3 %) patients. It had 
the mean of 89.9 ml/min (SD 51.9, median 81.1, IQR 113 – 54.7). GFR values were 
interpreted according to the stages of CKD and patient distribution is shown in the 
Table 3.20.  
Table 3.20: Interpretation of GFR value  
Stages of Chronic Kidney Disease CKD-EPI formula CG formula 
1: Normal kidney function 39 (38.6 %) 22 (22.8 %) 
2: Mildly reduced kidney function 32 (31.7 %) 22 (21.8 %) 
3: Moderately reduced kidney function 25 (24.8 %) 19 (18.8 %) 
4: Severely reduced kidney function 2 (2 %) 4 (4 %) 
5: Very severe kidney failure 3 (3 %) 1 (1%) 
Missing values  0 32 (31.7 %) 
Total  101 (100 %)  32 
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3.3.2 Adverse drug reaction risk score  
The cohort had ADR risk score from 0 to 9 (Figure 3.1). None of patients had a maxi-
mum of 10 points. The mean ADR risk score was 6.4 (SD 1.8, median 7, IQR 8 – 5.5). 
Following the score interpretation, occurrence of the ADR was doubtful in 1 (1 %) 
patient and possible in 14 (13.9 %) patients. In majority of patients, 78 (77.2 %), ADR 
occurrence was probable. In eight (7.9 %) patients ADR was predicted as definite. 
Figure 3.1: ADR risk score 
 
 
Each individual discrete variable producing the score was analysed. One patient (1 %) 
had less than five prescribed drugs, 11 (10.9 %) patents had 5 – 7 prescribed drugs and 
89 (88.1 %) of patients had more than eight drugs prescribed. Twenty-five (24.8 %) 
patients had less than four comorbidities and remaining 76 (75.2 %) had four or more 
comorbidities. Eighteen (17.8 %) patients had renal failure and five (5 %) had liver 
disease. Heart failure was diagnosed in 29 (28.7 %) patients. Previous ADR experi-
enced 74 (73.3 %) patients. 
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3.3.3  Drug-drug interactions 
DDIs assessment was performed by the software and by the pharmaceutical team.  
For each patient, DDIs were reviewed with the Mediq® software that provided DDI 
assessment in three different severity levels: 
1. Yellow – low DDI potential, relevant in exception cases 
2. Orange – middle DDI potential, clinically relevant 
3. Red – highly relevant DDI potential risk 
4. Summary – all potential DDIs (pDDI) 
As reported by the software, there were 24 DDI/patient. The pharmaceutical team 
assessed 14.5 % of DDIs clinically relevant (cr), 3 crDDI/patient. The results of the 
Mediq® software output and pharmaceutical DDI assessment are presented in the 
Table 3.21. 
Table 3.21: Mediq® output and clinically relevant DDIs 
№ Drugs pDDI DDI1 DDI2 DDI3 crDDI   crDDI    
with 
CTx 
Median 
(IQR) 
13   (16-
10) 
19   (30-
10) 
16   (24-
8) 
3     (7-1) 0     (0-
0) 
1     (6-
0) 
0     (0-
0) 
Sum 1315 2393 1900 477 16 347 45 
Min 4 0 0 0 0 0 0 
Max 26 115 95 20 2 25 7 
Legend: pDDI – potential DDIs reported by the Mediq® software; crDDI – clinically relevant DDI by 
the pharmaceutical DDI assessment; CTx – chemotherapeutics 
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3.3.4 Patient-Reported Outcomes version of the 
Common Terminology Criteria for Adverse 
Events 
(PRO-CTCAETM) 
The German PRO-CTCAE core set item questionnaire was successfully applied once a 
week to 101 patients in the study. From the 100 % response rate, in 23 cases (22.77 %) 
patient’s care-providers helped (backup method) to complete the questionnaire.  
Symptom burden calculated as a mean cohort PRO-CTCAE item cluster scores is pre-
sented in the Figure 3.2. The greatest symptom burden to the patients imposed fatigue 
(53.9 %), anxiety and sadness (47 %), pain (41.08 %) and insomnia (34.69 %). Appe-
tite loss (30.78 %), dyspnoea (28.11 %), mental concentration (24 %), nausea and 
vomiting (15.64 %) showed intermediate burden. Lighter burden indicated diarrhoea 
(10.59 %), mucositis and xerostomia (10.29 %), constipation (7.85 %) and the lowest 
numbness and tingling (4.46 %). Mean cohort attribute: frequency, severity and inter-
ference scores are shown in the attachment (Mean cohort attribute scores in Attach-
ments Model II). 
Figure 3.2: PRO-CTCAE symptom burden 
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If either one of the attributes: frequency, severity, interference was uncontrolled in any 
of the item clusters and the therapy was not appropriately adjusted, PR was provided 
to the medical team. That was the case in 13 patients (12.90 %) representing 6.67 % of 
all PRs provided. The items cluster included in recommendations were: anxiety and 
sadness (once), nausea and vomiting (once), appetite loss (once), mental concentra-
tion (once), numbness and tingling (once), dyspnoea (twice), insomnia (three times), 
fatigue (three times).  
Pearson’s multiple chi square testing 
The results of Pearson's chi square test of independence between low (value 0 – 1)/ 
high (value 2 – 4) mean cohort PRO-CTCAE attribute score and low/high mean cohort 
characteristics are presented here. Supporting material for the PRO-CTCAE attributes 
score relations with cohort characteristics is in the attachment (Pearson's chi square 
test of independence – Crosstabs Table in Attachments Model II). In explorative Pear-
son’s multiple chi square testing, there was a high probability that maximum two re-
sults are false positive (type I error). 
Mean cohort PRO-CTCAE frequency score showed a relationship with ECOG per-
formance status (p = 0.035). Patients with 0 and 1 ECOG performance status had 
mostly mean frequency score up to 2. Patients with impaired performance status 
(ECOG 2 – 4) had mostly mean frequency score higher than 2. Mean frequency score 
was independent in relation to number of drugs, number of DRPs, ADR risk score and 
cancer type. 
Mean cohort PRO-CTCAE severity score showed a relationship with number of DRPs 
(p = 0.025) and it was independent in relation to ECOG performance status, cancer 
type, number of drugs and ADR risk score. Though all patient with severe mean cohort 
PRO-CTCAE score had more than eight drugs prescribed (high number of medication) 
and more than five ADR risk score (high ADR risk score), no significance has been 
observed. 
Mean cohort PRO-CTCAE interference score showed a relationship with ECOG 
performance status (p = 0.013) and number of drugs (p = 0.038). Majority of patients 
with 0 and 1 ECOG performance status had mean interference score up to 2. Mean 
interference score higher than 2 had significantly more patients with impaired per-
formance status (ECOG 2 – 4) and more than eight drugs prescribed. Mean cohort 
PRO-CTCAE interference score was in relation with cancer type (p = 0.012) too, show-
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ing that more solid tumour patients had mean interference score higher than 2. Mean 
interference score was independent in relation to the number of DRPs and ADR risk 
score. 
PRO-CTCAE score over time 
Given the application of PRO-CTCAE item questionnaire was performed weekly, each 
patient had a different number of repeated questionnaires based on their different 
length of stay on ward. Some patients had 2, 3, 5 or even 7 repetitions of the question-
naire (see Figures 3.3 – 3.8). That caused inability to show unified mean cohort PRO-
CTCAE score over time. Individual cases of three patients are presented here. Mean 
patient PRO-CTCAE attribute score decreased over time on the study ward, having the 
lowest value at the last time point. The same pattern could be seen in majority of mean 
patient PRO-CTCAE item cluster scores.  
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Patient A with two PRO-CTCAE item questionnaires (PRO-CTCAE Output) 
Figure 3.3: Mean patient PRO-CTCAE item cluster score over time (patient A) 
 
Figure 3.4: Mean patient PRO-CTCAE attribute score over time (patient A) 
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Patient B with five PRO-CTCAE item questionnaires 
Figure 3.5: Mean patient PRO-CTCAE item cluster score over time (patient B) 
 
Figure 3.6: Mean patient PRO-CTCAE attribute score over time (patient B) 
 
Results 
 83 
Patient C with seven PRO-CTCAE item questionnaires 
Figure 3.7: Mean patient PRO-CTCAE item cluster score over time (patient C) 
 
Figure 3.8: Mean patient PRO-CTCAE attribute score over time (patient C) 
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3.3.5  Drug-related problems  
Type, frequency and occurrence 
Patients had on average 13 drugs prescribed (SD 4.5, median 13, IQR 16 – 10, min 4 
max 26) when the first MSR was performed. During the study time 191 DRPs led to PI. 
On average every patient had 1.9 DRPs (SD 2.1, median 1, IQR 3 – 0, min 0 max 13). 
Mean DRP incidence rate was 0.26 (SD 0.3, median 0.17, IQR 0.33 – 0). 
In the Figure 3.9 is shown the distribution of DRPs in APS-Doc® classification catego-
ries. In 21 cases (10.9 %) DRPs included anti-cancer drugs. The other DRPs were with 
supportive or concomitant therapy. Type and frequency of DRPs according to the 
APS-Doc® system are showed in the Table 3.22. 
Figure 3.9: APS-Doc® categories of DRPs 
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Table 3.22: APS-Doc® classification of DRPs  
APS-Doc®  
category  
APS-Doc®  
subcategory 
Frequency Percent (%) 
Administration /  
compliance 
AC 1 
AC 2 
AC 3 
AC 4 
1 
1 
1 
1 
0.5 
0.5 
0.5 
0.5 
Drug Rx 6 
Rx 8 
Rx 10 
Rx 11 
1 
10 
1 
4 
0.5 
5.2 
0.5 
2.1 
Dosage DOS 2 
DOS 3 
DOS 4 
DOS 5 
DOS 6 
1 
7 
5 
5 
8 
0.5 
3.7 
2.6 
2.6 
4.2 
Dosage form / 
drug strength 
DS 1 1 0.5 
Indication IND 1 
IND 2 
IND 3 
2 
9 
3 
1.1 
4.7 
1.6 
Contraindication CI 1 10 5.2 
Adverse drug reaction ADR 1 
ADR 2 
8 
1 
4.2 
0.5 
Drug-drug interactions DDI 1 
DDI 2 
98 
4 
51.3 
2.1 
Other:  
Information needed 
O 3 
O 4 
2 
7 
1.1 
3.7 
Total 191 100 
Legend: AC 1 – Lack of patient’s knowledge about correct administration; AC 2 – Patient does not 
take the drug; AC 3 – Patient alteration of the recommended dosage (without consultation with 
pharmacist or physician); AC 4 – Inappropriate duration (too short/too long); Rx 6 – Discontinua-
tion of ambulatory medication (complete drug history is available. but not each drug is prescribed); 
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Rx 8 – Transcription error/unintended discontinuation of drug therapy (during the hospital stay); 
Rx 10 – Unintended prescribing of a product from the same class of drugs; Rx 11 – No/inadequate 
drug monitoring; DOS 2 – Prescription of an incorrect dosage or no dosage prescribed; DOS 3 – Dose 
to low; DOS 4 – Dose to high; DOS 5 – Inappropriate administration interval; DOS 6 – No dosage 
adjustment in case of renal failure; DS 1 – Wrong dosage form prescribed; IND 1 – Medication inap-
propriate (better option available); IND 2 – No indication; IND 3 – Drugs missing (no drug pre-
scribed in patients with an existing indication) or suboptimal dosage; CI 1 – Contraindication not 
accounted for; ADR 1 – Symptoms of an adverse drug reaction; ADR 2 – Patient’s fear of an adverse 
drug reaction; DDI 1 – Drug–drug interaction as indicated by literature (clinical relevance not  
proven); DDI 2 – Symptoms of a drug-drug interaction; O 3 – Information requirement by patient;  
O 4 – Information requirement by physician/nurse 
Pharmaceutical intervention and implementation 
For each DRP pharmaceutical team provided adequate PR (intervention) to the medi-
cal team on the ward. The PRs were delivered in paper form and directly discussed on 
the ward. In some cases one DRP needed more than one PR. For 191 DRPs pharma-
ceutical team delivered 195 PRs. The recommendations were categorised according to 
the DokuPIK system into nine different categories of PIs. PIs and their relative fre-
quency were expressed in percentage and shown in the Figure 3.10. Implementation 
rate of the pharmaceutical recommendation was 93.3 %. 
In 78 (40 %) recommendations, preventive measure were suggested to the medical 
team on the ward and considered timely. One-hundred and four (53.3 %) recommen-
dations were directly implemented. In 13 (6.7 %) cases pharmaceutical recommenda-
tion were not implemented.  
Expenditure of time 
The time invested in patient recruitment and documentation, and the time invested in 
the complete pharmaceutical care was tracked in hours. The time invested on each 
patient case was on average 10 hours. Patient recruitment and documentation per se 
took 2 hours/patient. Expenditure of time for pharmaceutical care provided during the 
entire patient’s hospital stay was on average 8 hours/patient. From that, 6.4 h on  
average was individual work of the research pharmacist. The rest of 1.6 hours/patient 
on average were teamwork: within pharmaceutical team itself and interactions with 
the ward based team. 
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Figure 3.10: Doku-PIK categories of pharmaceutical intervention 
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3.3.6 Drug-related problem prediction model 
Model development 
Variable “number of DRPs” had count data, nonnegative integer numbers. Few DRPs 
leading to PI occur in many patients as it can be seen in the Figure 3.11. Representing 
rare events, it was assumed that the Poisson distribution was a natural candidate 
for modelling such data.  
Figure 3.11: Relative frequency of DRPs per patient 
 
Poisson distribution calculated the probability of a DRP occurring over the time inter-
val - stay on the study ward. Discrete random variable “number of DRPs” was a Pois-
son random variable with parameter µ as mean of expected DRPs, n as number of 
DRPs (n = 0.1.2.3…), λ incidence rate per time unit (day on the study ward) and prob-
ability P: 
!! !| !"!#$ !"#$ !  =  !!!!  ∗  !!! 
e was a mathematical constant approximately equal to 2.718, ! referred to the factorial.  
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Mean of expected DRPs was defined as: ! =  ! ∗ ! 
where T was an offset. Each patient had a different stay on the study ward i.e. individ-
uals did not follow the same time. The “offset” variable was calculated as natural loga-
rithm of the days on the study ward. 
The Poisson regression model function to estimate DRP incidence rate was: 
! =  !!  ∗  !!!!  ∗  !!!!  ∗…  ∗  !!!!  
where λ0 was baseline incidence rate, R relative risks, X influential factors. [165] 
For the outcome representing Poisson distribution, the Poisson regression model 
was the most appropriate choice.  
Model specification and performance  
The Poisson model assumed that the risk, in our case of DRP, was the same each day 
of the hospital stay. Based on the intervention provided in this study that was not the 
case. Two different time periods were distinguished: (A) initial and (B) follow-up. 
Initial time period (A) was at the beginning of the hospital stay on the ward, up to the 
5th day in the hospital. Within this time the patient was recruited and pharmaceutical 
team performed – extended patient medication history, medication reconciliation and 
MSR. If any DRP was detected, first pharmaceutical intervention was provided as 
described in the chapter 3.2.5 Intervention. Follow-up time period (B) in the hospital 
stay was considered from the 5th up to the 10th day – in other words comparable time 
span of 5 days as in the initial time period.  
The Poisson regression was run (I) to predict the number of DRPs based on 17 poten-
tial risk factors. Further, the adjusted model (ADR risk score as fixed variable) was run 
(II) to predict the number of DRPs based on ADR risk score. The results of univariable 
and multivariate regression models are presented below.  
Univariable analysis 
(I) In the Univariable Poisson regression model, 17 different predictors were explora-
tively assessed. Components of ADR risk score: “number of drugs”, “number of 
comorbidities”, “renal failure”, “heart failure”, “liver disease”, “previous ADR”, the 
score itself and oncological characteristics “ECOG performance status”, “therapy 
plan”, and “therapy regimen” had significance level p ≤ 0.2. They were selected as 
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potential predicting factors of the number of DRPs in the multivariate regression. The 
number of participants without missing values for each selected predictor and the 
corresponding number of DRPs in those participants is presented in the Table 3.23. 
Table 3.23: Participants characteristics in development data set 
Predictors Number of participants 
(n=101) 
Number of DRP   (n=191) 
ADR risk score, n (%) 
ADR doubtful, score 0  
ADR possible 1 – 4 
ADR probable 5 – 8 
ADR definite 9 – 10 
 
1 (0.9) 
14 (14) 
78 (77.2) 
8 (7.9) 
 
0 (0) 
12 (6.3) 
159 (83.2) 
20 (10.5) 
ECOG, n (%) 
0-1 
2 
3-4 
Missing values 
 
47 (46.5) 
22 (21.8) 
23 (22.8) 
9 (8.9) 
 
57 (29.8) 
55 (28.8) 
64 (33.5) 
15 (7.9) 
Therapy regimen, n (%) 
First line therapy 
Second line therapy 
Third line therapy 
Fourth line therapy 
Unknown 
 
57 (56.4) 
26 (25.7) 
12 (11.9) 
4 (4.0) 
2 (2.0) 
 
112 (58.6) 
47 (24.6) 
25 (13.1) 
2 (1.1) 
5 (2.6) 
Therapy plan, n (%) 
Curative 
Palliative 
Unclear further diagnostics 
needed 
 
19 (18.8) 
66 (65.4) 
16 (15.8) 
 
30 (15.7) 
136 (71.2) 
25 (13.1) 
 (II) It was assumed that the ADR risk score fit to our data. As a result, logistic linear 
influence was expected. ADR risk score with B 0.219 (95% CI 0.119 to 0.319), had 
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statistical significance of p < 0.001 in the univariable Poisson regression model. The 
predicted daily incidence rates (IR) of DRPs based on the ADR risk score were:  
!" = ! !!.!"#!!"×!.!"#  
where RS was ADR risk score with values from 0 to 10.  
The related Risk during the Time of 5 days (A) in the hospital was expressed as: !"#$ = !" × !"#$ 
The results are shown in the Table 3.24. The table shows that among 100 patients who 
based on the ADR risk score were interpreted as doubtful of experiencing an ADR, 
almost 25 % of them had experienced at least one DRP during five days in hospital. On 
the other hand, among 100 patients who were probable to experience an ADR, the risk 
of DRP was three to five times higher. A patient with a definite ADR risk was predicted 
to experience 2.1 DRPs up to day five on the study ward or in other words, a group of 
10 patients with a definite ADR risk was predicted to experience 21 DRPs. 
Table 3.24: Univariable Poisson regression model 
ADR risk score Score interpretation Five days incidence rates of DRPs 
0 point Doubtful 0.23 
1 – 4 points Possible 0.3 – 0.6 
5 – 8 points Probable 0.7 – 1.3 
9 – 10 points Definite 1.7 – 2.1 
Multivariate analysis 
(I) In the multivariate analysis the data was modelled considering two time periods. 
Consequently two different models were presented. Model (A) shows initial DRP risk 
and model (B) follow-up DRP risk. Both selection procedures: forward selection and 
backward elimination, are jointly presented below as they showed similar results. 
(A) Initial DRP risk model 
Initial DRP risk model assessed risk of DRP up to 5th day in hospital, on the study 
ward. Significant risk factors are ECOG performance score (p = 0.003), presence of 
heart failure diagnosis (p < 0.001) and ADR risk score (p < 0.001). Parameter 
estimates are presented in the Table 3.25.  
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Table 3.25: Parameter Estimates – Model A 
Parameter B 
Std. 
Error 
95% Wald Confi-
dence Interval  
Hypothesis Test 
 
Exp(B) 
95% Wald Confi-
dence Interval for 
Exp(B) 
Lower Upper 
Wald 
Chi-
Square df Sig. Lower Upper 
Intercept -
3.990 
.5345 -5.038 -2.942 55.727 1 .000 .018 .006 .053 
ECOG = 3,4 .680 .2115 .265 1.094 10.329 1 .001 1.973 1.304 2.986 
ECOG = 2 .542 .2095 .131 .952 6.686 1 .010 1.719 1.140 2.591 
ECOG = 0,1 0a . . . . . . 1 . . 
HF = present -1.001 .2305 -1.453 -.549 18.865 1 .000 .368 .234 .577 
HF = not  
present 
0a . . . . . . 1 . . 
ADR Risk Score .442 .0770 .291 .593 33.022 1 .000 1.556 1.338 1.810 
(Scale) 1b          
Legend: B – coefficient estimate, Sig. – significance probability (p – value), ECOG – performance 
score values from 0 up to 4, HF – heart failure diagnosis;  
Dependent Variable: event_t5_sum, Model: (Intercept), ECOG, HF, ADR RS, offset = offset_t5,  
a. Set to zero because this parameter was redundant, b. Fixed at the displayed value. 
Validation of the initial DRP risk model estimated AUC of 0.777 (95 % CI 0.686 – 
0.868, SE 0.046, p < 0.001). True-positive rate (sensitivity or probability of detection) 
against false-positive rate (fall-out, probability of false alarm, 1 – specificity) is plotted 
in Figure 3.12. Considering equal importance of sensitivity and specificity, maximized 
sensitivity and specificity values were 0.738 and 0.722, respectively. That is the point 
on the ROC curve where sensitivity is the highest and 1 – sensitivity the lowest. 
The Table 3.26 shows the probability of no event (patients without DRP) during the 
first five days on the study ward. Column “Valid” represents the calculated probabili-
ties of no events. Column “Frequency” shows number of patients with particular prob-
ability. “Valid Percent” shows the percent of patients with particular probability. From 
the column “Cumulative Percent” it can be derived that half of the study patients had a 
no-event probability below 0.2 or a high probability (0.8) of experiencing DRP. Fur-
ther, 25 % of patients had no-event probability of above 0.5 or in other words, a quar-
ter of patients had a probability of 0.5 and less to experience a DRP 
Results 
 93 
Figure 3.12: ROC curve – Model A 
 
Table 3.26: Probability of no event (up to 5th day) 
 Valid Frequency Valid Percent Cumulative Percent 
 .01 3 3.0 3.0 
...    
.13 4 4.0 28.7 
.16 7 6.9 35.6 
.20 18 17.9 53.5 
…    
.51 5 5.0 79.2 
.52 1 1.0 80.2 
.55 1 1.0 81.2 
…    
.89 1 1.0 100.0 
Total 101 100.0  
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(II) Additionally, the analysis was run to predict the number of DRPs based on ADR 
risk score, as fixed variable. It was assessed whether the single ADR risk score fit to 
our data to predict DRPs. ADR risk score had p < 0.001, B 0.442, 95% CI 0.291 – 593 
in the multivariate analysis of the initial risk. Next, results suggested including two 
corrections: consideration of ECOG performance status and change of individual com-
ponent’s weight, heart failure, in ADR risk score. The corrections were based on the 
significant probability and presented below in transformed form to ease the use of the 
model in the practice. Other variable did not significantly influence the initial model.  
First correction in the score was ECOG performance status. ECOG was an informative 
variable with p = 0.003 (B 0.542, 95% CI 0.131 – 0.954). As shown in the Table 3.27 to 
implement ADR risk score in our population of oncology patients and predict initial 
risk of DRPs, it was necessary to consider ECOG. For the patient with no or low degree 
of functional impairment (ECOG performance status ≤ 2) there was no change in the 
risk of DRP compared to the one predicted solely on ADR risk score. But the patients 
with impaired performance status (ECOG score 2 – 4) should be interpreted for a class 
higher. That means, for instance, a patient with ADR risk score 4 and ECOG perfor-
mance score ≥ 2 were not possible than probable to experience an ADR. The risk went 
up for one interpretation class. 
Table 3.27: Multivariate analysis – Incidence rates of DRPs based on ADR risk score and 
ECOG performance status 
ADR risk score Score interpretation ECOG performance 
score < 2 
ECOG performance 
score ≥ 2 
0 point   Doubtful 0.02 0.05 
1 – 4 points   Possible 0.03 – 0.1 0.09 – 0.3 
5 – 8 points   Probable 0.2 – 0.6 0.5 – 1.9 
9 – 12 points   Definite 1 – 1.5 2.9 – 4.5 
Second correction was change of weight of individual component of ADR risk score, 
particularly heart failure. Other components should not be weighted differently, as 
they showed no statistical significance in the initial DRP risk model. Presence of heart 
failure diagnose was statistically significant with p < 0.001, B –1.001, 95% CI 0.2305 – 
1.453 and thereby needed lower critical interpretation. As the coefficient estimate of 
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heart failure was two times higher and had a negative value (Table 3.28), interpreta-
tion in the new score should be that the presence of heart failure lowers the risk two 
times. ADR risk score as predicting factor was hard on patients with heart failure. In 
other words, heart failure was overestimated in our study population as a component 
of the ADR risk score. Patients with heart failure were half risky. 
Table 3.28: Coefficient estimates interpretation 
Parameter Coefficient estimate Interpretation 
ADR risk score 
(fixed variable) 
0.44 Measure taken to interpret 
other coefficients 
Heart failure – 1 Risk lowers two times 
Finally, when these two corrections were considered, a new prognostic model Initial 
DRP risk score for oncology inpatients (Table 3.29) was proposed on the basis of 
ADR risk score. Two corrections brought two new parameter weights. ECOG perfor-
mance status was a new included parameter, where one point went to patients with 
ECOG performance status ≥ 2. Presence of heart failure diagnosis was instead of +1, 
weighted –1, as explained earlier. Total number of points in Initial DRP risk score 
stayed the same as in the ADR risk score, 10 points. The cut off point of 4 remained the 
same and it was confirmed in validation analysis of coordinates of the ROC curve of 
the Initial DRP risk score (AUC of 0.790 (95 % CI 0.697 – 0.883, SE 0.048, p < 
0.001), showing the sensitivity of 0.83 and specificity of 0.56. The prognostic ability of 
the model is shown in Figure 3.13. As a result, the interpretation of the Initial DRP risk 
score should not differ from the validated ADR risk score. In the ADR risk score, pa-
tients who had a higher score than 5 were considered together as being more prone to 
ADRs then the patients with lower ADR risk score 0 – 4 [57, 167]. Consequently, for 
the interpretation of the prognostic model, it was proposed to combine “probable (5 – 
8 points)” and “definite (9-10 points)” naive interpretation class into “highly probable 
(5 – 10 points)” to experience DRP during the stay on the oncology ward (Table 3.30).  
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Table 3.29: New prognostic model “Initial DRP risk score” (* new weights of parameters) 
Parameter Weight of parameters:  
ADR risk score 
(points) 
New weight of parameters: 
Initial DRP risk score 
(points) 
Number of drugs ≤ 5 drugs      0 
6 or 7 drugs   +1 
≥ 8 drugs    +4 
≤ 5 drugs      0 
6 or 7 drugs   +1 
≥ 8 drugs    +4 
Previous ADR No 0. Yes +2 No 0. Yes +2 
Comorbidities No 0. Yes +1 No 0. Yes +1 
Heart failure No 0. Yes +1 No 0. Yes -1 * 
Renal failure No 0. Yes +1 No 0. Yes +1 
Liver disease No 0. Yes +1 No 0. Yes +1 
ECOG performance score / ECOG 0.1  0 *          ECOG ≥ 2  
+1 
Total (maximum) 10 points 10 points 
Table 3.30: Proposal of “Initial DRP risk score” interpretation 
DRP risk score    DRP occurrence 
0 point    Doubtful 
1 – 4 points    Possible 
5 – 10 points    Highly Probable 
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Figure 3.13: ROC curve – Score 
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(B) Follow-up DRP risk score 
Follow-up DRP risk model assessed the risk of DRP from 5th day up to 10th day in  
hospital on the study ward. Significant risk factors were ECOG performance status  
(p = 0.039) and presence of renal failure diagnosis (p = 0.016). Parameter estimates 
are presented in the Table 3.31. 
Table 3.31: Parameter Estimates – Model B 
Parameter B 
Std. 
Error 
95% Wald Confi-
dence Interval  
Hypothesis Test 
 
Exp(B) 
95% Wald Confi-
dence Interval for 
Exp(B) 
Lower Upper 
Wald 
Chi-
Square df Sig. Lower Upper 
Intercept -2.627 .3811 -3.374 -1.880 47.492 1 .000 .072 .034 .153 
ECOG = 3,4 .893 .4381 .034 1.751 4.155 1 .042 2.442 1.035 5.763 
ECOG = 2 .842 .5181 -.173 1.858 2.642 1 .104 2.321 .841 6.409 
ECOG = 0,1 0a . . . . . . 1 . . 
RF = present .931 .3877 .172 1.691 5.771 1 .016 2.538 1.187 5.427 
RF = not  
present 
0a . . . . . . 1 . . 
(Scale) 1b          
Legend: B – coefficient estimate, Sig. – significance probability (p – value), ECOG – performance 
score values from 0 up to 4, RF – renal failure diagnosis;  
Dependent Variable: event5_t10_sum, Model: (Intercept), ECOG, RF, offset = offset_t5_10,  
a. Set to zero because this parameter was redundant, b. Fixed at the displayed value. 
Validation of the follow-up DRP risk model estimated AUC of 0.683 (95 % CI 0.532 – 
0.835, SE 0.077, p = 0.033). True-positive rate (sensitivity or probability of detection) 
against false-positive rate (fall-out, probability of false alarm, 1 – specificity) is plotted 
in Figure 3.14. Considering equal importance of sensitivity and specificity, maximized 
sensitivity and specificity values were 0.688 and 0.667, respectively. That is the point 
on the ROC curve where sensitivity is the highest and 1 – sensitivity the lowest. 
Table 3.32 shows the probability of no event (patients without DRP) from the 5th day 
until the 10th day on the study ward. Column “Valid” represents the calculated proba-
bilities of no events. Column “Frequency” shows number of patients with particular 
probability, “Percent” shows the percent of patients with particular probability. “Valid 
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percent” is the percent of patients, when those discharged from the study ward before 
the 5th day are excluded. 60 % of patients stayed longer than 5 five days on the study 
ward. From the column “Cumulative Percent” it can be derived that less than 10 % of 
the study patients had a no-event probability below 0.2 between 5th and 10th day, or 
high probability (0.8) of experiencing DRP in that time. Further, 40 % of patients had 
no-event probability below 0.5. No patient had a no-event probability higher than 0.75 
after the 5th day on the study ward.  
Figure 3.14: ROC curve – Model B 
 
Probability of no event for the entire time period (Initial and Follow-up) up to 10th day 
in hospital is presented in Table 3.33. It can be seen that over 10 days on the ward 
50 % of patients had a no-event probability of 0.13 or below, in other words high prob-
ability of experiencing DRP. Furthermore, over 10 days on the study ward 92 % of 
patients had a no-event probability below 0.5 in other words – more than 90 % of 
patients had a probability of experiencing DRP 0.5 or higher during 10 days on the 
study ward.  
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Table 3.32: Probability of no event (from the 5th day up to 10th day) 
 Valid Frequency Percent Valid Percent Cumulative Percent 
 .17 4 4.0 6.3 6.3 
.18 1 1.0 1.6 7.9 
.48 7 6.9 11.1 19.0 
.49 15 14.9 23.8 42.9 
.51 11 10.9 17.5 60.3 
.75 25 24.8 39.7 100.0 
Total 63 62.4 100.0  
 Missing  38 37.6   
 Total 101 100.0   
Table 3.33: Probability of no event (up to 10th day on the study ward) 
 Frequency Percent Valid Percent Cumulative Percent 
 Valid .00 2 2.0 3.2 3.2 
.01 3 3.0 4.8 7.9 
...     
.10 3 3.0 4.8 42.9 
.11 3 3.0 4.8 47.6 
.13 1 1.0 1.6 49.2 
.15 7 6.9 11.1 60.3 
…     
.29 2 2.0 3.2 82.5 
.38 2 2.0 3.2 85.7 
.43 1 1.0 1.6 87.3 
.49 3 3.0 4.8 92.1 
.51 2 2.0 3.2 95.2 
.58 1 1.0 1.6 96.8 
.63 2 2.0 3.2 100.0 
Total 63 62.4 100.0  
 Missing  38 37.6   
 Total 101 100   
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3.4  Discussion 
In order to ensure safe and effective drug therapy for cancer patients, a structured 
approach in multi-professional collaboration is essential [21, 22, 118, 119, 168]. This 
feasibility study represents first steps toward an effective multi-professional teamwork 
on the oncology ward in the hospital setting and may be the basis for the model evalu-
ation on a big scale. 
Within the scope of this feasibility study the developed model was assessed for 
strengthening the drug management in cancer patients. The results showed that inte-
grating the pharmaceutical care service and applying the patient-related outcome 
questionnaire had contributed to the multi-professional collaboration and had a po-
tential to improve patient safety. DRP prediction model offers further optimisation of 
the pharmaceutical care service in oncology.  
Results with their strengths and limitations, as well as interpretation and generalisa-
bility of the study are discussed below.   
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3.4.1 Participants 
The inclusion and supervision of study patients was carried out consistently. All pa-
tients who fulfilled the inclusion criteria during the study period were included. How-
ever, it has to be mentioned that the inclusion criteria had to be solved individually on 
the ward. Based solely on electronically available patient documentation, eligible pa-
tients could not be identified. Notably greater time was needed than initially planned 
to identify patients with appropriate inclusion criteria. The documentation gaps in the 
hospital information system might have caused the exclusion of some patients in the 
study. However, this proportion of patients is estimated to be rather low.  
In this feasibility study 101 patients were included with fairly equal gender distribution 
(55 men and 46 women) and the average age was 65 (min 26, max 91). Previous feasi-
bility study of our research group had comparable population – 306 patients (ca. 100 
on every ward), equal gender balance (166 men and 140 women) and average age 66 
(min 18, max 97) [49]. Lenssen with colleagues conducted the study on three other 
UKA wards: urology, neurology gastroenterology, and had the same inclusion criteria 
when non-disease specific parts are concerned – minimum of three days on the ward 
and medication plan at the hospital admission. Each investigated ward defined the 
disease-specific characteristics of inclusion criteria. An average age of cancer patients 
on the national level is 69 years [70]. Present study has on average slightly younger 
patient population. 
Patients with solid and haematological tumour diagnosis were evenly distributed. The 
most frequent solid tumour type was malignant neoplasm of bronchus or lung with 
23.8 % and most frequent haematological tumour diagnoses were diffuse large B-cell 
lymphoma with 15.8 % and multiple myeloma with 13.9 %. The study ward had two 
focuses: haematology-haemostasis and oncology. The expertise of the study ward was 
in leukaemia, lymphoma, multiple myeloma among haematology-haemostasis diseas-
es, and the area of the bronchial carcinoma, the head and neck tumours among onco-
logical diseases. Given these points, it could be said the diagnosis distribution of the 
study met the expectations. However, this did not coincide with general distribution of 
cancer diagnosis in Germany, where beside the lung cancer - prostate, the breast and 
intestinal cancer were the most frequent cancer diagnosis as stated in last report “Can-
cer in Germany 2011/2012” by the Robert Koch Institute and Association of Popula-
tion-based Cancer Registries in Germany (GEKID) [70]. 
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3.4.2 Pharmaceutical care 
Provided pharmaceutical care service was based on the premise to maintain the cur-
rent state of good, evidence-based pharmaceutical recommendation [169]. Pharma-
ceutical team had access to the medical-scientific databases and interaction software 
available at the UKA. The service was tested in previous projects of our research group 
and was defined as SOP for the succeeding studies, corresponding to the recommenda-
tions on design and evaluation of complex interventions to improve health care service 
[170]. The equality of observation was thereby ensured for all patients throughout the 
study period. As stated in previous works of the clinical pharmacy research group in 
Bonn [171, 172], it is important for a scientific evaluation of a new service that the 
pharmaceutical care (intervention) as well as the collection of the data (observation, 
documentation) is consistently conducted throughout the entire study period to all 
participants. The research pharmacist, the author of the present work, conducted each 
phase of the service. The collection and documentation of the data was therefore uni-
form which is an optimal prerequisite for the comparability of the results. For the first 
time the comprehensive pharmaceutical care was applied on the oncology ward. How-
ever, it was tested before on different UKA wards and study populations [51]. This 
provides a possibility to optimally compare the study results and thereby the needs of 
pharmaceutical care on various wards and patient populations. 
Expenditure of time for pharmaceutical care provided during the entire patient’s hos-
pital stay was on average 8 h/patient. Therefrom, 6.4 hours on average were individual 
work of the research pharmacist. The rest of 1.6 hours/patient on average was team-
work: within pharmaceutical team itself and interactions with the ward based team. 
Time for data insertion, evaluation and analysis was not included. Previous studies on 
different ward of UKA [51] determined an overall time requirement of about 
6 h/patient for inpatient pharmaceutical care. Lenssen and the team had a single clini-
cal pharmacist supervising the patients, therefore no time expenditure for pharmaceu-
tical team discussions as in present study. Taking that into the consideration, the 
expenditure of time of the two studies is quite similar.  
An eight-hour care per patient with an average patient stay on the ward of ten days 
means a daily expenditure of about 50 minutes. For instance, on a ward with 30 beds, 
this represents a considerable need for additional medical stuff. Potential solution can 
be the involvement of a trained pharmacist [51] or trained pharmaceutical team 
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providing pharmaceutical care on the ward, as showed in this study. However, in order 
to achieve measurable benefit through pharmaceutical care an appropriate prior 
knowledge and training is needed. Further, it opens a discussion about task allocation. 
Different occupational groups involved in the medication process may potentially 
provide individual elements. Recent Cochrane Review showed several studies on inpa-
tient medication management in which pharmacists and/or physicians performed the 
intervention. It was not possible to determine which professional group and/or which 
team constellation shows as the best option [45]. Taken an example of UKA hospital, 
integrating comprehensive medication safety review within the framework of physi-
cians is simply not feasible in the determined physician’s working hours. Thus, further 
resources are necessary to enable complete medication management. Finally, a multi-
professional team with clearly defined roles and responsibilities, with integrated clini-
cal pharmacist within it, offers a solution for safer medication therapy and conse-
quently enhanced patient safety.  
Multi-professional team 
Good cooperation among all parties involved: patient, physicians, nurses and pharma-
cists underpin the successful study implementation. For the first time, such team con-
stellation was introduced on the UKA oncology ward. As described in 3.2 Methods the 
exciting team rolls of nurses, physicians and patients were maintained. Presence and 
structured activity of the pharmacist in the team as well as additional shift of focus on 
more active patient’s role caused the described adjustment. In this feasibility study, 
the main focus was to measure contribution of a new member – pharmacist, and 
structurally evaluate direct patient-provided outcome. Thereby, a solid foundation for 
further optimisation of the multi-professional medication management process was 
formed. Following the recommendations [173-175], our goals were achieved on ac-
count of evidence-based decision-making and improved communication between the 
participants, placing the patient at the centre of medical care attention.  
Throughout the whole study, the positive acceptance of the pharmacist in the team 
was present. Each cooperating party showed strong motivation and competent support 
in participation and contribution to the overall goal of safe patient and medication 
therapy. The high implementation rate of PR of 93 % has confirmed it. Previous stud-
ies of Lenssen et al. on other UKA wards obtained the acceptance rate ranging from 68 
up to 80 % [51]. Given these points, it is clear the pharmacist was welcomed and highly 
accepted in the multi-professional oncology-ward based team.  
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However, the acceptance of pharmacist on the ward varies among different German 
hospitals. Comparably high implementation rate of pharmaceutical intervention of 
93 % was shown in the departments of stem cell transplantation and intensive care 
medicine in the University hospital in Hamburg [176]. Optimising the medication 
management of neurological patients had 89 % [47] and of cardiological patients 63 % 
[46] successfully implemented interventions. A multi-centric study exploring the po-
tential of a hospital pharmacist on the ward addressed acceptance rate from 11% up to 
63 % [177].  
In light of international studies, for example in Norway, an acceptance rate of recom-
mendations on DRPs in discussion with the physicians was 50 % concerning the DRPs 
with low clinical relevance and up to 80 % with very important and clinically relevant 
DRPs [178]. A study from Switzerland determined an acceptance rate of 83 % [179]. 
An old review from 1990 showed an average acceptance rate of 85 % based on 23 stud-
ies [180]. Recent Cochrane review about inpatient care for elderly patients reported 
implementation rates of 18-94 % [45]. Giving emphasis to the haemato-oncology 
ward, the implementation rate of pharmaceutical interventions ranged from 60 % in 
Swedish hospital up to 96 % in French hospital [98, 181]. 
Putting in perspective, the present study is in the upper third of national and interna-
tional available literature data. 
Bias  
Concerns about infrastructure and information bias were raised during the methodol-
ogy development. Integrating pharmacist in the routine work of the ward-based team 
was highly accepted and welcomed on the study ward. Döhler et al. have shown the 
benefit of the integrated pharmacist, thereby supporting our approach. They compared 
two types of pharmaceutical care service for breast cancer patients. A pharmacist on-
demand provided first type of the service in multiple study centers, considered as 
control group, and a pharmacist integrated in the cancer care team in one study center 
provided the second service type, considered as intervention group. Significantly more 
DRPs (2.5 times) were identified in the intervention group with an integrated pharma-
cist than in the control group with on-demand pharmacist. Although the total number 
of interventions did not significantly differ, several specific interventions indicated the 
advantage of more team- and medication-related role of the integrated pharmacist. 
Both pharmacist types were highly recognized and considered as valued source of 
information for the cancer patients though, at the end of that study the integrated 
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pharmacist received significantly higher scores [182]. However, recent Cochrane sys-
tematic review of complex interventions using medication reviews in the hospital set-
ting indicated different professional groups performing the medication review. 
Focusing on patient-related outcomes, it is irrelevant who performs the medication 
review as long as the team performing medication review includes members that are 
competent to change patient medications [45]. This leads us to suggestion for further 
evaluation study. The present study did not assess if the infrastructure and infor-
mation biases could be avoided. For that purpose in the following study the team could 
organize the focus group to discuss the current status quo of the multi-professional 
team. Each profession should have a chance to address benefits and shortcomings of 
the current infrastructure and task allocation of the team. Further, each profession 
should suggest ways how to enhance communication and teamwork from the patient's 
point of view. 
Setting up the pharmaceutical team of two pharmacists was the best solution in the 
given circumstances at the UKA. DRPs detection, pre-selection and respective PR to it, 
showed great acceptance (implementation rate 93 %). However, the pre-selection of 
DRPs left many other potential DRPs, which the present pharmaceutical team did not 
considered. In order to evaluate the work of the pharmaceutical team, the following 
evaluation should consider documenting both: (1) all potential DRPs and (2) selected, 
relevant DRPs leading to the pharmaceutical intervention (as in the present study). In 
order to assess the value of the pre-selection, an external and blinded outcome as-
sessment committee may be involved in the study team. As a result, the detection bias 
would be more effectively controlled. 
3.4.3 Patient-Reported Outcomes version of the 
Common Terminology Criteria for Adverse 
Events (PRO-CTCAETM) 
Paper-based administration of PRO-CTCAE questionnaire was the most suitable in 
this setting. On behalf of the NCI PRO-CTCAE Study Group, Bennet et al. indicated 
the mode equivalence of tablet computer-, interactive voice response system- and 
paper-based administration of PRO-CTCAE, observing very small mean differences 
between modes intraclass correlation coefficients (median 0.80). This evidence sup-
ports study designs that are responsive to patient or investigator preference for mode 
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of administration, and justifies comparison of results and pooled analyses across stud-
ies that employ different PRO-CTCAE modes of administration [183]. 
The recall period in the study was the past seven days as suggested by NCI. The change 
of the PRO-CTCAE score over time was more of case reports, presented only descrip-
tively and for particular patients. A recent trial from Mendoza et al. evaluated the 
differences between one-, two-, three-, and four-week recall periods, using daily re-
porting as the reference. The trail reported that a one-week recall corresponded well to 
daily reporting. Small but progressively larger differences between daily and longer 
recall period were observed, although correlations remained stable over time. There-
fore, the preferred recall period was the past seven days. When longer recall periods 
have to be selected as dictated by logistics, it is recommended to consider some loss of 
information [184]. 
The German core set PRO-CTCAE was used in the present study merely descriptively. 
Further inspiration on how to measure the effect of multi-professional medication 
management by the German core set PRO-CTCAE can be gained from the recently 
published PhD thesis of the clinical pharmacy research group in Bonn. They developed 
and evaluated the best practice model to increase the medication safety in outpatient 
cancer care. The model included a basic module for medication analysis and modules 
for the symptoms such as nausea and vomiting, mucositis, fatigue and pain. In a ran-
domised two-arm intervention study, multi-professional medication management was 
evaluated by the onset time of four selected symptoms, or PRO-CTCAE score 3 or 4, 
measured over five cycles of therapy. The results showed that the median onset time of 
symptoms of PRO-CTCAE scores 3 or 4 could be extended from two cycles in the con-
trol group to three cycles in the intervention group. The results were not statistically 
significant. Nevertheless, a trend towards the later onset of serious symptoms could be 
observed for all four studied symptoms [174].  
Symptoms burden and attributes 
Fatigue occurred in over 50 % of all patients interviewed. Comparatively, a systematic 
review of 21 studies with a total of 4,067 patients from Reilly et al. revealed a pooled 
prevalence of fatigue of 60 % in patients under cancer therapy, chemotherapy and/or 
radiotherapy [185]. In a cross-sectional study with a total of 1,569 patients included, 
fatigue occurred in 80 % of patients receiving cancer therapy [186]. The other studies 
indicated fatigue as the most frequent symptom as well, with prevalence range from 
4 % to 92 % [174, 187].  
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The second most common symptom was anxiety and sadness present with almost 
every second patient (47 %). Similarly, the cross-sectional study reported prevalence of 
anxiety of 46 % [186]. In the review by Reilly et al. depression and sadness were mod-
erately present with a pooled value of 34 % [185].  
Pain was present with 41 %. This value was confirmed by other investigations [174, 
185, 186]. Sleep problems occurred in 35 % of patients, where other studies reported 
slightly higher prevalence range from 45 to 74 % [174, 185, 186]. Appetite loss with 
31 %, dyspnoea with 28 % and mental concentration with 24 % were to some degree 
less frequently present as the pooled values indicated the prevalence of each symptom 
of about 45 % [185]. Mucositis and xerostomia occurred in 10 % of patients. In the 
literature different values were reported. The review outlined pooled prevalence of oral 
lesions of 5 % [185] but in other literature sources the occurrence of mucositis and 
xerostomia was 25 % [174, 186]. Rather minor symptoms were: nausea and vomiting 
with 16 %, diarrhoea with 11 %, constipation 8 %, numbness and tingling with 5 %. 
Although the pooled prevalence of diarrhoea was quite similar with 15 % [185], a prev-
alence of about 40 % was described in the literature for these four symptoms. 
Eight different symptoms in 13 patients were not adequately controlled by patient self-
report and therefore needed a pharmaceutical recommendation. The two most com-
mon symptoms, fatigue and insomnia, were the most frequently included in the rec-
ommendations, which was three times. Dyspnoea was included twice. In 87 % of 
patients the symptoms, although present, had been appropriately controlled by the 
standard medical team on the ward. This represents good, close and trustful collabora-
tion between physicians, nurses and patients already existing on the study ward.  
The research pharmacist conducting the interview and directing PRO-CTCAE item 
questions to the patients was a new member in the well-coordinated standard ward 
team. The full response rate was indisputable. The research team considered the rec-
ommendations for incorporating PRO in the clinical trials such as limited time for data 
collection and real-time monitoring of adherence with backup data collection [164]. 
However, the approach can potentially raise a concern of response bias. A strategy 
called “self-administered questionnaires” involves isolating the participant before they 
begin answering the questionnaire to hopefully remove any social cues the researcher 
may present to the participant [188]. This may be a solution for the following trials. 
Important to mention here is that the potential response bias may be an answer why 
majority of symptoms are less frequently presented in this study than in the others.  
Discussion 
 109 
When concerned with PRO-CTCAE attributes, it was shown that patients with im-
paired performance status encountered more frequently adverse events and had self-
reported more adverse events that interfered with their usual or daily activities. Fur-
ther, patients with more than eight drugs prescribed faced more self-reported adverse 
events that interfered with their usual or daily activities than patients with less drugs 
prescribed, as well as the patients with solid tumour diagnosis. On the other hand, 
major part of patients, who had experience of severe self-reported adverse events, had 
at least one DRP. 
3.4.4  Drug-related problems 
Documentation and classification 
The research pharmacist, author of this work, documented DRPs during the entire 
pharmaceutical care process. This has ensured that the DRPs were documented 
promptly up on the detection and intervention, avoiding distortions in the documenta-
tion process.  
Paper-based system APS-Doc® for classification of DRPs in the hospital setting in 
Germany was used [64]. The system existed as a table where the user was required to 
design a corresponding data digitalisation for data evaluation. Given that UKA at the 
time had a purely paper-based documentation of the drug regulation and application 
on the wards, the data collection was paper-based. The exception on the study ward 
was that the cancer drugs were electronically prescribed making the cancer drug list of 
each patient electronically available. Although, the APS-Doc® system was the most 
suitable based on the previous work in UKA [51], it should be noted that the classifica-
tion into such system is always dependent on the observer’s assessment of the respec-
tive case. When Hohmann and the team developed the APS-Doc® system they 
reported kappa correlation coefficient of 0.71 [64]. However, an analysis of the Dres-
den University hospital showed a kappa coefficient of 0.52 for the same system [189]. 
This shows the assessment of DRPs with APS-Doc® system leaves a certain room for 
individual interpretation. To minimise that, in the present study the classification of 
the data was performed by a single person, the research pharmacist - the same person 
who knew the patient’s case, who was present at the study ward and who had collected 
the DRPs. In addition, all classifications were checked for consistency within the 
pharmaceutical team, the research pharmacist and the oncology pharmacist. 
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Types of DRPs and resulting interventions 
DRPs leading to a pharmaceutical intervention were collected for the first time from 
the oncology ward and classified into ten main DRPs categories defined by the 
APS-Doc® classification system. Each DRP category had one or more subcategories, 
making together 48 different DRP subcategories [64]. 
The predominant category of DRPs leading to pharmaceutical intervention was DDI 
with 53 %. Unsurprisingly, as the median of prescribed drugs was 13. The large num-
ber of prescribed drugs administered to cancer patients leads to a high potential for 
DDIs [72]. In addition to antineoplastic agents and drugs to treat comorbid condi-
tions, cancer patients usually receive medications to treat both therapy-induced toxici-
ty and cancer-related syndromes, such as pain, seizures, and venous thrombosis. The 
risk of drug interactions is further heightened because the cancer patient’s pharmaco-
kinetic parameters may be altered. The change in pharmacokinetic parameters may be 
due to a number of factors: impaired drug absorption due to mucositis and malnutri-
tion, variation in a drug’s volume of distribution because of reduced levels of serum-
binding proteins and generalised oedema, or, in patients with renal and/or hepatic 
dysfunction, altered drug excretion [91, 92]. Prevalence of DDIs among cancer pa-
tients has been reported from 18 % up to 83 % [91, 190]. For instance patient X in the 
present study had chemotherapy-induced myelosuppression. Although predictable 
side effect of doxorubicine, in this case was intensified due to concomitant use of on-
dansetron, citalopram and melperone. Another example, patient Y, had strong comor-
bid DDI. Amlodipine, carvedilol, mirtazapine and phenoxubenzamine in a 
concomitant therapy caused serious oedema. Those are examples that not all DDIs can 
be predicted, and those that are predictable are not always avoidable. However, in-
creased awareness of the potential for these interactions allows healthcare providers to 
minimize the risk by choosing appropriate drugs and also by monitoring for signs of 
interaction [90]. The appropriate DDI evaluation is, thereby, highly beneficial. As 
described in 3.2.6.2 DDI Assessment, the pharmaceutical team directed special atten-
tion to the assessment of DDIs. That contributed to the continuous monitoring of all 
potential DDIs and adequate intervention when needed. Furthermore, the software 
detection of drug interaction supplied the supporting information in order not to miss 
any interaction. Although usual heavy information load provided by the software was 
particularly time consuming, it provided reassurance mechanism of full commitment 
to the details in the process of medication therapy management.  
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In the previous work on other UKA wards, DDI was the most common DRP category 
leading to PI on the neurology ward. Comparable value of 55 % of DDIs could be ex-
plained with a high interaction potential neurological drugs have. On the urology ward 
26 % of DRPs were related to DDIs that led to PI and notably lower 15 % on the gas-
troenterology ward [49]. 
Second most common category of DRPs leading to PI on the oncology ward was  
“Dosage” with 14 %. The subcategories: “Dose to low/high”, “Inappropriate admin-
istration interval” and “No dosage adjustment in case of renal failure” were the most 
prominent. The proportion on the urology ward and the gastroenterology ward of UKA 
was similar with 13 % and 15 %, respectively [49]. These DRPs can be identified and 
solved within the comprehensive MSR underling thereby its importance. 
Third, in the descending order of DRP frequencies, was a category “Drug” 8 %, where 
in the present study the subcategories “Transcription error/unintended discontinua-
tion of drug therapy (during the hospital stay)” and “No/inadequate drug monitoring” 
dominate. Transcription error happened mostly at the transition of care from the 
emergency department to the oncology ward. On the other side, at the urology ward 
30 % of the DRPs were found in the category “Drug” (e.g. “incomplete drug history” or 
“unintended discontinuation of drug therapy” and “inadequate generic substitution”), 
21 % on gastroenterology ward and 14 % on neurology ward [49]. Extended medica-
tion history and following medication reconciliation offer a solution to reduce those 
issues. Implementing the proposed pharmaceutical activities in the routine ward-
based work could prevent them from happening. The following substantial DRP cate-
gory was “Indication”, e.g. no indication for certain medication, or inappropriate med-
ication for the given indication, no medication prescribed/suboptimal dosage with an 
existing indication. Recognised more as a setback (higher percentage of DRPs) at the 
internal wards where patients have extensive medication therapies: the study ward 
had 13 average medications prescribed and at the gastroenterology ward, where 
Lenssen with her team worked, there were 16 average medications prescribed [49]. 
The standard national medication record as part of the Action Plan for the improve-
ment of medication safety in Germany, as mentioned before, was introduced at the 
end of 2016. The present study was not influenced by it. However, that step represents 
one of the strategies to uniformly transfer patient’s medication therapy record between 
the interfaces such as ambulatory care - hospital care, and to a certain extend to avoid 
above given problems. 
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DRPs led to various pharmaceutical interventions. To a large extent, the pharmaceuti-
cal team suggested to stop/pause the drug, advised to change the drug dose or initiat-
ed further diagnostic tests. Further, during the intensive discussions, the 
pharmaceutical team provided additional information to the attending physicians and 
nurses regarding the drugs and also, different solutions on variety of potential scenari-
os were suggested. Thereby, the most appropriate drug choice in terms of efficacy, 
dosage, adverse events, and interactions was specified. The close collaboration with 
the medical team resulted in measurable and valuable contribution to the optimisation 
of the pharmacotherapy.  
Taking into consideration comparable literature on the national level on the oncology 
ward, it is relevant to refer to the evaluation of ward-based clinical pharmacists inter-
ventions at the university hospital in Hamburg. Among 10 different wards where the 
intervention was provided, haematology/oncology and stem cell transplantation ward 
outnumbered the others wards. DRPs leading to clinical pharmacist intervention were, 
above all, wrong dose or no dose adjustment, inappropriate drug or no clear indication 
for the drug and advice to the medical team/selection of drug. The most frequent in-
terventions on those DRPs were recommendations for addition, withdrawal or re-
placement of a certain drug and recommendations for changes of dosage, dosing 
intervals or dose adjustment according to the level of renal or liver impairment [176]. 
Further, in the recent PhD thesis from the clinical pharmacy research group in Bonn, 
two pharmaceutical care services for breast cancer patients were compared. Pharma-
cist on-demand in the control group recorded on average 2.7 DRPs (median 2, IQR 1 – 
4, range 0 – 9), where the pharmacist integrated in the team documented 6.7 DRPs 
(median 6, IQR 4 – 8, range 1 – 33). The observed difference of 4 DRPs/patient was 
statistically significant (p < 0.001, Mann-Whitney U-test). ADR was the most recur-
rent DRP, making 76 % of all DRPs. The most repeated intervention was interviewing 
and counselling the patients, 25 % of all interventions. Other frequent interventions 
were recommendation of a drug/treatment (15 %) and documentation of symptoms of 
an ADR (14 %) [182]. 
In the context of international literature, there are several studies on outpatient cancer 
care, DRPs and therapy optimisation. Prospective studies showed that pharmacy-
directed seamless care could identify from 1 up to 3 DRPs per patient and had high 
acceptance rate of the intervention of 93 % [191-194]. It is important here to mention, 
that the studies that have identified 3 DRPs per patient, reported all DRPs a pharma-
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cist could detect [192, 194]. Given that in the present study only DRPs leading to PI 
were evaluated (2 DRPs per patient) and not all DRPs pharmaceutical team that could 
have potentially be detected, there is a limited use of such a comparison. On the other 
hand, the studies in inpatient setting, reported from 1.1 DRP/patient up to 
2 DRPs/patient leading to PI, presenting thereby similar results. Further, those stud-
ies had resemblance in character of DRPs when compared to the present study. The 
most common DRPs were untreated/not enough treated indications, inappropriate 
medications and DDIs [98, 181, 195]. Although one can observe the similarity of the 
DRP characteristics, it has to be considered that every study uses different DRP classi-
fication system and thereby partially limits the comparison effect.  
3.4.5 Drug-related problem prediction model 
To provide more in-depth understanding of DRP risk pattern the Poisson regression 
model was performed. As throughout this study, DRP referred to those DRPs leading 
to PI in oncology patients. With the Poisson regression model multiple predictors were 
investigated. The significant multiple predictors were combined in a tool by assigning 
relative weights to each predictor. The tool, also commonly called “prediction model” 
or “prognostic model” or “risk score” was transformed to ease its use in practice. The 
developed prediction model can be used to aid health care provider in estimating the 
risk that the DRP will occur during the stay on the oncology ward and to inform their 
decision-making.  
The Poisson regression model assumed the risk of experiencing a DRP was the same 
each day of the hospital stay. However, nature of the provided intervention did not 
assure it. Instead, the two time periods could be distinguished during which the pro-
vided intervention assured the same risk of DRP. That was the initial and the follow-
up time on the study ward. The initial time period was related to the beginning of the 
stay on ward, up to the 5th day in hospital. In that time, the patient was recruited in the 
study (within first three days of the hospital stay) and pharmaceutical team performed 
extended patient medication history, medication reconciliation and MSR. If any DRP 
had been detected, first pharmaceutical intervention was provided up to the 5th day 
(the latest). Follow-up time period was related to the time after the initial time. On 
average patient stayed on the ward for 10 days. Hence, the time span of five days was 
considered, from the 5th day up to 10th day of the hospital stay. This proved compara-
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ble number of days with the initial time period. Under those circumstances, two DRP 
risk models were presented: Initial and Follow-up. Initial DRP risk model referred to 
the initial time period that is up to the 5th day and Follow-up DRP risk model from the 
5th up to the 10th day on the study ward.  
When the two models were compared, the initial model showed more significant risk 
factors predicting what patients were more likely to experience DRPs than the follow-
up model. This could be explained by the fact that all patients were treated equally at 
the beginning of the hospital stay. Pharmaceutical team with no exception implement-
ed step-by-step intervention (3.2.5 Intervention). Particularly at the hospital begin-
ning, the intervention took a considerable amount of time. Once the initial time period 
was over, every further step of the pharmaceutical care was adjusted to each patient. 
That means that the pharmaceutical care was at that stage (follow-up period) nar-
rowed and adjusted entirely to the patients’ needs. Certain parameters were more 
important to one patient and different ones for the other patient. Consequently, the 
Follow-up DRP risk model was as expected less informative. Only two risk factors were 
shown as potential predictor of DRPs leading to pharmaceutical intervention. In the 
follow-up time period it was more difficult to foresee which oncology patient subgroup 
was more prone to DRPs leading to pharmaceutical intervention. Further, pharmaceu-
tical care approach was at that time rather individualised then generalised.  
Initial DRP risk prognostic model showed as significant risk factors ADR risk score 
and ECOG performance score. ADR risk score itself [57, 167] contains six risk factors: 
presence of renal failure/heart disease/liver disease/four or more comorbidities,  
history of ADRs and polypharmacy. These risk factors were prominent in the literature 
for DRPs concerning the general inpatient population as well [107, 114, 116, 166]. The 
ECOG performance status represented one of the recommendations for researchers 
planning oncological clinical trials [163]. It was a significant factor in both (Initial and 
Follow-up) models, indicating relevant parameter for following oncology studies in 
our research group. In the Follow-up model, impaired renal function was the signifi-
cant risk factor. Thus, the patients with instable renal function were more likely to 
experience a DRP leading to a pharmaceutical intervention during the longer stay on 
the study ward.  
Further, DRP risk models were presented in light of the probability of no event. No-
event probability up to 10 days on the study ward was in more than 90% of patients 
equal or below 0.5. When observing only the follow-up time period, from the day 5 up 
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to day 10 on the study ward, it could be seen that only 40% of patients have no-event 
probability equal or below 0.5. On the other hand, in the initial time period, up to day 
5 on the study ward, 75% of patients had no-event probability equal or below 0.5. On 
that account, in the study sample patients had a higher probability of experiencing 
DRP leading to pharmaceutical intervention in the initial time period (up to 5th day) 
on the ward. This could be explained by fact that in the initial time period DRPs exist-
ing prior to hospitalization were recognized and resolved, too. 
Additionally, the initial DRP prediction model was transformed to ease its use in the 
routine work and the scoring system was proposed. The prognostic ability of the model 
was graphically plotted in the ROC curve and the AUC was 0.790 (95% CI 0.697 – 
0.883). As an AUC of the ROC curve of 0.5 indicates no discrimination and an AUC of 
1.0 indicates perfect discrimination, the AUC of the DRP prediction model indicates a 
fair, not terminally reliable or accurate model. The DRP score for general inpatient 
from Urbina et al. had comparable AUC of 0.776 (95% CI 0.759 – 0.792) in the valida-
tion set cohort [116]. As the DRP model was based on ADR risk score fixed variable, 
the interpretation in the new score was proposed on the same basis. Cut off was at five 
points i.e. patients with five and more points were prone to DRP. The cut off point was 
confirmed in the analysis of coordinates showing good sensitivity (0.83) and slightly 
lower specificity (0.56). The tools available in the literature were either self-
assessment tools or screening tools for clinical pharmacists. Either of them showed 
comparable sensitivity ranging from 0.81 to 0.95 and specificity from 0.58 up to 0.61 
[113-115]. 
Strengths and limitations of the DRP prediction model 
Based on the current results, the Initial DRP risk score has a modest role in predicting 
DRPs up to day five on the oncology ward. The score strengths are that it is based on a 
statistical analysis of variables and supplemented with data from the literature. 
Knowledge of the variables associated with DRP can assist in early prediction of  
oncology at-risk patients. Despite the thorough statistical approach, the critical score 
limitation is the prediction model development on a small cohort. Study sample of 101 
patients was restricted to produce valid and relevant tool. Only the prediction ability of 
the model could be shown and no internal or external validation.  
Quantifying the predictive ability of a model on the same data from which the model 
was developed tend to give an optimistic estimate of performance, owing to over-
fitting (too few outcome events relative to the number of candidate predictors) and the 
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use of predictor selection strategies [196]. Therefore, it is suggested that studies devel-
oping new prediction models include some form of internal validation to quantify any 
optimism in the predictive performance (for example, calibration and discrimination) 
of the developed model [106]. Internal validation techniques use the original study 
sample and include such methods as bootstrapping or cross-validation. However, in 
the present pilot study the small cohort disabled to produce a cross-validation as in-
ternal validation. Consequently, the proposed model was not further investigated on a 
new independent patient sample and no external validation was provided.  
After developing a prediction model, it is strongly recommended to evaluate the per-
formance of the model in other participant data than was used for the model develop-
ment. Such external validation may use participant data collected by the same 
investigators, typically using the same predictor and outcome definitions and meas-
urements, but sampled from a later period (temporal or narrow validation); by other 
investigators in another hospital, sometimes using different definitions and measure-
ments (geographic or broad validation); in similar participants but from an intention-
ally different setting (for example, model developed in secondary care and assessed in 
similar participants but selected from primary care); or even in other types of partici-
pants. [106] 
Implication for the future research is therefore development of the model in a bigger 
cohort, with adequately planned internal and external validation strategies.  
3.4.6 Interpretation and generalisability 
The study outcomes could be interpreted in terms of internal and external generalisa-
bility. 
The pharmaceutical team composed of the research pharmacist and the oncology 
pharmacist specialist was consistent during the study time applying the predefined 
study intervention. The oncology pharmacist supervised the pharmaceutical work of 
the research pharmacist. On the other hand, the attending physicians and nurses on 
the ward were not. The study ward has more than 20 attending physicians supervising 
46 beds on the study ward. Having such a high acceptance rate of pharmaceutical 
recommendations in those circumstances indicate the inherent repeatability of find-
ings or more precisely ensures the reliability of the study outcomes. Having two phar-
Discussion 
 117 
macists in the pharmaceutical team protected internal validity, or that the intervention 
used in the present study measured what it was supposed to measure.  
The comparability of the results of the present study with results of the work from 
Lenssen and the team has been discussed above. Each sector in the UKA has shown 
variety in DRP pattern and occurrence. That underlines the need of assessment and 
evaluation of each sector independently [51]. Pharmaceutical contribution to the ward-
based teamwork offered a uniform approach (in terms of SOP) to identify and solve 
DRPs. Comparable number of DRPs per patient within the UKA and in external set-
tings, and high acceptance rate of pharmaceutical intervention within the ward-based 
team, confirmed the success of the intervention. In the present study, the intervention 
was continuously reflecting on the routine workflow showing thereby beneficial out-
come. This corresponds to the sense of health service research [37]. Furthermore, the 
approach provided the basis for further development of the most optimised patient-
oriented, quality-driven, outcome-based ward teamwork [22]. To emphasize the 
strength of this phenomenon and to quantify the effect size, a larger study with bigger 
patient samples and comparison groups is needed. 
Interpretation of the Initial DRP risk score should be provisional. The prognostic abil-
ity of the score might provide optimistic estimates but the implementation of the mod-
el as a tool to estimate the probability that the DRP will occur during the stay on the 
oncology ward is currently limited. To start, it may help pharmacists to prioritise their 
medication reviews and to optimise their workload in the local setting. However, due 
to a development on a small cohort and lack of internal validity, further development 
and validation studies for such a prognostic model are required. Only then, the predic-
tive model may serve as a valid tool applicable in various oncological populations and 
settings. This pilot study should therefore present the potential solution how the pre-
dictive model could be developed and pave the way for further oncology DRP prognos-
tic model development. Additionally, qualitative research approach would be useful. It 
could address variety of contributing factors to the DRP occurrence underpinned by 
communication failures (between patients and healthcare professionals and different 
groups of healthcare professionals) and knowledge gaps (about drugs and patients’ 
medical and medication histories) [117]. Development and implementation of a DRP 
risk assessment tool should not be isolated, but rather followed by the team optimisa-
tion, as introduced in the present study. 
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In terms of external generalisability, results of such examination cannot be easily 
transferred to other health systems, as it was noticed in the previous works [51, 53, 
197]. The intervention in the present study represents only the development phase of 
the ward-based complex intervention team. Number of interacting components within 
the ward-base team, difficulty of behaviour required by those delivering or receiving 
the intervention, and number and variability of outcomes make the intervention com-
plex [37]. The present study did not take into account only one measure, such as pa-
tient training, but a complex supplement in the therapeutic team. It provided a 
realistic care and evaluated the benefits in daily routine. The first step is taken, but 
successful and effective teamwork based on its complexity is a long-term goal. The 
extension of the intervention is necessary in terms of additional patient training, con-
tinuous review and enhancement of the intervention, particularly from the patient's 
point of view and improvement of workflows in terms of communication and consulta-
tion within the team [123]. For the stepwise improvement, the regular measurement of 
endpoints should determine the success of each step [119]. Besides focusing on quanti-
tative endpoints, as in the present study, future research and ward-based team im-
provement should shift the focus and include qualitative methods, too. Qualitative 
methods provide better understanding of complex pathways capturing emerging 
changes in implementation and experiences of the intervention. Further, it could help 
identify unexpected mechanisms and generate new theory [39], and understand strong 
points and flaws of team communication and collaboration. In present work, economic 
aspect has not been considered. Having almost 200 DRPs in a group of 100 patients 
during the four months, proclaim a need for optimisation of the health care structure 
in pharmacotherapy. The intervention tested here represents a measurable benefit for 
the patients. In order to further verify current supposition, the study results represent 
a starting point and motivation to carry out further studies using the methodology that 
was developed here. 
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4  Conclusion and outlook 
The present work described two models to optimise medication safety in the hospital 
setting.  
The first model was developed as optimised multi-professional model to reduce time 
to drug-related hospital readmissions of care-dependent elderly. The primary end-
point – time-dependent occurrence of drug-related rehospitalisation is to be measured 
during a 12-month follow-up period. In comparison with other RCTs included in a 
recent Cochrane review [45], the follow-up period is relatively long. Care-dependent 
elderly represent high-risk population. Thus, the present model follows review’s rec-
ommendations what novel studies concerned with medication safety review need. 
Previous work on this model [49, 51] suggests that the primary endpoint is a good 
reflection of real care. Further in the pilot study [51] multi-professional teamwork 
indicated a tendency to prolong time to DRR, especially early DRRs up to tenth week 
after hospital discharge. The model exhibited thereby lasting measurable effect and 
patients’ health-related quality of life was improved. The clear sign was that ADRs 
were of notable relevance in the daily care, particularly those preventable or ameliora-
ble leading to DRRs. Integrating surgical, internal and neurological wards in the mod-
el, a cross-section between different disciplines was formed.  
By combining quantitative and qualitative methodologies, the model corresponds to 
the recommendations of the health service research [37-39]. Beside quantification of 
the model’s intervention effectiveness, qualitative assessment of the team’s individuals 
in their natural setting should assist to characterise and explain certain multi-
professional team behavioural phenomena. The evaluation of the model using mixed-
methods approach should provide a useful example for further improvements of  
multi-professional complex intervention models and medication safety in Germany. 
The benefits and building blocks of model’s evaluation will offer interesting questions 
for studies to follow. 
The second model was developed and applied as optimised pharmaceutical care model 
contributing to the oncology ward-based team in medication management. The model 
was focused on a core multi-professional ward-based team, which consisted of pa-
tients, physicians, nurses and pharmacists. Further development of the model should 
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include additional professional groups, such as psycho-oncologists, dieticians or phys-
iotherapists. Thereby, a potential follow-up project may develop and evaluate compre-
hensive multi-professional cancer care.  
The pharmaceutical team providing pharmaceutical care service in this pilot study was 
introduced to the oncology ward for the first time. The pilot study showed that cancer 
patients exhibit many DRPs requiring a pharmaceutical intervention. The high ac-
ceptance of the intervention indicates the need of a pharmacist as integrated part of 
the oncology ward-based team. The initial DRP risk score may assist pharmacist to 
prioritise their service and to optimise their workload. But small study sample limits 
score interpretation and validation. Considering current results provisional, there is a 
call for the score development and validation on a larger cohort. The approach, how-
ever, provides the methodology for further research of the most optimised oncology 
ward teamwork and prognostic model development, and the foundation for cancer 
medication safety improvements.  
Validity and reliability of the German PRO-CTCAE core item set was demonstrated in 
the previous work of the clinical pharmacy research group from the University of Bonn 
[147]. As illustrated in the present pilot study, the German PRO-CTCAE core item set 
may support pharmaceutical care on the oncology ward. Thus, the questionnaire is 
useful in the following cancer patient studies and represents a valuable tool for as-
sessing benefits and safety of an intervention from the patient's point of view, in addi-
tion to the medical assessment. Further, the validated PRO-CTCAE core questionnaire 
was used in the best-practice model for outpatient care developed by the clinical 
pharmacy research group in Bonn. For the analysis of the primary and secondary end-
points of the best-practice model, they considered the highest value of all items be-
longing to a symptom scale. They evaluated multi-professional cancer medication 
management by the onset time of the four selected symptoms, or PRO-CTCAE score 3 
or 4, measured over five cycles of therapy. A trend towards later onset of serious symp-
toms could be observed for all four symptoms studied [174]. Succeeding evaluation of 
the endpoints is in a follow-up project in cooperation with the Center for Integrated 
Oncology in Bonn [175]. However, the NCI who has developed the PRO-CTCAE pro-
vided no exact recommendations for the evaluation of the individual items and symp-
tom scales. In the future, a scoring manual should be developed in collaboration with 
the NCI to simplify and standardise the interpretation of PRO-CTCAE items. 
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Despite some limitations, both models present first indication of a positive effect of 
multi-professional medication safety management and may serve as a basis for hy-
pothesis generation and planning of the following study samples and study designs. If 
possible, future studies should be multi-centred, in order to allow cluster randomisa-
tion and supplementary increase validity of the results. Finally, in view of sustainabil-
ity, upcoming studies should promote further implementation of the models in the 
routine care. 
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5  Summary 
Medication therapy is recognised as a high-risk process. German Federal Ministry of 
Health has proposed certain measures to ensure an optimal medication process with 
the aim of reducing medication errors and thereby avoidable risks for the patient in 
drug therapy. The concept is called medication safety. Its centre of attention is foster-
ing awareness of medication safety among patients, physicians, pharmacists and care-
givers, to improve information on medicines and intersectional communication about 
drug therapy as well as facilitation of medication safety research. A central point rep-
resents the need for greater involvement and information of the patient with regard to 
his medication therapy. 
The focus of this thesis is to propose models to optimise medication safety in the  
hospital setting. 
The first part of the thesis presents a study protocol for multi-professional model to 
reduce drug-related readmissions in care-dependent elderly. The protocol is based on 
the foundation of Spirit 2013 statement, which defines standard protocol items for 
clinical trials. The model recognises the need for safer medication use through the 
concerted efforts of all caregivers. It has been developed and recently tested in a pilot 
study. First results showed the model’s tendency toward active collaboration among 
the ward-based caregivers and outlined a positive impact on medication safety. How-
ever, its effectiveness has still to be assessed in a full-scale evaluation with an adequate 
sample size.  
The planed evaluation study is an open randomised controlled trial supplemented by a 
qualitative evaluation of the intervention. During the hospital stay, patients are ran-
domly allocated to either a control or an intervention group. Control group represent 
current medical standard of care where the intervention represents multi-professional 
care according to the defined Standard Operating Procedure for this purpose. After the 
hospital stay, both patient groups are followed up in the same manner for 12 months 
to assess the long-term efficacy of the model with a patient-relevant outcome – drug-
related hospital readmissions. Qualitative assessment in this evaluation study consists 
of patient interviews at the end of the hospital stay and focus group for care providers 
after the study intervention time. Integrating qualitative methodologies implies study-
ing individuals in their natural setting to characterise and provide potential explana-
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tions for particular events and behaviours. Evaluation of the model using mixed-
methods approach should provide a useful example for further improvements of mul-
ti-professional complex intervention models and medication safety in Germany. 
The second part of this thesis presents the model of optimised pharmaceutical care 
service on the oncology ward and development of a prediction model. It is a pilot study 
outlined by STROBE and TRIPOD statement. Pharmaceutical care service was as-
sessed in terms of management of drug-related problems (DRPs). The aim was to 
develop DRP prognostic model. The pharmaceutical care model was further assessed 
in terms of number, type and risk factors of DRPs leading to intervention, type of in-
tervention provided, and PRO-CTCAE symptom burden and impact on pharmaceuti-
cal intervention. The most important measurements were: German PRO-CTCAE core 
item set (weekly assessment, recall period 7 days, 12 symptom item clusters, three 
dimensions: frequency, severity, interference), adverse drug reaction risk score on 
admission, APS-Doc® classification system for drug-related problems and Doku-PIK 
documentation system for pharmaceutical intervention, both developed for the hospi-
tal setting.  
In the study sample of 101 patients, 46 were women. Average age was 65 years and 
average stay on the ward was 10 days. The most frequent diagnoses were malignant 
neoplasm of bronchus or lung, diffuse large B-cell lymphoma and multiple myeloma. 
On average each patient had two DRPs leading to pharmaceutical intervention. The 
most common drug-related problems were drug-drug interactions, drug dosage, drug 
prescription/monitoring, indication and contraindication. The most frequent pharma-
ceutical interventions were symptom surveillance, information to physicians and 
nurses, initiated diagnostic tests, stop/pause the drug and change of the drug dose. 
The most frequently reported PRO-CTCAE symptoms were fatigue, anxiety and sad-
ness, and pain. For 13 patients pharmaceutical recommendations were based on the 
PRO-CTCAE items. The implementation rate of pharmaceutical recommendations by 
the ward-based team was 93 %. Poisson regression model was performed to assess risk 
factors predicting pattern of DRPs leading to pharmaceutical intervention on the on-
cology ward. In the second step, the regression was used to combine multiple predic-
tors by assigning relative weights to each predictor to obtain a probability of DRP 
during the stay on the oncology ward. There are two models to be distinguished: the 
initial or up to 5th day on the study ward, and follow-up model from the 5th day up to 
10th day on the study ward. Significant risk factors in the initial model were ECOG 
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performance score, adverse drug reaction risk score and presence of heart failure; in 
the follow-up model ECOG performance score and presence of renal failure. Prognos-
tic ability of both regression models was assessed with ROC curve showing AUC of 
0.777 (95 % CI 0.686 – 0.868, SE 0.046, p < 0.001) and AUC of 0.683 (95 % CI 0.532 
– 0.835, SE 0.077, p = 0.033), respectively. Based on the initial regression model, DRP 
prognostic model has been proposed (AUC of 0.790 (95 % CI 0.697 – 0.883, SE 0.048, 
p < 0.001), with a scoring system from 0 to 10 and cut off at 5. That means patients 
with 5 or more points are according to the Initial DRP prognostic model highly proba-
ble to experience DRP leading to a pharmaceutical intervention during the five-day 
stay on oncology ward.  
The pilot study has showed that cancer patients exhibit many DRPs requiring a phar-
maceutical intervention. PRO-CTCAE may support pharmaceutical care on the oncol-
ogy ward. The high acceptance of the intervention indicates the need of a pharmacist 
as integrated part of the oncology ward-based team. The initial DRP prognostic model 
may assist pharmacist to prioritise their service and to optimise their workload. But 
small study sample and lack of internal validation limits score interpretation, consid-
ering current results provisional and calling for the score development and validation 
in a study with bigger sample size. The approach, however, provides the methodology 
for further research of the most optimised patient-oriented, quality-driven, outcome-
based oncology ward teamwork. 
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5.4.6	AA1-1	
Prüfung	der	Arzneimitteltherapiesicherheit	
	
	
1. Ziel	und	Zweck		
	
Ziel	der	SOP	ist	die	Festlegung	von	Prozessen	im	Rahmen	der	Studie	„AMTS	älterer	Patienten	
in	der	 stationären	Versorgung	unter	besonderer	Berücksichtigung	der	Schnittstellen	Heim	–	
Klinik	und	Klinik	–	Heim	und	in	der	ambulanten	Versorgung“.	Der	Ablauf	der	Datenerhebung,	
der	Umfang	der	multiprofessionellen	Betreuung	durch	Apotheker,	Arzt	und	Pflege	im	Rahmen	
der	Studie	sowie	die	zur	Dokumentation	zu	verwendenden	Vorlagen	werden	hier	aufgeführt.	
	
	
2. Anwendungsbereich	
	
Diese	 SOP	 gilt	 für	 die	 entsprechende	 Studiendauer	 für	Apotheker,	 Ärzte	 und	Pflege,	 die	 im	
Rahmen	der	Studie	‚„AMTS	älterer	Patienten	in	der	stationären	Versorgung	unter	besonderer	
Berücksichtigung	der	 Schnittstellen	Heim	–	Klinik	 und	Klinik	 –	Heim	und	 in	der	 ambulanten	
Versorgung“	 tätig	 sind.	Eine	spätere	 Implementierung	des	Prozesses	 in	den	allgemeinen	Ar-
beitsablauf	des	UKA	nach	Studienende	ist	angedacht.	
	
	
3. Begriffe,	Abkürzungen	
	
Arzneimittelbezogene	Probleme	 ABP	
Arzneimitteltherapiesicherheit	 AMTS	 	
Forschergruppe	 FG	
Standardisierte	Prozessbeschreibung		
(engl.	Standard	Operating	Procedure)	
SOP	
Studienapotheker	 SA	
Studienleiter	 SL	
Universitätsklinikum	Aachen	 UKA	
	 	
4. Verantwortlichkeiten	
	
Die	Aufgaben	und	Verantwortlichkeiten	des	Studienapothekers	sowie	die	Aufgaben,	die	Ärzte	
und	Pflege	zusätzlich	zu	 ihren	Standardaufgaben	übernehmen	werden	hier	 im	Weiteren	be-
schrieben.	 Bei	 den	 in	 dieser	 SOP	 erwähnten	 Patienten,	 handelt	 es	 sich	 ausschließlich	 um	
Patienten	die	der	Intensivbetreuungsgruppe	zugewiesen	wurden.	
5. Prozessbeschreibung,	SOP	
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Beschreibung	 verantwortlich	
Information	der	Station	 	
- Information	der	studienbeteiligten	Stationen	über	die	Weiterfüh-
rung	der	multiprofessionellen	Studie	
SL	
Training	vor	dem	Studienbeginn	 	
Schulung		
- Schulung	von	Ärzten	und	Pflege	auf	den	studienbeteiligten	Sta-
tionen	bezüglich	des	Berichtens	aller	den	Patienten	betreffenden	
studienrelevanten	Ereignisse	
- Schulung	des	Studienapothekers	bezüglich	seiner	Aufgaben	im	
Studienprotokoll	sowie	in	der	Verwendung	der	Dokumenta-
tionsbögen	
SL/FG	
Tag	1	nach	Aufnahme	des	Patienten	 	
1.	Pflege	-	SA	Gespräch		
- Bericht	der	Pflege	über	Besonderheiten	und	aufgetretene	Symp-
tome	des	Patienten	
- Dokumentation	durch	den	SA	im	Dokubogen	0.1	(Anlage1).	
Pflege	und	SA	
2.	Arzneimittelanamnese	
- Gespräch	zwischen	SA	und	Patient	über	die	derzeitige	Arzneimit-
teltherapie	
- Arzneimittelanamnese	durch	den	SA	unter	Verwendung	der	Patien-
tenakte,	der	vom	Patienten	mitgeführten	Dokumente,	der	mün-
dlichen	Auskunft	des	Patienten	und	sonstiger	Informationsquellen;	
die	Dokumentation	erfolgt	im	Dokumentationsbogen	1.1	(Anlage2).	
SA	
3.	Vergleich	stationäre	Medikation	und	Hausmedikation		
- Vergleich	der	Arzneimittel	aus	der	Arzneimittelanamnese	
(Hausmedikation;	Anlage	2)	mit	stationären	Anordnungen	und/oder	
der	Dokumentation	der	ärztlichen	Anamnese.	Die	Dokumentation	
erfolgt	im	Dokumentationsbogen	1.1	(Anlage2).	Im	Feld	„Be-
merkungen“	werden	die	Abweichungen	aufgeführt.	
SA	
4.	AMTS-Prüfung	und	pharmazeutische	Empfehlungen	
- AMTS-Prüfung	der	Arzneimitteltherapie	nach	der	Checkliste	AMTS-
Prüfung	(Anlagen	5).	
- Dokumentation	identifizierter	ABPs	im	Dokumentationsbogen	1.5	
(Anlage	4).	Relevante	Informationen	aus	der	AMTS-Prüfung	werden	
im	Bemerkungsfeld	des	Dokumentationsbogens	1.1	festgehalten.	
(z.B.	Hinweise	auf	Überdosierung,	vorangegangene/abgebrochene	
Arzneimitteltherapien,	Arzneimittelinteraktionen,	wichtige	Infor-
mationen	aus	Gesprächen	mit	anderen	Mitgliedern	des	multiprofes-
sionellen	Teams	(Patienten,	Pflege,	Ärzte,	etc.)).	
Weitergabe	der	Empfehlungen	des	SA	zur	Medikation	basierend	auf	den	
ABPs	der	AMTS-Prüfung	an	alle	Mitglieder	des	multiprofessionellen	
Teams	(vgl.	Punkt	5,	6	und	7).	
SA	
5.	Arzt	-	SA	Gespräch	
- Besprechung	der	Empfehlungen	aus	der	AMTS-Prüfung	mit	dem	
Behandelnden	Arzt	und	Klärung	eventueller	Rückfragen	
Arzt	und	SA	
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6.	Pflege	-	SA	Gespräch	(ggf.)	
- Besprechung	der	Empfehlungen	aus	der	AMTS-Prüfung	mit	der	
betreuenden	Pflegekraft	und	Klärung	eventueller	Rückfragen	
7.	Patient	-	SA	Gespräch	(ggf.)	
- Informationen	zu	neuen	Therapien	
- Einführung	in	die	richtige	Anwendung	neuer	Darreichungsformen	
- Klärung	eventueller	Rückfragen	
8.	Umsetzung	der	pharmazeutischen	Empfehlungen	
- Überprüfung	der	Umsetzung	von	Empfehlungen	zu	ABPs.	Dokumen-
tation	im	Dokumentationsbogen	1.5	(Anlage	4).	
Während	des	stationären	Aufenthalts	(täglich	an	Werktagen)	
9.	Follow	Up	des	Zustands	des	Patienten:	
- Einsicht	des	SA	in	die	elektronische	Dokumentation	auf	Station:	
Laborwerte,	Vitalparameter,	Untersuchungsergebnisse,	Ver-
laufsdokumentationen	(schriftliche	Dokumentation	von	Besonder-
heiten	durch	Arzt	und	Pflege)	
- Visite	des	Patienten	auf	Station,	wobei	der	Patient	über	Veränder-
ungen	seines	Gesundheitszustandes	berichten	kann	
10.	Pflege	-	SA	Gespräch		
- Bericht	der	Pflege	über	Besonderheiten	und	neue	Symptome	des	
Patienten	
- Dokumentation	durch	den	SA	im	Dokumentationsbogen	0.1	(Anla-
ge1).	
11.	Veränderungen	der	Arzneimitteltherapie	
- Bei	Veränderungen	der	Arzneimitteltherapie	wird	eine	erneute	
AMTS-Prüfung	durch	den	SA	nach	der	Checkliste	AMTS-Prüfung	(An-
lage	5)	durchgeführt	(Siehe	Punkt	4).	
- Erneute	Durchführung	Schritte	5-9	
Bei	Entlassung	
12.	Pflege	-	SA	Gespräch		
- Bericht	der	Pflege	über	Besonderheiten	und	neu	aufgetretene	
Symptome	des	Patienten	
- Dokumentation	durch	den	SA	im	Dokumentationsbogen	0.1	(Anla-
ge1).	
13.	Entlassgespräch		
- Bei	Entlassung	findet	zusätzlich	zu	den	Informationen	durch	den	
Arzt	ein	Entlassgespräch	mit	dem	Patienten	durch	den	SA	bezogen	
auf	Veränderungen	in	der	Arzneimitteltherapie	statt.	
14.	Entlassungsbrief		
- Zusammenfassung	der	pharmazeutischen	Empfehlungen	für	den	
behandelnden	Arzt	in	Textform.	Der	Arzt	entscheidet	ob	die	
Empfehlungen	Teil	des	Entlassungsbriefs	werden.	
- Ausgabe	des	Entlassungsbrief	an	den	Patienten	
15.	Zeitaufwand	
- Zeiterfassung	der	pharmazeutischen	Tätigkeiten	des	SA	im	Doku-
mentationsbogen	3.1	(Anlage	6).	
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7. Anlagen	
	
	Anlage	1	 Dokumentationsbogen	0.1	Multiprofessionelles	Team	Gespräch	
	Anlage	2	 Dokumentationsbogen	0.2	Vulnerable	Elders	Survey	(VES-13)	
	Anlage	3	 Dokumentationsbogen	0.3	The	GerontoNet	ADR	Risk	Score	
	Anlage	4	 Dokumentationsbogen	1.1	Arzneimittelanamnese	
	Anlage	5	 Dokumentationsbogen	1.4	Stationäre	Medikation	
	Anlage	6	 Dokumentationsbogen	1.5	Datenerfassung	ABP	
	Anlage	7				 Checkliste	AMTS-Prüfung		
	Anlage	8				 Dokumentationsbogen	3.1	Dokumentation	Interventionsapotheker	
	
	
8. Änderungshistorie	
	
Bei	der	vorliegenden	SOP	handelt	es	sich	um	die	erste	Version.	Änderungen	liegen	daher	nicht	
vor.	
	
	 Erstellung	 Prüfung	 Freigabe	
Name	 Sarcevic	 Eisert	 01.07.16	
Datum	 	 	 	
Unterschrift	 	 	 	
Dokumentenablage	 	 	 	
	
	
Gelesen	und	verstanden:	
Kürzel		
Mitarbeiter	
	 	 	 	 	 	 	 	 	
	
Unterschrift	
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0.1	Multiprofessionelles	Team	Gespräche	
	
Patientennummer	______________________	
Studienstation	_________________________	
Datum________________________________	
Gespächsnummer________________________	
Zeitpunkt			□	bei	der	Aufnahme	
											□	während	des	stationären	Aufenthalts	
											□	bei	der	Entlassung	
	
Gespräch	Pflege	–	Studienapotheker		
Ein	Gespräch	hat	stattgefunden:				ja	□		nein	□		wenn	nein	bitte	Grunde	angeben	
																																															_______________________________________	
□	keine	Anmerkung	durch	die	Pflege	
Noti-
zen_______________________________________________________________
_________________________________________________________________
_________________________________________________________________
______________________________________________________________	
	
Gespräch	Arzt	–	Studienapotheker		
Ein	Gespräch	hat	stattgefunden:				ja	□		nein	□			wenn	nein	bitte	Grunde	angeben	
																																															_______________________________________	
□	keine	Anmerkung	durch	den	Arzt	
Notizen	
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________	
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0.2	Vulnerable	Elders	Survey	(VES-13)	 	
Kennzeichen__________________________	
Geschlecht:	□	weiblich	□	männlich	
Datum_______________________________	
	
	
	
	
F1.	Alter	___________________																													PUNKTZAHL:		1	PUNKT	FÜR	JAHRE	75-84	
																																																																																																		3	PUNKTE	FÜR	JAHRE	≥	85	
	
Punktzahl	□	
	
F2.	Im	Vergleich	zu	anderen	Menschen	in	Ihrem	Alter,	wie	würden	Sie	generell	Ihren	Gesund-
heitszustand,	einschätzen:	
	
	
□	schlecht,*	(1	PUNKT)																																															PUNKTZAHL:	1	PUNKT	FÜR	SCHLECHT		
□	mäßig,*	(1	PUNKT)																																																																											ODER	MAßIG					
□	gut,	
□	sehr	gut,	oder	
□	ausgezeichnet	
Punktzahl	□	
	
F3.	Wie	viele	Schwierigkeiten	haben	Sie,	üblicherweise,	mit	den	folgenden	körperlichen	Akti-
vitäten:	
	
	
keine										wenig										einige											viele											nicht	dazu		
Schwierigkeiten		Schwierigkeiten		Schwierigkeiten			Schwierigkeiten			in	der	Lage																			
	
	
a)	Bücken,											
Hocken	oder		
Knien?	…….…..........□											□											□											□*							□*	
	
	
	
SOP for medication safety with CRFs 
 
 147 
	
keine										wenig										einige											viele											nicht	dazu		
Schwierigkeiten		Schwierigkeiten		Schwierigkeiten			Schwierigkeiten			in	der	Lage																			
	
	
b)	Heben	oder		
Tragen	von		
Gegenständen		
mit	einem	Gewicht		
von	5kg……………........□											□											□											□*								□*	
	
	
	
c)	Etwas	erreichen		
oder	Ausstrecken		
der	Arme	über		
Schulterhöh..…..........□											□											□											□*								□*	
	
	
	
d)	Schreiben	oder		
Anfassen	und	Greifen		
kleiner	Gegenstände..□											□											□											□*								□*	
	
	
e)	einen	500m	gehen..□											□											□											□*								□*	
	
	
f)	schwere	Hausarbeit		
wie	Boden	wischen		
oder	Fenster	putzen.....□											□											□											□*							□*	
	
	
																																																																															PUNKTZAHL:		1	PUNKT	FÜR	JEDE	*	ANTWORT	
																																																																																																									IN	F3	VON	a	BIS	f	
																																																																																																								MAXIMAL	2	PUNKTE	
	
Punktzahl	□	
	
F4.	Haben	Sie	aufgrund	Ihres	Gesundheitszustandes	oder	körperlichen	Zustandes	irgendwel-
che	Schwierigkeiten	bei:	
a) Einkaufen	persönlicher	Gegenstände	(wie	Hygieneartikel	oder	Medikamente)?	
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□	JA	→	Erhalten	Sie	Hilfe	beim	Einkaufen?																					□	JA*					□	NEIN	
□	NEIN	
□	MACHE	ICH	NICHT	→	Aufgrund	Ihres	Gesundheitszustandes?		□	JA*					□	NEIN	
b)	Finanzielle	Angelegenheiten	(wie	das	Auflisten	von	Ausgaben	oder	Zahlung	von	Rech-
nungen)?	
□	JA	→	Erhalten	Sie	Hilfe	bei	finanziellen	Angelegenheiten?					□	JA*				□	NEIN	
□	NEIN	
□	MACHE	ICH	NICHT	→	Aufgrund	Ihres	Gesundheitszustandes?		□	JA*					□	NEIN	
			c)	durch	den	Raum	gehen	(Verwendung	von	Spazierstock	oder	Rollator	ist	ok)?	
□	JA	→	Erhalten	Sie	Hilfe	beim	Gehen?																								□	JA*				□	NEIN	
□	NEIN	
□	MACHE	ICH	NICHT	→	Aufgrund	Ihres	Gesundheitszustandes?		□	JA*					□	NEIN	
d)	Erledigen	leichter	Hausarbeit	(wie	Geschirrspülen,	Aufräumen	oder	leichte	Reinigun-
gen)	?	
□	JA	→	Erhalten	Sie	Hilfe	bei	leichter	Hausarbeit?														□	JA*				□	NEIN	
□	NEIN	
□	MACHE	ICH	NICHT	→	Aufgrund	Ihres	Gesundheitszustandes?		□	JA*					□	NEIN	
e)	Baden	oder	Duschen?	
□	JA	→	Erhalten	Sie	Hilfe	beim	Baden	oder	Duschen?											□	JA*				□	NEIN	
□	NEIN	
□	MACHE	ICH	NICHT	→	Aufgrund	Ihres	Gesundheitszustandes?		□	JA*					□	NEIN	
	
																										
																																																																								PUNKTZAHL:		4	PUNKTE	FÜR	EIN	ODER	MEHR	*			
																																																																																																	ANTWORT	IN	F4	VON	a	BIS	e	
Punktzahl	□	
Gesamtpunktzahl	□	
Quelle:	Saliba	D	et	al.	The	Vulnerable	Elders	Survey:	A	Tool	for	Identifying	Vulnerable	Older	People	in	the	Commu-
nity,	The	American	Geriatrics	Society	JAGS	49:1691–1699,	2001	
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0.3	The	GerontoNet	ADR	Risk	Score	
Kennzeichen:	__________________	 	
Alter:____________________________		
Geschlecht:	□	weiblich	□	männlich	
Datum:	_________________________	
	
	
	
	
Quelle:	
Onder	G,	Petrovic	M,	Tangiisuran	B,	et	al.	Development	and	validation	of	a	score	to	assess	risk	of	adverse	drug	
reactions	among	in-hospital	patients	65	years	or	older:	the	GerontoNet	ADR	Risk	Score.	Arch	Intern	Med	2010;	
170:1142-8	
Risikofaktor	 Punkt	 Punktzahl	
4	oder	mehr	Komorbiditäten	 1	 	
Herzinsuffizienz	 1	 	
Lebererkrankungena	 1	 	
Anzahl	der	Medikamente	 	 	
		<5	 0	 	
		5-7	 1	 	
		≥	8	 4	 	
Früher	ADR	 2	 	
Nierenversagenb	 1	 	
a	Definiert	als	die	Leberfunktionswerte	>2x	oberen	Grenzwert		
b	Definiert	als	berechnete	glomeruläre	Filtrationsrate	<60mL/min/	1,73	m2	
	ADR=	adverse	drug	reaction	
Gesamtpunktzahl	
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1.1	Arzneimittelanamnese	
	
	
	
	
	
	
	
Medikation	bei	Aufnahme	 Ersatz	Medikation	auf	Station	
Name	 Stärke	 Arznei-
form	
Dosierung	 Name	 Stärke	 Arznei-
form	
Dosierung	 E	 S	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	
E	=	Ersatzmedikament	gleicher	Wirkstoff														S=	Substitution	gleiche	Wirkstoffgruppe	
	
	
	
	
	
	
	
Erledigt	am:	
Erledigt	durch:		
	
Attachments	Model	II	
	
Erledigt	am:	
Erledigt	durch:  
	 	
Patientennummer: 
Größe: 
Gewicht: 
Allergien: 
Alkohol: 
Rauchen: 
Kreatinin [mg/dl]: 
GFR [ml/min]: 
Sonstiges: 
Bemerkung:  
Klinik:                   Station:                      Arzt: 
SOP for medication safety with CRFs 
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1.4	Stationäre	Medikation:	
Kennzeichen:	________________	
Verordnungsdatum	
Name	Stärke	Arzneiform	Dosierung	(vermutete)	Indikation	Bemerkung/	
Verord-
nungs-
datum 
Name Stärke Arznei-
form 
Dosie-
rung 
(vermutete) 
Indikation 
Bemerkung/ 
ATC-code 
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1.5	Datenerfassung	Azneimittelbezogene	Probleme	(ABPs):	
	
Patientennummer:	_____________________	
Arzneimittel:	
______________________________________________________________________________	
Beschreibung	des	Problems:	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
Intervention:	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
Klassifikation	nach	APS-Doc:	_____________________	
Problem	entstand:												vor	Aufnahme																			Schnittstelle																						während	stat.	Aufenthalt	
Problem	wurde:																	gelöst																																	teilweise	gelöst																	nicht	gelöst	
Bemerkung:	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________	
___________________________________________________________________________________ 
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Checklist	AMTS-Prüfung	[198]	
Studie:	„AMTS	älterer	Patienten	in	der	stationären	Versorgung	unter	besonderer	Berück-
sichtigung	der	Schnittstellen	Heim	–	Klinik	und	Klinik	–	Heim	und	in	der	ambulanten	Versor-
gung“	
	
Begriffe	 Abkürzungen	
Arzneimittel	 AM	
Azneimittelbezogene	Probleme	 ABP	
Arzneimitteltherapiesicherheit	 AMTS	 	
C-reaktives	Protein	 CRP	
Dosisanpassung	bei	Leberinsuffizienz	 DALI	
Dosisanpassung	bei	Niereninsuffizienz	 DANI	
Glomeruläre	Filtrationsrate	 GFR	
Therapeutisches	Drug	Monitoring	 TDM	
	
	
	 er-
folgt	
nicht	
erfolgt	
nicht		zu-
treffend	
1. Abgleich	der	Anamnese	mit	der	stationären	Medi-
kation	
Gibt	es	gewollte/ungewollte	Abweichungen	(Arznei-
mittelname,	Stärke,	Dosierung,	Darreichungsform)	
zwischen	Hausmedikation	oder	vorangegangener	Me-
dikation	und	der	stationären	Anordnung?	
¨	 ¨	 ¨	
2.		Plausibilität	der	Medikation		
(Abgleich	Diagnosen	–	Arzneimittel)	
				Gibt	es	AM	zu	denen	keine	Diagnose	dokumentiert	ist?		
				Gibt	es	Diagnosen,	bei	denen	keine	AM-Therapie	be-
steht?	
¨	 	¨	 		¨	
3.		Prüfung	auf	Allergien	
				Rückfrage	im	Anamnesegespräch,		
				Abgleich	mit	Dokumentationen	in	Akte	und	elektronisch	
¨	 			¨	 		¨	
4.		Überprüfung	der	Nierenfunktion,		
Prüfung	der	Arzneimitteltherapie	auf	DANI	
Prüfung	der	Nierenfunktion	(GFR	Berechnung	nach	
Cockroft-Gault),	bei	GFR<60ml/min	AM	auf	DANI	prü-
fen,	ggf.	Dosisanpassung	oder	Alternativmedikation	
vorschlagen	
		¨	 			¨	 			¨	
5.		Überprüfung	der	Leberfunktion,		
Prüfung	der	Arzneimitteltherapie	auf	DALI	
Prüfung	ob	Leberfunktionsstörung	in	Anamne-
se/Diagnosen;	Berechnung	der	Leberfunktion	(Bestimmun	
Child	Pugh),	bei	Child	A,B,C:	AM	auf	DALI	prüfen,	ggf.	Do-
sisanpassung	oder	Alternativmedikation	vorschlagen	
¨	 ¨	 ¨	
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	 erfolgt	
nicht	
erfolgt	
nicht		zu-
treffend	
6.		Prüfung	relevanter	Laborwerte	(Kalium,	CRP	usw.)	
				Welche	Laborwerte	weichen	von	Normwert	ab?		
Gibt	es	einen	Zusammenhang	zur		Arzneimitteltherapie?	
¨	 ¨	 ¨	
7.		Prüfung	auf	Kontraindikationen	
Sind	AM-Kombinationen	kontraindiziert?	Sind	AM		
aufgrund	von	bestehenden	Vorerkrankungen	kontraindiziert?	
¨	 ¨	 ¨	
8.		Medikationsplan:		
Dosierung:	gibt	es	Unterdosierungen	und/oder	Überdosierun-
gen	bei	den	AM?	
Interaktionen:	welche	Interaktionen	und	mit	welchem	Schwe-
regrad?	
Leitliniengerechte	Therapie:	entspricht	die	Medikation	einer	
bestehenden	Leitlinien-Stufe?	Fehlen	AM?	Ist	die	Kombination	
bestimmter	AM	sinnvoll	und	wurde	diese	berücksichtigt?	
Altersspezifiesche	Medikation	(PRISCUS):	sind	an	der	PRISCUS-
List	im	Medikationsplan	enthalten?	Gibt	es	bestimmte	Monito-
ring-Empfehlungen	oder	eine	Alternativmedikation,	auf	die	
umgestellt	werden	sollte?	
¨	 ¨	 ¨	
9.		Patient	prä-OP?	(Evaluation	der	Medikation)	
Gibt	es	AM,	die	prä-OP	pausiert	werden	müssen		
(wenn	ja	wie	lange	vor	OP?),	Vermerk	der	pausierten	Medika-
tion	in	der	Anordnung;	ggf.	Rucksprache	mit	anderen	Fachab-
teilungen	(z.B.	Anästhesie),	wenn	offene	Fragen	
¨	 ¨	 ¨	
10.	Patient	vor	einer	Untersuchung?	(z.B.	Endoskopie)	
Gibt	es	AM,	die	vor	der	Untersuchung	abgesetzt/	pau-
siert	werden	müssen	(wenn	ja,	wie	lange	vor	der	Unter-
suchung?),	Vermerk	der	pausierten	Medikation	in	der	
Anordnung	
¨	 ¨	 ¨	
11.	Therapiedauer	
Evaluation	von	Therapiedauern,	z.B.	Antibiotikatherapie	–	wie	
lange	wird	das	Antibiotikum	schon	gegeben?	Wie	sieht	die	kli-
nische	Entwicklung	der	Situation	aus?		
Infektionsparameter	rückläufig?	Antibiose	weiter?		
¨	 ¨	 ¨	
12.	Neue	Arzneimitteltherapien	
Bei	neu	angesetzten	AM	wird	seitens	der	Apotheke	eine		
Patientenberatung/-schulung	zu	dem	neuen	AM	angeboten	
¨	 ¨	 ¨	
13.	TDM	
Bei	critical	dose	drugs	(z.B.Aminoglykoside)	Empfehlung	einer	
Blutspiegelbestimmung	und	Unterstützung	der	Ärzte	bei	Do-
sisanpassung	
	
¨	 ¨	 ¨	
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Warum	erfolgt	nicht	die	Bearbeitung	eigenen	Punkten:	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
	
Bemerkungen	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
____________________________________________________________________	
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3.1	Zeiterfassungen	für	die	Intervention	
Datum	 Patientennummer	 Tätigkeit	 Apotheker	 Uhrzeit	 Handzeichen	
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Apotheke	des	Universitätsklinikums	Aachen	
Dr.	Albrecht	Eisert	
Steinbergweg	20	
52074	Aachen	
Tel.:	0241-8080063	
Fax:	0241-8082402	
	
	
Einwilligungserklärung	zur	Teilnahme	an	dem	Forschungsvorhaben:	
„	Multiprofessionelles	Arznemitteltherapiesicherheitsmodell						
zur	Senkung	der	arzneimittelbezogenen	Krankenhauswiedereinwei-
sungen	älterer	Patienten	“	
Name	des	Patienten:___________________________________	
Ggf.	Name	des	gesetzlichen	Betreuers:	__________________________________	
Name	des	Aufklärenden	 ___________________________________	
Ich	 bestätige	 hiermit,	 dass	 ich	 durch	 Frau/Herr...........................................	 mündlich	 über	
Wesen,	Bedeutung,	Risiken	und	Tragweite	der	beabsichtigten	Studie	aufgeklärt	wurde	und	für	
meine	Entscheidung	genügend	Bedenkzeit	hatte.	
	
Ich	habe	die	Patienteninformation	gelesen.	 Ich	 fühle	mich	ausreichend	 informiert	und	habe	
verstanden,	worum	es	geht.	Es	wurde	mir	ausreichend	Gelegenheit	gegeben,	Fragen	zu	stel-
len,	die	alle	für	mich	ausreichend	beantwortet	wurden.	Ich	hatte	genügend	Zeit	mich	zu	ent-
scheiden.	
	
Mir	wurde	mitgeteilt,	dass	für	den	Fall	einer	Gesundheitsschädigung	infolge	meiner	Teilnah-
me	an	diesem	Forschungsvorhaben	eine	Versicherung	bei	der	nachfolgend	genannten	Versi-
cherungsgesellschaft	zu	meinen	Gunsten	besteht.	
Klinische Pharmazie 
Pharmazie 
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Es	besteht	eine	Haftpflichtversicherung	 für	die	 Zeit	 des	 stationären	Aufenthaltes,	wenn	der	
Versicherungsfall	 auf	 das	 Verschulden	 des	Hauses	 oder	 eines	 seiner	 Angestellten	 zurückzu-
führen	 ist.	Die	Haftpflichtversicherung	des	UK	Aachen	besteht	bei	der	Zürich	Versicherungs-
AG,	Versicherungsschein-Nr.	813.380.000.270.		
Meine	Einwilligung,	an	dieser	Studie	als	Patient	teilzunehmen,	erfolgt	ganz	und	gar	freiwillig.	
Ich	wurde	darauf	hingewiesen,	dass	ich	meine	Einwilligung	jederzeit	ohne	Angaben	von	Grün-
den	widerrufen	kann,	ohne	dass	mir	dadurch	irgendwelche	Nachteile	für	meine	weitere	ärztli-
che	Behandlung	und	medizinische	Versorgung	entstehen.	
Ich	bin	mit	einer	Kontaktaufnahme	nach	dem	stationären	Aufenthalt	und	den	beschriebenen	
Datenerhebungen	durch	das	Studienteam	einverstanden.	Ich	erteile	zudem	dem	Studienteam	
die	Erlaubnis,	auch	nach	dem	stationären	Aufenthalt	Einblick	in	meine	aktuelle	Medikations-	
und	Patientendaten	zu	nehmen	und	ggf.	den	behandelnden	Arzt	zur	aktuellen	Medikation	zu	
kontaktieren.		
Ich	habe	eine	Kopie	der	Patienteninformation	und	dieser	unterschriebenen	Einwilligungser-
klärung	erhalten.		
Ich	habe	verstanden,	dass	bei	wissenschaftlichen	Studien	persönliche	Daten	und	medizini-
sche	Befunde	erhoben	werden.	Die	Weitergabe,	 Speicherung	und	Auswertung	dieser	 stu-
dienbezogenen	Daten	erfolgt	nach	gesetzlichen	Bestimmungen	und	setzt	vor	Teilnahme	an	
der	Studie	meine	freiwillige	Einwilligung	voraus:	
Ich	 erkläre	 mich	 damit	 einverstanden,	 dass	 im	 Rahmen	 der	 Studie	 erhobene	 Da-
ten/Krankheitsdaten	 auf	 Fragebögen	 und	 elektronischen	Datenträgern	 aufgezeichnet	 und	
ohne	Namensnennung	weitergegeben	werden	an.	
	
a. die	Mitglieder	 des	 Studienteams	 aus	 dem	Universitätsklinikum	Aachen	 und	
dem	 Pharmazeutischen	 Institut	 der	 Universität	 Bonn.	 Dies	 kann	 auch	 die	
Veröffentlichung	 der	 Daten	 für	 wissenschaftliche	 Darstellungen	 und	 Veröf-
fentlichungen	in	anonymisierter	Form	einschließen.		
b. die	 zuständige	 Überwachungsbehörde	 (Landesamt	 oder	 Bezirksregierung)	
oder	 Bundesoberbehörde	 (Bundesinstitut	 für	 Arzneimittel	 und	Medizinpro-
dukte,	Bonn)	zur	Überprüfung	der	ordnungsgemäßen	Durchführung	der	Stu-
die.		
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Ich	willige	hiermit	ein,	als	Patient	an	der	Studie	„Arzneimitteltherapiesicherheit	älterer	Patien-
ten	 in	der	 stationären	Versorgung	unter	besonderer	Berücksichtigung	der	 Schnittstellen	bei	
Aufnahme	und	Entlassung“	teilzunehmen.	
	
Aachen,	den	____________							______________________________________	
	 	 (Datum)	 	 (Name	und	Unterschrift	des	Patienten/gesetzl.	Betreuer)	
	
Ich	habe	den	Patienten	mündlich	über	Wesen,	Bedeutung,	Reichweite	und	Risiken	der	Studie	
aufgeklärt.	
	
Aachen,	den____________							______________________________________	
	 	 (Datum)	 	 (Name	und	Unterschrift	des/der	Aufklärenden)
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Verantwortliche	Leiter	
Dr.	Albrecht	Eisert	
Chefapotheker,	Apotheke	des	Universitätsklinikums	Aachen	
Steinbergweg	20	
52074	Aachen	
Tel.:	0241-80	80063		
Fax.:	0241-80	82402	
Prof.	Dr.	Ulrich	Jaehde	
Pharmazeutisches	Institut	der	Universität	Bonn,	Klinische	Pharmazie	
An	der	Immenburg	4	
53121	Bonn	
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Patienteninformation	für:	___________________________________	
Sehr	geehrte	Patientin,	sehr	geehrter	Patient,	
Sie	sind	im	Universitätsklinikum	Aachen	(UKA)	stationär	aufgenommen	worden.		
Während	Ihres	stationären	Aufenthaltes	werden	Sie	rund	um	die	Uhr	von	einem	multiprofes-
sionellen	Team	aus	Ärzten,	Pflegenden	und	vielen	anderen	Personen	betreut.		
Zusammen	mit	der	Universität	Bonn	führen	wir	zurzeit	am	UKA	eine	Studie	durch.	Ziel	unserer	
Studie	ist	es,	herauszufinden,	welche	Risiken	in	der	Arzneimitteltherapie	zum	einen	im	Kran-
kenhaus	und	zum	anderen	in	der	sich	anschließenden	Weiterbehandlung	außerhalb	des	Kran-
kenhauses	bestehen	können.	 Insbesondere	 interessiert	uns	dabei	die	Fragestellung,	wie	die	
Arzneimitteltherapie	bei	älteren	Patienten	sicherer	gestaltet	werden	kann	und	ob	die	Unter-
stützung	des	multiprofessionellen	Teams	durch	einen	Apotheker	 für	Sie	als	Patienten	einen	
Nutzen	zeigt.	
Dafür	benötigen	wir	Ihre	Mithilfe.	
Auf	den	 folgenden	Seiten	haben	wir	 für	 Sie	alle	wichtigen	 Informationen	 zur	 Studie	 zusam-
mengestellt.	
Sollten	Sie	Fragen	haben,	stehen	wir	Ihnen	selbstverständlich	jederzeit	gerne	zur	Verfügung.		
Vielen	Dank	für	Ihr	Interesse	und	Ihre	Unterstützung!	
Dr.	rer.	nat	Albrecht	Eisert	 	
(leitender	Studienapotheker)	
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I. Darstellung	der	Studie
Um	die	Qualität	der	Gesundheitsversorgung	zu	verbessern,	ist	es	erforderlich,	eine	aktive	und	
effektive	Zusammenarbeit	 zwischen	Fachkräften	des	Gesundheitswesens	 zu	 schaffen.	Wenn	
sich	ein	Team	aus	Ärzten,	Pflegern	und	Apothekern	um	die	Versorgung	der	Patienten	küm-
mert,	wird	dies	als	„multiprofessionelle	Zusammenarbeit“	bezeichnet.		
Weltweit	gibt	es	viele	Bemühungen,	die	Sicherheit	des	Patienten	zu	verbessern.	Ein	besonde-
res	 Interesse	 liegt	dabei	oft	auf	der	Arzneimitteltherapie.	Hierfür	wurde	der	Begriff	„Arznei-
mitteltherapiesicherheit“	 etabliert.	 Die	 Arzneimitteltherapiesicherheit	 stellt	 so	 gut	 wie	
möglich	sicher,	dass	Patienten	ihre	Arzneimittel	richtig	anwenden.	Insbesondere	sollen	uner-
wünschte	Arzneimittelereignisse	durch	Medikationsfehler	vermieden	werden.	Damit	werden	
die	Risiken	einer	Arzneimitteltherapie	minimiert.		
Im	Rahmen	der	sowohl	bundes-	als	auch	weltweiten	Initiativen	zur	Untersuchung	der	Arznei-
mitteltherapiesicherheit	sollen	in	dieser	Studie	vor	allem	die	Übergänge	im	Behandlungspro-
zess	näher	betrachtet	werden:		
Insbesondere	bei	der	Einweisung	ins	Krankenhaus	und	bei	Entlassung	aus	dem	Krankenhaus	
können	sich	viele	Veränderungen	 in	der	medikamentösen	Versorgung	ergeben.	Dies	bedeu-
tet,	dass	Arzneimittel,	die	vor	dem	Krankenhausaufenthalt	regelmäßig	eingenommen	wurden,	
nach	der	Entlassung	nicht	mehr	nötig	sind	oder	das	neue	Arzneimittel	hinzukommen.	Eventu-
ell	ändert	sich	auch	nur	der	Zeitpunkt,	zu	dem	ein	Arzneimittel	eingenommen	werden	muss	
oder	dessen	Stärke.	Da	bei	Aufnahme	und	Entlassung	 in	ein	Krankenhaus	 Informationen	 zu	
diesen	Änderungen	verloren	gehen	können,	steigt	das	Risiko	für	Medikationsfehler.	
Die	geplante	Studie	soll	dazu	beitragen,	diese	Risiken	so	gering	wie	möglich	zu	halten	und	auf	
diese	Weise	die	Arzneimitteltherapiesicherheit	zu	verbessern.		
II. Hintergrund
Bei	 der	 Anwendung	 von	 Arzneimitteln	 können	 neben	 den	 gewünschten	 positiven	 Effekten	
auch	Risiken	auftreten	–	sowohl	bei	unsachgemäßer	Anwendung	(z.B.	Überdosierung,	falsche	
Einnahme),	als	auch	bei	bestimmungsgemäßem	Gebrauch	(z.B.	durch	gegenseitige	Beeinflus-
sung	der	Medikamente	in	der	Wirkung	oder	durch	Auftreten	von	Nebenwirkungen).		
Je	mehr	Arzneimittel	Sie	einnehmen,	desto	höher	ist	das	Risiko	für	Probleme	in	der	Arzneimit-
teltherapie.	Viele	Risiken	können	frühzeitig	aufgedeckt	werden,	vor	allem,	wenn	Sie	gut	über	
Ihre	Arzneimittel	informiert	sind	und	die	aktuell	eingenommenen	Arzneimittel	gut	dokumen-
tiert	 sind.	Zusätzlich	kann	bei	Veränderungen	 in	 Ihrer	Versorgungssituation,	 z.B.	bei	Einwei-
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sung	 in	 ein	 Krankenhaus	 oder	 bei	 Verlegung	 in	 eine	 andere	 Klinik,	 ein	 Informationsverlust	
entstehen.		
Um	 die	 Abläufe	 und	mögliche	 Risiken/Probleme	 in	 der	 Arzneimitteltherapie	 an	 den	 unter-
schiedlichen	Orten,	an	denen	Sie	mit	Arzneimitteln	versorgt	werden,	zu	untersuchen,	haben	
wir	diese	Studie	entworfen.	Mit	Hilfe	der	Ergebnisse	sollen	Strukturen	und	Abläufe	entwickelt	
werden,	die	der	Sicherheit	der	Arzneimitteltherapie	dienen.	
III.	Ziel	der	Studie	
Ziel	der	Studie	ist	die	Untersuchung	von	Arzneimittelrisiken	im	Krankenhaus	und	des	Nutzens	
einer	 intensiveren	 multiprofessionellen	 Zusammenarbeit	 unter	 stärkerer	 Einbeziehung	 des	
Apothekers	zur	Verbesserung	der	Arzneimitteltherapiesicherheit.	
IV.	Erläuterung	des	Forschungsplans	(Studiendesign)	
In	die	Studie	werden	insgesamt	138	Patienten	aufgenommen	und	in	zwei	Gruppen	eingeteilt.	
Nach	Einwilligung	in	die	Studienteilnahme	werden	Sie	nach	dem	Zufallsprinzip	entweder	der	
Kontrollgruppe	 oder	 der	 Intensivbetreuungsgruppe	 zugeteilt.	 Der	 Ablauf	 ist	 in	 Abbildung	 1	
schematisch	dargestellt.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Abbildung	1:	Schematische	Darstellung	des	Studienablaufs	
Alle	Patienten	erhalten	eine	Therapie	nach	aktuellem	Standard.	Sie	werden	weiterhin	 in	ge-
wohntem	Umfang	 durch	 Ihren	 Arzt	 und	 durch	 die	 anderen	Mitglieder	 des	 therapeutischen	
Teams	betreut.		
Entlassung	aus	dem	UKA	
Zufällige	Zuteilung		
in	eine	der	Gruppen	
Standardbetreuungsgruppe:	
Normale	Arzneimittelversorgung	
durch	Arzt,	Pflege	und	Apotheker	
Intensivbetreuungsgruppe:	
Intensivierte	Arzneimittel-
versorgung	durch	Arzt,	Pflege		
und	Apotheker	einschließlich	
einer	besonderen	Beratung		
durch	den	Apotheker	
 
Kontaktaufnahme	nach	1	Woche	und	2,	6,	12	Monaten	
- Erfassung von Änderungen in der Medikation 
- Erfassung,	ob	ein	Krankenhausbesuch	in	den	vergan-
genen	Monaten	erfolgt	ist	
- Erfassung,	ob	Probleme	bei	der	Arzneimitteltherapie	
aufgetreten	sind	
Stationäre	Aufnahme	im	UKA	
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Eine	der	beiden	Gruppen	wird	als	Standardbetreuungsgruppe	(Kontrollgruppe)	geführt.	Hier	
wird	die	Arzneimitteltherapie	in	der	gewohnten	Weise	durch	Ärzte,	Pflegekräfte	und	Apothe-
ker	durchgeführt.		
In	der	anderen	Gruppe	 (Intensivbetreuungsgruppe)	arbeiten	die	verschiedenen	Berufsgrup-
pen	intensiver	zusammen.	Vor	allem	der	Apotheker	tritt	wesentlich	stärker	in	Erscheinung	als	
in	der	Kontrollgruppe.	Der	Apotheker	berät	Sie,	sowie	die	Ärzte	und	die	Pflege	intensiver	zu	
den	einzelnen	Arzneimitteln.	Ob	eine	Therapie	verändert	wird,	entscheidet	jedoch	weiterhin	
der	Arzt.	Am	Ende	des	 stationären	Aufenthalts	bitten	wir	 Sie	 an	einer	Befragung	 teilzuneh-
men.	Hierbei	werden	Ihnen	Fragen	zu	Ihrer	Zufriedenheit	mit	der	Betreuung	durch	Arzt,	Pfle-
ge	und	Apotheker	gestellt.	
Welche	Daten	werden	erhoben?	
Am	Anfang	des	stationären	Aufenthaltes	werden	Daten	über	 ihren	Gesundheitszustand	und	
ihre	körperlichen	und	kognitiven	Fähigkeiten	erhoben.	Während	des	stationären	Aufenthaltes	
werden	Daten	 zu	 Ihrer	Hausmedikation	und	 zu	 Ihrer	 aktuellen	Arzneimitteltherapie	 erfasst.	
Die	Erhebung	der	Daten	erfolgt	anhand	der	Angaben	in	der	Patientenakte.		
Diese	Dokumentation	ist	für	alle	Patienten	der	Studie	gleich!	
Nach	der	Krankenhausentlassung	werden	zu	vier	Zeitpunkten	(1	Woche	nach	Entlassung	und	
2,	6	und	12	Monate	nach	Entlassung)	Ihre	aktuellen	Medikamente	und	Ihre	aktuellen	Diagno-
sen	erhoben.		
Diese	 Erfassung	wird	 durch	 ein	 telefonisches	Gespräch	 oder	 ein	 persönliches	Gespräch	mit	
Ihnen	oder	einem	Ihrer	Betreuer	oder	Angehörigen	erfolgen.		
Wichtig:		
Nach	der	Entlassung	werden	alle	Patienten	gleich	behandelt,	egal	in	welche	Gruppe	sie	zuge-
teilt	wurden.	Die	Kontaktaufnahme	nach	der	Entlassung	durch	ein	Mitglied	des	Studienteams	
aus	dem	Uniklinikum	Aachen	dient	der	Dokumentation.		
Wenn	unerwünschte	Arzneimittelwirkungen	bei	der	Dokumentation	auffallen,	wird	der	Arzt	
aus	Gründen	der	Sicherheit	hierzu	informiert,	gleich	welcher	Betreuungsgruppe	Sie	zugehö-
ren.		
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IV.	Zeitplan	/	Ablauf	der	Studie	
Zu	 Beginn	 des	 Aufenthaltes	 im	 Universitätsklinikum	 Aachen	 erhalten	 Sie	 Informationen	 zu	
dieser	Studie	und	werden	zur	Teilnahme	eingeladen	(Aufklärungsgespräch).		
Nach	Ihrer	Zustimmung	zur	Studienteilnahme	werden	Sie	nach	dem	Zufallsprinzip	in	eine	der	
beiden	Behandlungsgruppen	(Kontrollgruppe	oder	Intensivbetreuungsgruppe)	zugeteilt.		
Wie	ist	der	Ablauf,	wenn	ich	in	die	Kontrollgruppe	zugeordnet	werde?		
Bei	Zuteilung	in	die	Kontrollgruppe	werden	Sie	nach	dem	derzeitigen	Standard	durch	Arzt	und	
Pflegekräfte	stationär	betreut.	Ein	Apotheker	wird	Sie	während	des	stationären	Aufenthaltes	
nur	in	Einzelfällen	kontaktieren.		
Um	den	 Langzeit-Effekt	 zu	 erfassen,	werden	wir	 Sie	 nach	 Entlassung	 aus	dem	Krankenhaus	
nach	1	Woche	und	nach	2,	6	und	12	Monaten	nochmals	kontaktieren	und	Sie	zu	Ihren	aktuel-
len	Medikamenten,	unerwünschten	Ereignissen	im	Zusammenhang	mit	Arzneimitteln	und	zu	
weiteren	Krankenhausaufenthalten	befragen.		
Die	 Kontaktaufnahme	wird	 telefonisch/schriftlich	 oder	 persönlich	 erfolgen.	 Ein	 persönlicher	
Kontakt	wird	vor	allem	dann	erfolgen,	wenn	Sie	 in	einer	betreuten	Einrichtung	wohnen.	Pro	
Kontaktaufnahme	werden	etwa	30	Minuten	veranschlagt.	
Wie	ist	der	Ablauf,	wenn	ich	in	die	Intensivbetreuungsgruppe	eingeteilt	werde?	
Im	 Falle	 der	 Zuteilung	 in	 die	 Intensivbetreuungsgruppe	 erfolgt	 ein	 Arzneimittel-
Anamnesegespräch	 durch	 einen	 Apotheker.	 Im	 Verlaufe	 des	 stationären	 Aufenthaltes	 wird	
durch	 den	 Apotheker	 Ihre	 Medikation	 regelmäßig	 auf	 mögliche	 Probleme	 untersucht.	 Bei	
Fragen	zu	Arzneimitteln	steht	Ihnen	der	Apotheker	gerne	zur	Verfügung.		
Zum	 Ende	 des	 stationären	 Aufenthaltes	 besteht	 für	 Sie	 auf	 Wunsch	 die	 Möglichkeit	 eines	
weiteren	Gesprächs,	vor	allem,	wenn	sich	während	des	Aufenthaltes	 im	UKA	Änderungen	in	
Ihrer	Arzneimitteltherapie	ergeben	haben	 (Arzneimittel-Entlassgespräch).	Die	 Informationen	
können	auch	in	schriftlicher	Form	zur	Verfügung	gestellt	werden.	
a) Aufklärungsgespräch	und	Folgegespräch	
Im	ersten	Gespräch	werden	Sie	über	die	Ziele	und	Hintergründe	der	geplanten	Studie	in-
formiert.	In	diesem	Gespräch	wird	Ihnen	vermittelt,	was	Sie	von	der	Teilnahme	an	dieser	
Studie	erwarten	können	und	was	als	Patient/-in	auf	Sie	zukommt.	Sie	erhalten	die	Patien-
teninformation,	 die	 Sie	 gerade	 lesen,	 sowie	 eine	 Einverständniserklärung	 zur	 Teilnahme	
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an	der	Studie	und	eine	Datenschutzerklärung.	Im	Verlauf	dieses	Gespräches	haben	Sie	die	
Gelegenheit,	 Fragen	 zu	 stellen	 und	 sich	 Dinge	 erläutern	 zu	 lassen,	 die	 Ihnen	 unklar	 er-
scheinen.	
Im	folgenden	Gespräch	können	Sie	Ihre	Entscheidung	mitteilen,	ob	Sie	bereit	sind,	an	der	
Studie	teilzunehmen	oder	lieber	davon	absehen	möchten.	Zuvor	besteht	die	Möglichkeit,	
weitere	Fragen	zu	klären.	Falls	Sie	an	der	Studie	teilnehmen	möchten,	werden	Sie	gebe-
ten,	Ihre	Einwilligung	zur	Teilnahme	und	zur	Speicherung	Ihrer	persönlichen	Daten	schrift-
lich	zu	bestätigen.	Diese	Daten	werden	ausschließlich	für	Zwecke	der	Studie	verwendet.	
b) Arzneimittel-Anamnesegespräch	durch	den	Apotheker	
Im	Arzneimittel-Anamnesegespräch	wird	der	betreuende	Apotheker	 sich	mit	 Ihnen	über	
Ihre	 aktuellen	 Medikamente	 unterhalten.	 Hierbei	 werden	 alle	 von	 Ihnen	 bisher	 einge-
nommenen	Medikamente	nochmals	erfasst,	neben	weiteren	persönlichen	Daten.		
Im	Gespräch	haben	Sie	außerdem	die	Möglichkeit,	Fragen	zu	klären.	
c) Weitere	Gespräche	mit	dem	Apotheker	
Weitere	Gespräche	mit	dem	Apotheker	erfolgen	auf	Wunsch	des	Patienten	oder	der	Ärz-
te.	
d) Arzneimittel-Entlassgespräch	
Auf	 Wunsch	 kann	 zum	 Ende	 des	 Krankenhausaufenthaltes	 ein	 Arzneimittel-
Entlassgespräch	 erfolgen,	 in	 dem	eventuell	 vorliegende	Änderungen	 im	Medikamenten-
plan	besprochen	werden	können.	Die	Informationen	können	auch	in	schriftlicher	Form	zur	
Verfügung	gestellt	werden.	
e)	Zufriedenheitsbefragung		
Ihre	Meinung	ist	uns	wichtig.	Daher	werden	Sie	gebeten	am	Ende	des	stationären	Aufent-
halts	 einen	 Fragebogen	 mit	 offenen	 und	 geschlossenen	 Fragen	 zu	 beantworten.	 Dabei	
geht	es	um	Ihre	Erfahrung	und	Zufriedenheit	zu	der	Kommunikation	mit	dem	multiprofes-
sionellen	Team	unter	Einbeziehung	des	Apothekers.		
Um	den	 Langzeit-Effekt	 zu	 erfassen,	werden	wir	 Sie	 nach	 Entlassung	 aus	dem	Krankenhaus	
nach	1	Woche	und	nach	2,	6	und	12	Monaten	nochmals	kontaktieren	und	Sie	zu	Ihren	aktuel-
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len	Medikamenten,	unerwünschten	Ereignissen	im	Zusammenhang	mit	Arzneimitteln	und	zu	
weiteren	Krankenhausaufenthalten	befragen.		
Die	 Kontaktaufnahme	wird	 telefonisch/schriftlich	 oder	 persönlich	 erfolgen.	 Ein	 persönlicher	
Kontakt	wird	vor	allem	dann	erfolgen,	wenn	Sie	 in	einer	betreuten	Einrichtung	wohnen.	Pro	
Kontaktaufnahme	werden	etwa	30	Minuten	veranschlagt.	
V.	Risiko/Nutzen-Relation:		
Bei	der	Teilnahme	an	der	Studie	bestehen	für	Sie	keinerlei	medizinische	Risiken.	
Falls	 einem	 Apotheker	 während	 der	 Dokumentation	 eine	 schwerwiegende,	 unerwünschte	
Wirkung	auffällt,	welches	durch	ein	Arzneimittel	eingetreten	sein	könnte,	wird	unverzüglich	
Ihr	behandelnder	Arzt	 informiert	 -	egal	 in	welche	der	beiden	Behandlungsgruppen	Sie	zuge-
teilt	worden	sind!		
Über	die	weiteren	Maßnahmen	entscheidet	Ihr	behandelnder	Arzt.	
Bei	 Zuteilung	 in	 die	 Kontrollgruppe	 erfahren	 Sie	weiterhin	 die	 gewohnte	 Betreuung	 durch	
erfahrene	Ärzte	und	Pflegepersonal.	
Ihr	 zusätzlicher	Aufwand	durch	die	Teilnahme	an	der	Studie	besteht,	neben	dem	Lesen	der	
Patienteninformation	 und	 dem	 Aufklärungsgespräch,	 aus	 einer	 Zusammenarbeit	 mit	 dem	
Forschungsteam	und	einer	Kontaktaufnahme	nach	dem	Krankenhausaufenthalt.	
Nach	Entlassung	aus	dem	Krankenhaus	wird	ein	Mitglied	des	Studienteams	Sie	 zu	vier	Zeit-
punkten	 kontaktieren.	 Die	 Gespräche	 werden	 etwa	 30	 Minuten	 dauern.	 Diese	 Gespräche	
können	auch	von	Ihnen	beauftragte	Angehörige	oder	andere	betreuende	Personen	überneh-
men.		
Bei	der	Zuteilung	 in	die	 Intensivbetreuungsgruppe	kann	sich	durch	die	 intensivere	pharma-
zeutische	Beratung	in	dem	multiprofessionellen	Team	ein	positiver	Nutzen	für	Sie	als	Patient	
ergeben.	 Möglicherweise	 lässt	 sich	 Ihre	 Arzneimitteltherapie	 durch	 einen	 Apotheker	 noch	
weiter	verbessern.	Der	Apotheker	steht	Ihnen	für	alle	aufkommenden	arzneimittelbezogenen	
Fragen	zur	Verfügung.	
Der	Apotheker	hat,	entsprechend	den	gesetzlichen	Bestimmungen,	nur	eine	beratende	Funk-
tion	gegenüber	Ihnen	und	Ihrem	Arzt.	Weiterhin	entscheidet	ausschließlich	der	behandelnde	
Arzt	über	Ihre	Medikamente	und	Ihre	Therapie.		
Ihr	 zusätzlicher	Aufwand	durch	die	Teilnahme	an	der	Studie	besteht	 in	dem	Aufklärungsge-
spräch,	aus	einer	Zusammenarbeit	mit	dem	Forschungsteam,	dem	multiprofessionellem	Team	
mit	einbezogenem	Apotheker	und	einer	Kontaktaufnahme	nach	dem	Krankenhausaufenthalt.		
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Während	des	 stationären	Aufenthaltes	ergeben	 sich	 für	 Sie	oder	 Ihre	Angehörigen	etwa	15	
minütige	Betreuungsgespräche	mit	dem	Apotheker.	
Nach	Entlassung	aus	dem	Krankenhaus	wird	ein	Mitglied	des	Studienteams	Sie	 zu	vier	Zeit-
punkten	 kontaktieren.	 Die	 Gespräche	 werden	 etwa	 30	 Minuten	 dauern.	 Diese	 Gespräche	
können	auch	von	Ihnen	beauftragte	Angehörige	oder	andere	betreuende	Personen	überneh-
men.		
Es	besteht	eine	Haftpflichtversicherung,	wenn	der	Versicherungsfall	auf	das	Verschulden	des	
Hauses	oder	eines	seiner	Angestellten	zurückzuführen	ist.	Die	Haftpflichtversicherung	des	UK	
Aachen	besteht	bei	der	Zürich	Versicherungs-AG,	Versicherungsschein-Nr.	813.380.000.270.		
VI.	Datenschutz	und	Patienteneinwilligung	
Die	Teilnahme	an	der	Studie	birgt	für	Sie	keine	zusätzlichen	Risiken.		
Sie	haben	das	Recht,	 jederzeit	und	ohne	Angaben	von	Gründen	von	der	Teilnahme	an	der	
Studie	 zurückzutreten.	 Ihre	 personenbezogenen	 Daten	 werden	 nach	 Widerruf/Rücktritt	
unverzüglich	 gelöscht	 bzw.	 anonymisiert.	 Es	 entstehen	 Ihnen	 dadurch	 keine	 Nachteile	 in	
Ihrer	Behandlung.	
Wie	oben	erläutert,	werden	wir	erst	nach	Ihrem	Einverständnis	zur	Teilnahme	an	der	Studie	
personenbezogene	Daten	erheben.	Zum	einen	sind	bestimmte	Daten	zur	Beratung	notwen-
dig,	 zum	anderen	 sollen	 Informationen,	die	 sich	 im	Gespräch	ergeben,	gespeichert	werden.	
Außerdem	sollen	Daten	gespeichert	werden,	die	speziell	für	die	Auswertung	der	Studie	wich-
tig	sind	und	auch	nach	der	Entlassung	eine	Kontaktaufnahme	zu	Ihnen	ermöglichen.		
Die	gesammelten	 Informationen	sollen	 in	einer	Datenbank	gespeichert	werden,	die	nur	den	
Studienbeteiligten	 zugänglich	 ist	 (Kennwortschutz).	 Die	 Daten	 dienen	 ausschließlich	 dem	
Zweck	 der	 Durchführung	 der	 Studie	 und	 werden	 in	 diesem	 Zusammenhang	 entsprechend	
ausgewertet.	Für	die	Auswertung	werden	die	Daten	ausschließlich	in	pseudonymidierter,	d.h.	
verschlüsselter	Form	verwendet.		
	
Die	Ergebnisse	werden	ausschließlich	anonymisiert	veröffentlicht	und	stehen	Ihnen	dann	auf	
Anfrage	zur	Verfügung.		
Wir	 arbeiten	 ausschließlich	mit	 klinikeigener	 Hard-	 und	 Software	 des	 Universitätsklinikums	
Aachen.	 Diese	 entspricht	 den	 aktuellen	 Datensicherheits-	 und	 Datenschutzanforderungen.	
Nach	 Ablauf	 der	 Studie	 bzw.	 uns	 bindender	 spezieller	 Aufbewahrungsvorschriften	 werden	
Ihre	personenbezogenen	Daten	gelöscht	bzw.	anonymisiert.	
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Die	 erhobenen	 Daten	 unterliegen	 den	 gesetzlichen	 Bestimmungen	 des	 Datenschutzes	 und	
setzen	Ihre	schriftliche	Einwilligung	zur	Weitergabe,	Speicherung	und	Auswertung	im	Rahmen	
der	Studie	voraus	(Datenschutzerklärung,	Einverständniserklärung).		
Wenn	 Sie	 die	 Informationen	 in	 diesem	 Informationsblatt	 gelesen	 haben	 und	 noch	 Fragen	
offen	geblieben	sind,	so	können	Sie	diese	gerne	mit	uns	im	persönlichen	Gespräch	klären.		
Sie	können	frei	über	die	Teilnahme	an	der	Studie	entscheiden.		
Wir	würden	uns	freuen,	wenn	Sie	Interesse	haben,	an	der	Studie	teilzunehmen.		
Ihr	Einverständnis	und	Ihre	Teilnahme	bestätigen	Sie	schriftlich	mit	einer	so	genannten	Pati-
enten-Einwilligungserklärung	 und	 einer	 Datenschutzerklärung,	 die	 Sie	 auf	 einem	 separaten	
Bogen	erhalten.		
	
Für	Ihre	Bemühungen	und	Ihre	Mitarbeit	danken	wir	Ihnen	recht	herzlich!!!	
	
Hinweis:	
Aus	Gründen	der	besseren	Lesbarkeit	wurde	auf	die	Verwendung	weiblicher	Schreibformen	verzichtet.	Alle	ent-
sprechend	verwendeten	Bezeichnungen	beinhalten	auch	die	weibliche	Form	
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Patient diagnosis 
Mean cohort attribute scores 
Person's chi square test of independence- Crosstabs table 
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0	Patientennummer	
	
 
 
 
 
 
 
 
 
 
 
   
Patientennummer___________	
Name_________________________________	
Geschlecht_____________________________	
Alter__________________________________	
Aufnahmedatum________________________	
Entlassdatum___________________________ 
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0.1	The	GerontoNet	ADR	Risk	Score	
Kennzeichen:	__________________	 	
Alter:_________________________		 	
Geschlecht:	□	weiblich	□	männlich	
Datum:	_______________________	
	
	
	Quelle:	Onder	G,	Petrovic	M,	Tangiisuran	B,	et	al.	Development	and	validation	of	a	score	to	assess	risk	of	adverse	drug	
reactions	among	in-hospital	patients	65	years	or	older:	the	GerontoNet	ADR	Risk	Score.	Arch	Intern	Med	2010;	170:1142-8	
	 	
Risikofaktor	 Punkt	 Punktzahl	
4	oder	mehr	Komorbiditäten	 1	 	
Herzinsuffizienz	 1	 	
Lebererkrankungena	 1	 	
Anzahl	der	Medikamente	 	 	
		<5	 0	 	
		5-7	 1	 	
		≥	8	 4	 	
Früher	ADR	 2	 	
Nierenversagenb	 1	 	
a	Definiert	als	die	Leberfunktionswerte	>2x	oberen	Grenzwert		
b	Definiert	als	berechnete	glomeruläre	Filtrationsrate	<60mL/min/	1,73	m2	
	ADR=	adverse	drug	reaction	
Gesamtpunktzahl	
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Klinische Pharma-
zie 
0.2	PRO-CTCAE:	Fragebogen	zu	Symptomen	bei	Krebspatienten	unter	me-
dikamentöser	Tumortherapie	
	
	
 
 
 
 
 
Bitte beantworten Sie die folgenden Fragen zu häufig vorkommenden Symptomen 
während einer Krebstherapie selbst, indem Sie die Antwort ankreuzen, die für 
Sie am besten zutrifft. Bitte beziehen Sie sich bei der Antwort immer auf die 
schwerste Ausprägung des jeweiligen Symptoms in den letzten 7 Tagen 
(gemeint ist nicht der Durchschnittswert). 
 
________________________________________________________________ 
 
1. Während der letzten 7 Tage: wie HÄUFIG hatten Sie Übelkeit? 
 
 
 
 
2. Während der letzten 7 Tage: wie STARK war Ihre Übelkeit im schlimmsten Fall? 
 
 
 
 
3. Während der letzten 7 Tage: wie HÄUFIG mussten Sie erbrechen? 
 
 
 
 
4. Während der letzten 7 Tage: wie STARK war Ihr Erbrechen im schlimmsten Fall? 
 
 
________________________________________________________________ 
5. Während der letzten 7 Tage: wie HÄUFIG hatten Sie Schmerzen? 
 
 
6. Während der letzten 7 Tage: wie STARK waren Ihre Schmerzen im schlimmsten Fall? 
 
 
	 	
         Nie          Selten      Gelegentlich      Häufig      Fast immer 
          
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
         Nie          Selten      Gelegentlich      Häufig      Fast immer 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
         
 
         Nie          Selten      Gelegentlich      Häufig      Fast immer 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
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7. Während der letzten 7 Tage: wie SEHR haben Schmerzen Sie in Ihren täglichen Aktivitä-
ten GESTÖRT? 
 
________________________________________________________________ 
8. Während der letzten 7 Tage: wie STARK war Ihre Verstopfung im schlimmsten Fall? 
 
 
9. Während der letzten 7 Tage: wie HÄUFIG hatten Sie Durchfall?  
 
 
________________________________________________________________ 
10. Während der letzten 7 Tage: wie STARK war Ihr Appetitmangel im schlimmsten Fall? 
 
 
 
11. Während der letzten 7 Tage: wie SEHR hat Ihr Appetitmangel Sie in Ihren täglichen 
Aktivitäten GESTÖRT? 
 
 
________________________________________________________________ 
12. Während der letzten 7 Tage: wie STARK waren Ihre Schwierigkeiten beim Schlucken 
im schlimmsten Fall? 
 
 
 
13. Während der letzten 7 Tage: wie STARK war Ihre Mundtrockenheit im schlimmsten 
Fall? 
 
 
 
14. Während der letzten 7 Tage: wie STARK hatten Sie wunde oder offene Stellen in 
Mund oder Hals im schlimmsten Fall? 
 
 
 
15. Während der letzten 7 Tage: wie SEHR haben wunde oder offene Stellen in Mund 
oder Hals Sie in ihren täglichen Aktivitäten GESTÖRT? 
 
	
	 	
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
         Nie          Selten      Gelegentlich      Häufig      Fast immer 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
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16. Während der letzten 7 Tage: wie STARK waren Taubheit oder Kribbeln in Händen 
oder Füßen im schlimmsten Fall? 
 
 
 
17. Während der letzten 7 Tage: wie SEHR hat Sie Taubheit oder Kribbeln in Händen 
oder Füßen in Ihren täglichen Aktivitäten GESTÖRT? 
 
________________________________________________________________ 
18. Während der letzten 7 Tage: wie STARK war Ihre Kurzatmigkeit im schlimmsten Fall? 
 
 
 
19. Während der letzten 7 Tage: wie SEHR hat Kurzatmigkeit Sie in Ihren täglichen Aktivi-
täten GESTÖRT? 
 
________________________________________________________________ 
20. Während der letzten 7 Tage: wie STARK war Ihre Müdigkeit, Erschöpfung oder feh-
lende Energie im schlimmsten Fall? 
 
________________________________________________________________ 
21. Während der letzten 7 Tage: wie SEHR haben Müdigkeit, Erschöpfung oder fehlende 
Energie Sie in Ihren täglichen Aktivitäten GESTÖRT? 
 
________________________________________________________________ 
22. Während der letzten 7 Tage: wie STARK waren Ihre Probleme sich zu konzentrieren 
im schlimmsten Fall? 
 
 
 
23. Während der letzten 7 Tage: wie SEHR haben Ihre Probleme sich zu konzentrieren 
Sie in Ihren täglichen Aktivitäten GESTÖRT? 
 
 
________________________________________________________________ 
	 	
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
           
 
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
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24. Während der letzten 7 Tage: wie STARK waren Ihre Probleme beim Schlafen (wie z.B. 
Schwierigkeiten beim Einschlafen, Durchschlafen oder zu frühes Aufwachen) im schlimmsten 
Fall? 
 
 
 
 25. Während der letzten 7 Tage: wie SEHR haben Probleme beim Schlafen (wie z.B. 
Schwierigkeiten beim Einschlafen, Durchschlafen oder zu frühes Aufwachen) Sie in Ihren 
täglichen Aktivitäten GESTÖRT? 
 
 
________________________________________________________________ 
26. Während der letzten 7 Tage: wie HÄUFIG hatten Sie Angst? 
 
 
 
27. Während der letzten 7 Tage: wie STARK war Ihre Angst im schlimmsten Fall? 
 
 
 
28. Während der letzten 7 Tage: wie SEHR hat Angst Sie in Ihren täglichen Aktivitäten GE-
STÖRT? 
 
 
________________________________________________________________ 
29. Während der letzten 7 Tage: wie HÄUFIG waren Sie traurig? 
 
 
 
30. Während der letzten 7 Tage: wie STARK war Ihre Traurigkeit im schlimmsten Fall? 
 
 
 
31. Während der letzten 7 Tage: wie sehr hat Ihre Traurigkeit Sie in Ihren täglichen Aktivitä-
ten GESTÖRT? 
 
 
 
 
PRO-CTCAE: Fragebogen zu Symptomen bei Krebspatienten unter medikamentöser Tumortherapie Version 
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       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
         Nie          Selten      Gelegentlich      Häufig      Fast immer 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
 
         Nie          Selten      Gelegentlich      Häufig      Fast immer 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
          
 
 
       Gar nicht      Ein wenig       Mäßig         Ziemlich       Sehr 
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1 Arzneimittelanamnese 
 
 
 
 
 
 
Medikation bei Aufnahme Ersatzmedikation auf Station 
Name Stärke Arznei-
form 
Dosierung Name Stärke Arznei-
form 
Dosierung E S 
          
          
          
          
          
          
          
          
          
          
          
          
          
E = Ersatzmedikament gleicher Wirkstoff              S= Substitution gleiche Wirkstoff-
gruppe 
 
 
 
 
 
 
 
 
 
 
 
Erledigt am: 
Erledigt durch:  
	
	 	
	
 
Erledigt am: 
Erledigt durch:  
	 	
Patientennummer: 
Größe: 
Gewicht: 
Allergien: 
Alkohol: 
Rauchen: 
Kreatinin [mg/dl]: 
GFR [ml/min]: 
Sonstiges: 
Bemerkung:  
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2	Stationäre	Medikation:	
Patientennummer:	________________	
Verordnungsdatum	
Name	Stärke	Arzneiform	Dosierung	(vermutete)	Indikation	Bemerkung/	
Verord-
nungs-
datum 
Name Stärke Arznei-
form 
Dosie-
rung 
(vermutete) 
Indikation 
Bemerkung/ 
ATC-code 
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3	Datenerfassung	Azneimittelbezogene	Probleme	(ABPs):	
	
Patientennummer:	_____________________	
Arzneimittel:	_______________________________________________________________________	
Beschreibung	des	Problems:	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
Intervention:	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
	
Klassifikation	nach	APS-Doc:	_____________________	
	
Problem	entstand:											vor	Aufnahme																			Schnittstelle																						während	stat.	Aufenthalt	
Problem	wurde:															gelöst																																		teilweise	gelöst																	nicht	gelöst	
	
Bemerkung:	________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
__________________________________________________________________________________	
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4	Zeiterfassungen	für	die	Intervention	
	
Datum Patientennummer Tätigkeit Apotheker Uhrzeit 
(von-bis) 
Handzeichen 
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Empfehlungen	aus	dem	Medikationscheck	
Folgende	Angaben	betreffen	die	Arzneimitteltherapie	Ihres	Patienten	
Herr/Frau	__________________________________________________	
Unterschrift	des	Apothekers:	_____________________________	
Empfehlungen	wurden	mit	_____________________________	besprochen.	
Datum_____________________	
ONKO	Pilotstudie,	Apotheke	der	Uniklinik	RWTH	Aachen,	A.	Šarčević,	Tel.:	0241	8085046	
K. Schmitz		2014©,	Update	A.	Šarčević	2016
Approval from the oncology ward 
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Ethic Committee opinion 
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Patient diagnosis 
 Cancer type ICD-
10  
Frequency Per-
cent 
Valid C04.1 Malignant neoplasm of lateral floor of mouth 1 1.0 
C07 Malignant neoplasm of parotid gland 1 1.0 
C10.8 Malignant neoplasm of overlapping sites of oropharynx 1 1.0 
C15.9 Malignant neoplasm of esophagus, unspecified 1 1.0 
C22.0 Liver cell carcinoma 1 1.0 
C25.1 Malignant neoplasm of body of pancreas 1 1.0 
C32.8 Malignant neoplasm of overlapping sites of larynx 1 1.0 
C34.0 Malignant neoplasm of main bronchus 5 5.0 
C34.1 Malignant neoplasm of upper lobe, bronchus or lung 13 12.9 
C34.2 Malignant neoplasm of middle lobe, bronchus or lung 2 2.0 
C34.3 Malignant neoplasm of lower lobe, bronchus or lung 4 4.0 
C43.5 Malignant melanoma of lower limb, including hip 1 1.0 
C43.7 Malignant melanoma of trunk 1 1.0 
C45.0 Mesothelioma of pleura 1 1.0 
C50.4 Malignant neoplasm of upper-outer quadrant of breast 1 1.0 
C50.9 Malignant neoplasm of breast of unspecified site 1 1.0 
C53.8 Malignant neoplasm of overlapping sites of cervix uteri 1 1.0 
C56 Malignant neoplasm of ovary. 3 3.0 
C57.0 Malignant neoplasm of fallopian tube 1 1.0 
C61 Malignant neoplasm of prostate 3 3.0 
C62.0 Malignant neoplasm of undescended testis (C62.1 the same) 1 1.0 
C62.1 Malignant neoplasm of overlapping sites of bladder 1 1.0 
C67.8 Secondary malignant neoplasm of retroperitoneum and peri-
toneum 
2 2.0 
C78.6 Secondary malignant neoplasm of bone and bone marrow 1 1.0 
C80.0 Disseminated malignant neoplasm, unspecified 2 2.0 
C81.1 Hodgkin-lymphom 1 1.0 
C81.7 Other Hodgkin lymphoma 1 1.0 
C82.0 Follicular lymphoma grade I 1 1.0 
C82.1 Follicular lymphoma grade II 1 1.0 
C83.1 Mantle cell lymphoma 3 3.0 
C83.3 Diffuse large B-cell lymphoma (DLBCL or DLBL) 16 15.8 
C84.4 Peripheral T-cell lymphoma, not classified 1 1.0 
C86.5 Angioimmunoblastic T-cell lymphoma 1 1.0 
C88.0 Waldenström macroglobulinemia 1 1.0 
C90.0 Multiple Myeloma not having achieved remission 14 13.9 
C90.10 Plasma cell leukemia not having achieved remission 1 1.0 
C91.1 Chronic lymphocytic leukemia of B-cell type 1 1.0 
Patient diagnosis 
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C91.6 Prolymphocytic leukemia of T-cell type 1 1.0 
C91.8 Burkitt acute lymphoblastic leukaemia 1 1.0 
C92.0 Acute myeloblastic leukemia 2 2.0 
C92.1 Chronic myeloid leukemia 1 1.0 
C92.4 Acute promyelocytic leukemia (AML M3) 1 1.0 
C92.5 Acute myelomonocytic leukemia (AML M4) 1 1.0 
C96.5 Multifocal and unisystematic Langerhans-cell histiocytosis 1 1.0 
Total 101 100.0 
Attachments 
 190 
	
0.00 
10.00 
20.00 
30.00 
40.00 
50.00 
60.00 
70.00 
80.00 
1 3 5 7 9 11
 
13
 
15
 
17
 
19
 
21
 
23
 
25
 
27
 
29
 
31
 
33
 
35
 
37
 
39
 
41
 
43
 
45
 
47
 
49
 
51
 
53
 
55
 
57
 
59
 
61
 
63
 
65
 
67
 
69
 
71
 
73
 
75
 
77
 
79
 
81
 
83
 
85
 
87
 
89
 
91
 
93
 
95
 
97
 
99
 
10
1 
PR
O
-C
T
C
A
E
 m
ea
n 
at
tir
bu
te
 lo
ad
 sc
or
e 
(%
) 
Patient number 
Mean cohort attribute: frequency, severity and interference scores  
mean 
frequency score 
mean severity 
score 
mean 
interference 
score 
Pearson’s chi square test of independence 
 191 
Pearson's chi square test of independence – Crosstabs Table 
Mean cohort    
PRO-CTCAE  
attribute score 
 p < 0.05  
Number of  
medication  
LOW            HIGH 
(≤ 7)              (>	8) 
Number of drug-
related problems  
LOW            HIGH 
(=	0)               (>	1) 
Adverse drug  
reaction risk score 
LOW             HIGH 
(≤ 4)               (>	5) 
Cancer type        
Solid        
Haematological 
ECOG    
performance score 
LOW             HIGH 
(0-1)               (2-4) 
Frequency      
(0-1)   LOW 
 
(2-4)  HIGH 
 
8 
 
56 
 
22 
 
42 
 
11 
 
53 
 
31 
 
33 
 
35 
 
24 
 
4 
 
33 
 
8 
 
29 
 
4 
 
33 
 
20 
 
17 
 
12 
 
21 
Severity      
(0-1)   LOW 
 
(2-4)  HIGH 
 
12 
 
73 
 
29 
 
56 
 
15 
 
70 
 
41 
 
44 
 
40 
 
37 
 
0 
 
16 
 
1 
 
15 
 
0 
 
16 
 
10 
 
6 
 
7 
 
8 
Interference     
 (0-1)   LOW 
 
(2-4)  HIGH 
 
10 
 
46 
 
19 
 
37 
 
10 
 
46 
 
22 
 
34 
 
32 
 
19 
 
2 
 
43 
 
11 
 
34 
 
5 
 
40 
 
29 
 
16 
 
15 
 
26 
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